%PDF-1.4%âãÏÓ
82 0 obj
<</JT 79 0 R/Metadata 140 0 R/PageLabels 68 0 R/Pages 69 0 R/Type/Catalog>>
endobj
79 0 obj
<</A[70 0 R]/Cn[78 0 R]/V 1.10001>>
endobj
140 0 obj
<</Length 1612/Subtype/XML/Type/Metadata>>stream
<?xpacket begin="ï»¿" id="W5M0MpCehiHzreSzNTczkc9d"?>
<x:xmpmeta xmlns:x="adobe:ns:meta/" x:xmptk="Adobe XMP Core 4.2.1-c043 52.389687, 2009/06/02-13:20:35        ">
   <rdf:RDF xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#">
      <rdf:Description rdf:about=""
            xmlns:pdf="http://ns.adobe.com/pdf/1.3/">
         <pdf:Producer>Acrobat Distiller 4.05 for Macintosh</pdf:Producer>
      </rdf:Description>
      <rdf:Description rdf:about=""
            xmlns:xmp="http://ns.adobe.com/xap/1.0/">
         <xmp:CreateDate>2005-04-07T17:56:03Z</xmp:CreateDate>
         <xmp:ModifyDate>2023-12-03T12:24:20-08:00</xmp:ModifyDate>
         <xmp:CreatorTool>QuarkXPressÂª: AdobePS 8.8.0 (301)</xmp:CreatorTool>
         <xmp:MetadataDate>2023-12-03T12:24:20-08:00</xmp:MetadataDate>
      </rdf:Description>
      <rdf:Description rdf:about=""
            xmlns:dc="http://purl.org/dc/elements/1.1/">
         <dc:format>application/pdf</dc:format>
         <dc:creator>
            <rdf:Seq>
               <rdf:li>Heather</rdf:li>
            </rdf:Seq>
         </dc:creator>
         <dc:title>
            <rdf:Alt>
               <rdf:li xml:lang="x-default">2004-566.may</rdf:li>
            </rdf:Alt>
         </dc:title>
      </rdf:Description>
      <rdf:Description rdf:about=""
            xmlns:xmpMM="http://ns.adobe.com/xap/1.0/mm/">
         <xmpMM:DocumentID>uuid:5ad6dd3f-1dd2-11b2-0a00-d40827bd7200</xmpMM:DocumentID>
         <xmpMM:InstanceID>uuid:5ad6dd42-1dd2-11b2-0a00-880000000000</xmpMM:InstanceID>
      </rdf:Description>
   </rdf:RDF>
</x:xmpmeta>
<?xpacket end="r"?>
endstream
endobj
68 0 obj
<</Nums[0 67 0 R]>>
endobj
69 0 obj
<</Count 9/Kids[83 0 R 1 0 R 4 0 R 7 0 R 10 0 R 13 0 R 16 0 R 27 0 R 30 0 R]/Type/Pages>>
endobj
83 0 obj
<</Annots 141 0 R/Contents 142 0 R/CropBox[0 0 612 792]/MediaBox[0 0 612 792]/Parent 69 0 R/QInserted true/Resources<</ExtGState<</GS0 116 0 R/GS1 143 0 R/GS2 144 0 R>>/Font<</T1_0 85 0 R/T1_1 93 0 R/T1_2 97 0 R/T1_3 100 0 R/T1_4 121 0 R/T1_5 145 0 R>>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 46 0 R/Type/Page>>
endobj
1 0 obj
<</Annots 146 0 R/Contents 147 0 R/CropBox[0 0 612 792]/MediaBox[0 0 612 792]/Parent 69 0 R/QInserted true/Resources<</ExtGState<</GS0 116 0 R/GS1 148 0 R/GS2 149 0 R>>/Font<</T1_0 97 0 R/T1_1 33 0 R/T1_2 85 0 R/T1_3 34 0 R/T1_4 121 0 R/T1_5 145 0 R>>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 48 0 R/Type/Page>>
endobj
4 0 obj
<</Annots 150 0 R/Contents 151 0 R/CropBox[0 0 612 792]/MediaBox[0 0 612 792]/Parent 69 0 R/QInserted true/Resources<</ExtGState<</GS0 116 0 R/GS1 152 0 R/GS2 153 0 R>>/Font<</T1_0 97 0 R/T1_1 85 0 R/T1_2 34 0 R/T1_3 33 0 R/T1_4 121 0 R/T1_5 145 0 R>>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 50 0 R/Type/Page>>
endobj
7 0 obj
<</Annots 154 0 R/Contents 155 0 R/CropBox[0 0 612 792]/MediaBox[0 0 612 792]/Parent 69 0 R/QInserted true/Resources<</ExtGState<</GS0 116 0 R/GS1 156 0 R/GS2 157 0 R>>/Font<</T1_0 97 0 R/T1_1 85 0 R/T1_2 121 0 R/T1_3 145 0 R>>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 52 0 R/Type/Page>>
endobj
10 0 obj
<</Annots 158 0 R/Contents 159 0 R/CropBox[0 0 612 792]/MediaBox[0 0 612 792]/Parent 69 0 R/QInserted true/Resources<</ExtGState<</GS0 116 0 R/GS1 160 0 R/GS2 161 0 R>>/Font<</T1_0 97 0 R/T1_1 34 0 R/T1_2 85 0 R/T1_3 121 0 R/T1_4 145 0 R>>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 54 0 R/Type/Page>>
endobj
13 0 obj
<</Annots 162 0 R/Contents 163 0 R/CropBox[0 0 612 792]/MediaBox[0 0 612 792]/Parent 69 0 R/QInserted true/Resources<</ExtGState<</GS0 116 0 R/GS1 164 0 R/GS2 165 0 R>>/Font<</T1_0 97 0 R/T1_1 33 0 R/T1_2 85 0 R/T1_3 34 0 R/T1_4 121 0 R/T1_5 145 0 R>>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 56 0 R/Type/Page>>
endobj
16 0 obj
<</Annots 166 0 R/Contents 167 0 R/CropBox[0 0 612 792]/MediaBox[0 0 612 792]/Parent 69 0 R/QInserted true/Resources<</ExtGState<</GS0 116 0 R/GS1 168 0 R/GS2 169 0 R>>/Font<</T1_0 97 0 R/T1_1 85 0 R/T1_2 35 0 R/T1_3 121 0 R/T1_4 145 0 R>>/ProcSet[/PDF/Text]/XObject<</Fm0 26 0 R>>>>/Rotate 0/Thumb 58 0 R/Type/Page>>
endobj
27 0 obj
<</Annots 170 0 R/Contents 171 0 R/CropBox[0 0 612 792]/MediaBox[0 0 612 792]/Parent 69 0 R/QInserted true/Resources<</ExtGState<</GS0 116 0 R/GS1 172 0 R/GS2 173 0 R>>/Font<</T1_0 97 0 R/T1_1 33 0 R/T1_2 85 0 R/T1_3 121 0 R/T1_4 145 0 R>>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 60 0 R/Type/Page>>
endobj
30 0 obj
<</Annots 174 0 R/Contents 175 0 R/CropBox[0 0 612 792]/MediaBox[0 0 612 792]/Parent 69 0 R/QInserted true/Resources<</ExtGState<</GS0 116 0 R/GS1 176 0 R/GS2 177 0 R>>/Font<</T1_0 97 0 R/T1_1 85 0 R/T1_2 121 0 R/T1_3 145 0 R>>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 62 0 R/Type/Page>>
endobj
174 0 obj
[178 0 R]
endobj
175 0 obj
<</Length 10395>>stream
1 g
/GS0 gs
0 792 m
0 792 l
f
q
13.5 787.5 585 -783 re
W n
q
0 792.03 612 -792 re
W n
BT
0 0 0 1 k
/GS1 gs
/T1_0 1 Tf
8 0 0 8 73.868 737.0303 Tm
(1995;22:1606-8.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(12.)-875.1 (Breitbart )17.7 (W)91.9 (, McDonald MV)128.8 (, Rosenfeld B, Monkman ND, Passik S.)]TJ
2.175 -1.25 Td
[(Fatigue in ambulatory )54.8 (AIDS patients. J Pain Symptom Manage)]TJ
0 Tc 0 Tw 0 -1.25 TD
(1998;15:159-67.)Tj
0.0249 Tw -2.175 -1.25 Td
[(13.)-875 (Chang )17.7 (WK, Hung KY)128.9 (, Huang JW)91.8 (, )17.7 (W)39.9 (u KD, )17.7 (T)70 (sai )17.7 (TJ. Chronic fatigue)]TJ
-0.00011 Tc 2.175 -1.25 Td
[(in long-term peritoneal dialysis patients. )54.8 (Am J Nephrol)]TJ
0 Tc 0 Tw T*
(2001;21:479-85.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(14.)-875.1 (W)79.9 (olfe F)79.7 (, Hawley DJ, )17.7 (W)39.8 (ilson K. )17.7 (The prevalence and meaning of)]TJ
2.175 -1.25 Td
(fatigue in rheumatic disease. J Rheumatol 1996;23:1407-17.)Tj
-2.175 -1.25 Td
[(15.)-875.1 (Whalley D, McKenna SP)110.7 (, de Jong Z, van der Heijde D. Quality of)]TJ
2.175 -1.25 Td
(life in rheumatoid arthritis. Br J Rheumatol 1997;36:884-8.)Tj
-2.175 -1.25 Td
[(16.)-875.1 (Abdel-Nasser )54.8 (AM, Rasker JJ, )17.7 (V)110.8 (alkenbur)17.7 (g HA. Epidemiological and)]TJ
2.175 -1.25 Td
(clinical aspects relating to the variability of rheumatoid arthritis.)Tj
T*
[(Semin )54.8 (Arthritis Rheum 1997;27:123-40.)]TJ
-2.175 -1.25 Td
[(17.)-875.1 (Lawrence RC, Helmick CG, )54.8 (Arnett FC, et al. Estimates of the)]TJ
2.175 -1.25 Td
(prevalence of arthritis and selected musculoskeletal disorders in the)Tj
T*
[(United States. )54.8 (Arthritis Rheum 1998;41:778-99.)]TJ
-2.175 -1.25 Td
[(18.)-875.1 (Pinals RS, Masi )54.8 (A)110.8 (T)74 (, Larsen RA, and the Subcommittee for Criteria)]TJ
2.175 -1.25 Td
[(of Remission in Rheumatoid )54.8 (Arthritis of the )54.8 (American Rheumatism)]TJ
T*
[(Association Diagnostic and )17.7 (Therapeutic Criteria Committee.)]TJ
T*
(Preliminary criteria for clinical remission in rheumatoid arthritis.)Tj
T*
(Arthritis Rheum 1981;24:1308-15.)Tj
-2.175 -1.25 Td
[(19.)-875.1 (T)69.9 (ack BB. Self-reported fatigue in rheumatoid arthritis: )54.8 (A)-220.1 (pilot)]TJ
2.175 -1.25 Td
[(study)64.9 (. )54.8 (Arthritis Care Res 1990;3:154-7.)]TJ
-2.175 -1.25 Td
[(20.)-875.1 (Schumacher HE, editor)54.8 (. Primer on the rheumatic diseases. )54.8 (Atlanta:)]TJ
2.175 -1.25 Td
[(The )54.8 (Arthritis Foundation; 1993.)]TJ
-2.175 -1.25 Td
[(21.)-875.1 (Belza BL. Comparison of self-reported fatigue in rheumatoid )]TJ
2.175 -1.25 Td
(arthritis and controls. J Rheumatol 1995;22:639-43.)Tj
-2.175 -1.25 Td
[(22.)-875.1 (Y)99.8 (ellen SB, Cella DF)79.7 (, )17.7 (W)79.9 (ebster K, Blendowski C, Kaplan E.)]TJ
2.175 -1.25 Td
(Measuring fatigue and other anemia-related symptoms with the)Tj
T*
[(Functional )54.8 (Assessment of Cancer )17.7 (Therapy \(F)73.9 (ACT\) Measurement)]TJ
T*
(System. J Pain Symptom Manage 1997;13:63-74.)Tj
-2.175 -1.25 Td
[(23.)-875.1 (Cella DF)79.7 (, )17.7 (T)35 (ulsky DS, Gray G, et al. )17.7 (The Functional )54.8 (Assessment of)]TJ
2.175 -1.25 Td
[(Cancer )17.7 (Therapy \(F)73.9 (ACT\) Scale: Development and validation of the)]TJ
T*
[(general measure. J Clin Oncol 1993;1)36.8 (1:570-9.)]TJ
-2.175 -1.25 Td
[(24.)-875.1 (Felson DT)73.9 (, )54.8 (Anderson JJ, Boers M, et al. )54.8 (American College of)]TJ
2.175 -1.25 Td
(Rheumatology preliminary definition of improvement in )Tj
T*
[(rheumatoid arthritis. )54.8 (Arthritis Rheum 1995;38:727-35.)]TJ
-2.175 -1.25 Td
[(25.)-875.1 (Strand )17.7 (V)128.9 (,)-0.1 ( )17.7 (T)35 (ugwell P)110.7 (, Bombardier C, et al. Function and )]TJ
2.175 -1.25 Td
(health-related quality of life: Results from a randomized controlled)Tj
T*
(trial of leflunomide versus methotrexate or placebo in patients with)Tj
T*
[(active rheumatoid arthritis. )54.8 (Arthritis Rheum 1999;42:1870-8.)]TJ
-2.175 -1.25 Td
[(26.)-875.1 (Bathon JM, Martin R)54.8 (W)91.8 (, Fleischmann RM, et al. )54.8 (A)-220.1 (comparison of)]TJ
2.175 -1.25 Td
(etanercept and methotrexate in patients with early rheumatoid)Tj
T*
(arthritis. New Engl J Med 2000;343:1586-93.)Tj
-2.175 -1.25 Td
[(27.)-875.1 (Lipsky PE, van der Heijde DMFM, St. Clair EW)91.7 (, et al. Infliximab)]TJ
2.175 -1.25 Td
(and methotrexate in the treatment of rheumatoid arthritis. New Engl)Tj
0 Tc T*
(J Med 2000;343:1594-602.)Tj
-0.00011 Tc -2.175 -1.25 Td
[(28.)-875.1 (Food and Drug )54.8 (Administration. Guidance for industry: Clinical)]TJ
2.175 -1.25 Td
(development programs for drugs, devices and biological products)Tj
T*
(for the treatment of rheumatoid arthritis [draft]. Rockville, MD: US)Tj
T*
[(Food and Drug )54.8 (Administration; 1999.)]TJ
-2.175 -1.25 Td
[(29.)-875.1 (W)79.9 (are JE, Snow KK, Kosinski M, Gandek B. SF-36 health survey)]TJ
2.175 -1.25 Td
[(manual and interpretation guide. Boston: )17.7 (The Health Institute, New)]TJ
T*
(England Medical Center; 1993.)Tj
30.825 67.5 Td
[(30.)-875.1 (T)69.9 (alamo J, Frater )54.8 (A, Gallivan S, )36.8 (Y)99.8 (oung )54.8 (A. Use of the Short Form 36)]TJ
2.175 -1.25 Td
(\(SF-36\) for health status measurement in rheumatoid arthritis. Br )Tj
T*
(J Rheumatol 1997;36:463-9.)Tj
-2.175 -1.25 Td
[(31.)-875.1 (Ruta DA, Hurst NP)110.7 (, Kind P)110.7 (, Hunter M, Stubbing )54.8 (A. Measuring)]TJ
2.175 -1.25 Td
(health status in British patients with rheumatoid arthritis:)Tj
T*
[(Reliability)64.8 (, validity and responsiveness of the Short Form 36-Item)]TJ
T*
(Health Survey \(SF-36\). Br J Rheumatol 1998;37:425-36.)Tj
-2.175 -1.25 Td
[(32.)-875.1 (Mathias SD, Colwell HH, Miller DP)110.7 (, Moreland L)73.9 (W)91.8 (, Buatti M,)]TJ
2.175 -1.25 Td
[(W)79.9 (anke L. Health-related quality of life and functional status of)]TJ
T*
(patients with rheumatoid arthritis randomly assigned to receive)Tj
T*
[(etanercept or placebo. Clin )17.7 (Ther 2000;22:128-39.)]TJ
-2.175 -1.25 Td
[(33.)-875.1 (T)69.9 (ack BB. Dimensions and correlates of fatigue in older adults with)]TJ
2.175 -1.25 Td
(rheumatoid arthritis [dissertation]. San Francisco: University of)Tj
T*
(California; 1991.)Tj
-2.175 -1.25 Td
[(34.)-875.1 (Bormann J, Shively M, Smith )17.7 (TL, Gif)17.7 (ford )54.8 (AL. Measurement of)]TJ
2.175 -1.25 Td
[(fatigue in HIV)91.7 (-positive adults: Reliability and validity of the Global)]TJ
T*
[(Fatigue Index. J )54.8 (Assoc Nurses )54.8 (AIDS Care 2001;12:75-83.)]TJ
-2.175 -1.25 Td
[(35.)-875.1 (Schwartz CE, Coulthard-Morris L, Zeng Q. Psychosocial correlates)]TJ
2.175 -1.25 Td
[(of fatigue in multiple sclerosis. )54.8 (Arch Phys Med Rehabil)]TJ
0 Tc 0 Tw T*
(1996;77:165-70.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(36.)-875.1 (Meek PM, Nail LM, Barsevick )54.8 (A, et al. Psychometric testing of)]TJ
2.175 -1.25 Td
(fatigue instruments for use with cancer patients. Nurs Res)Tj
0 Tc 0 Tw T*
(2000;49:181-90.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(37.)-875.1 (Guyatt G, )17.7 (W)79.9 (alter S, Norman G. Measuring change over time:)]TJ
2.175 -1.25 Td
(Assessing the usefulness of evaluative instruments. J Chron Dis)Tj
0 Tc 0 Tw T*
(1987;40:171-87.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(38.)-875.1 (W)59.9 (yrwich KW)91.7 (, Nienaber NA, )17.7 (T)35 (ierney )17.7 (WM, )17.7 (W)79.9 (olinsky FD. Linking)]TJ
2.175 -1.25 Td
(clinical relevance and statistical significance in evaluating )Tj
T*
(intra-individual changes in health-related quality of life. Med Care)Tj
0 Tc 0 Tw T*
(1999;37:469-78.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(39.)-875.1 (W)59.9 (yrwich K, )17.7 (T)35 (ierney )17.7 (W)91.9 (,)-0.1 ( )17.7 (W)79.9 (olinsky F)79.7 (. Further evidence supporting a)]TJ
2.175 -1.25 Td
(SEM-based criterion for identifying meaningful intra-individual)Tj
T*
(changes in health-related quality of life. J Clin Epidemiol)Tj
0 Tc 0 Tw T*
(1999;52:861-73.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(40.)-875.1 (Cohen J. )54.8 (A)-220.1 (coef)17.7 (ficient of agreement for nominal scales. Educ)]TJ
2.175 -1.25 Td
(Psychol Meas 1960;10:37-46.)Tj
-2.175 -1.25 Td
[(41.)-875.1 (Cohen J. Statistical power analysis for the behavioral sciences. 2nd)]TJ
2.175 -1.25 Td
[(ed. Hillsdale, NJ: Lawrence Earlbaum )54.8 (Associates; 1988.)]TJ
-2.175 -1.25 Td
[(42.)-875.1 (W)59.9 (yrwich KW)91.7 (, )17.7 (W)79.9 (olinsky FD. Identifying meaningful )]TJ
2.175 -1.25 Td
(intra-individual change standards for health-related quality of life)Tj
T*
(measures. J Eval Clin Pract 2000;6:39-49.)Tj
-2.175 -1.25 Td
[(43.)-875.1 (T)35 (ugwell P)110.7 (, Boers M, for the OMERACT)-257.3 (Committee. Developing)]TJ
2.175 -1.25 Td
[(consensus on preliminary core ef)17.7 (ficacy endpoints for rheumatoid)]TJ
T*
(arthritis clinical trials. J Rheumatol 1993;20:555-6.)Tj
-2.175 -1.25 Td
[(44.)-875.1 (Portenoy RK, Itri LM. Cancer)19.7 (-related fatigue: Guidelines for )]TJ
2.175 -1.25 Td
(evaluation and management. Oncologist 1999;4:1-10.)Tj
-2.175 -1.25 Td
[(45.)-875.1 (Mock )17.7 (V)128.9 (,)-0.1 ( )54.8 (Atkinson )54.8 (A, Barsevick )54.8 (A, et al. National Comprehensive)]TJ
2.175 -1.25 Td
[(Cancer Network practice guidelines for cancer)19.7 (-related fatigue.)]TJ
0 Tc T*
(Oncology Huntingt 2000;14:151-61.)Tj
-0.00011 Tc -2.175 -1.25 Td
[(46.)-875.1 (Flowers N, )17.7 (W)79.9 (olfe F)79.7 (.)-0.1 ( )17.7 (What do rheumatologists do in their practices?)]TJ
2.175 -1.25 Td
[([abstract]. )54.8 (Arthritis Rheum 1998;41 Suppl:S337.)]TJ
-2.175 -1.25 Td
[(47.)-875.1 (W)79.9 (olfe F)79.7 (, Pincus )17.7 (T)74 (. Listening to the patient: )54.8 (A)-220.1 (practical guide to )]TJ
2.175 -1.25 Td
[(self-report questionnaires in clinical care. )54.8 (Arthritis Rheum)]TJ
0 Tc 0 Tw T*
(1999;42:1797-808.)Tj
ET
0 0 0 1 K
53.468 76.5 m
558.468 76.5 l
S
0 0 0 0 k
494.29 69.365 64.178 -15.665 re
f*
BT
0 0 0 1 k
/T1_1 1 Tf
8 0 0 8 545.468 56.4344 Tm
(819)Tj
ET
0 0 0 0 k
53.532 70.501 203 -16.591 re
f*
BT
0 0 0 1 k
/T1_1 1 Tf
-0.00011 Tc 0.02499 Tw 8 0 0 8 54.532 56.6447 Tm
[(Cella, et al: F)128.8 (ACIT)-257.3 (scale in RA)]TJ
ET
0 0 0 0 k
/GS0 gs
103.631 82.583 407.5 -10.833 re
f*
0.5 w 
/GS1 gs
103.631 82.583 407.5 -10.833 re
S
Q
Q
q
0 0 612 792 re
W n
BT
0 g
/GS2 gs
/T1_2 8 Tf
108.828 74 Td
(Personal non-commercial use only.  The Journal of Rheumatology Copyright\ \251 2005.  All rights reserved.)Tj
ET
Q
BT
0 g
/GS2 gs
/T1_3 1 Tf
10 0 0 10 540 17 Tm
( )Tj
0 0.48627 0.77255 rg
/GS2 gs
-7.22298 0 Td
(www.jrheum.org)Tj
0 g
/GS2 gs
-18.00796 0 Td
(Downloaded on December 3, 2023 from )Tj
ET

endstream
endobj
62 0 obj
<</BitsPerComponent 8/ColorSpace 66 0 R/Filter[/ASCII85Decode/FlateDecode]/Height 99/Length 869/Width 76>>stream
8;Z\6>>iC)#itt$j>rTrd#SKsc,Q:r/!O5?&fscr,kJ9jA[0qA^[q-+s+1d9-[4D&
l`&M).BW^+4so8HM>9DS6.7Rn$COu1^b4PVQ$#XFF_b9&LlagjECY0Gl8/GE8Oa]k
$Bk2%M!;;g'=EeD0!ufg"E++^JA]1K.K$HG<=m+$KI'9QOSDCQiIbSSa[%[TNN0r*
4/3f5[SbuhrI%Kq>,;No=-jO2lidRnmbg$05\P-O!"6aPA//e#>$Ipa4_AG,<BYOK
j`d+ROQ+Ff:6B2#][\4kP!(cm3oa6r%\]G49VrIYC#OV.M(Qn6E7\QrJmJPW?Bp-Q
i=DSfZBFB]G@(:XSi.?Q7hhOnXJp2nU'Q.&AN]=BeHD(FfCCa4F$-8:s.m]=)G4c9
6\X0f>_CE=6;_bliC\Cd5lXE_YgIS'(GuG.i37:LS?SX`>&)P#\b,$7N?k..U;F$m
Qh`u$P.47d#ITE\aV[7u8!8B>,7=`#H\qbU1FRpj$^_$-W!_s":.F.DTfFVC2%f0R
TIEEphq7dV:>!)t*^^E2#e6rmPsKuQcHtfQ*27#X]',.oPEGV_fMV-T/LHR5e_>ub
gk#RoUett1eb-!AA[C3rOkY$m,k,p(Vh8\&V70Z`q51AAl3$qe1F6-r<Y&RW4?0CQ
7HIlj62]ie8Cg\#:`q*iT^nX`0N./im*q=BOf,oMPmpB-50TZmC7i-?ZMV)"95T9E
eueBd+E_`GJJX(Ah60p=SC>&IO=e$*\m]P88n#sF1.$K?0nM(fq(dQr%D%X<8g,<"
/c6Mg1iHisg#NkLr0rs`qDO(TZ[tQ*0rt/U`u]SDJ]/(f7_,(=<F'X_DS.&R1AoeK
IKff)Z2*;~>
endstream
endobj
66 0 obj
[/Indexed/DeviceRGB 255 65 0 R]
endobj
65 0 obj
<</Filter[/ASCII85Decode/LZWDecode]/Length 481>>stream
J,g]g+e/h_!_gCtO=0f)$P%cIi8Zdfc5&3j_8$7g.@L`YKUJNGBP\poR=_;Dl'P(T
(7Boo^^S:71(MN]ZQX/+Cbu.lK"p74pe1T%s.DY%&\1TdJhr54.M9au6>79n6`Q:4
PbLSZTLEE(8E@'*1mg_*eTnN*;*'V3+gm-EEetX%;Bo$ur2ss*N`.-!.kG_q6GDD'
dKoL!8Ka#EV,@V!\j8ZFbp6EE<9cn=N6j<M8Q?[#7"dq'1>0nf;(&;QU6bUD')c@\
9-d\DA=cZ0Q>gIM$$;cd2O@&a;X,Nn_a<?V-PVE%?Sf]idH6WRZqHGq]Zm<uCi"]?
Stg(<gV-H9NB<SA\T=sN)Il%(BDIak7/H&mV!kmDUo4X;8;]V>P(]I1aRc(K1^ue>
gF/(+GaKo$qneLWDrQ#;5\S(\$q'4Q,85`-8;S(=Z"WSBOV*FM)4,?B],R<gbPN=#
OmIK<a:\o8+ioO-!W~>
endstream
endobj
97 0 obj
<</BaseFont/PMJHBA+Times-Roman/Encoding/MacRomanEncoding/FirstChar 32/FontDescriptor 96 0 R/LastChar 240/Subtype/Type1/Type/Font/Widths[250 333 408 500 500 833 778 180 333 333 500 564 250 333 250 278 500 500 500 500 500 500 500 500 500 500 278 278 564 564 564 444 921 722 667 667 722 611 556 722 722 333 389 722 611 889 722 722 556 722 667 556 611 722 722 944 722 722 611 333 278 333 469 500 333 444 500 444 500 444 333 500 500 278 278 500 278 778 500 500 500 500 333 389 278 500 500 722 500 500 444 480 200 480 541 250 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 500 0 500 500 0 0 0 0 0 760 980 0 0 250 0 0 250 564 250 250 0 500 250 250 250 250 250 0 0 250 0 0 0 0 0 250 0 250 250 0 0 0 250 0 0 0 0 0 500 1000 444 444 0 333 0 250 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 250]>>
endobj
85 0 obj
<</BaseFont/PMJGIJ+Times-Italic/Encoding/WinAnsiEncoding/FirstChar 32/FontDescriptor 86 0 R/LastChar 181/Subtype/Type1/Type/Font/Widths[250 333 420 500 500 833 778 214 333 333 500 675 250 333 250 278 500 500 500 500 500 500 500 500 500 500 333 333 675 675 675 500 920 611 611 667 722 611 611 722 722 333 444 667 556 833 667 722 611 722 611 500 556 722 611 833 611 556 556 389 278 389 422 500 333 500 500 444 500 444 278 500 500 278 278 444 278 722 500 500 500 500 389 389 278 500 444 667 444 444 389 400 275 400 541 250 250 250 250 250 250 250 250 250 250 250 250 250 250 250 250 250 250 250 250 250 250 250 250 250 250 250 250 250 250 250 250 250 250 250 500 500 250 250 250 250 250 760 250 250 250 250 250 250 250 675 250 250 250 500]>>
endobj
121 0 obj
<</BaseFont/Helvetica-Bold/Encoding/MacRomanEncoding/Subtype/Type1/Type/Font>>
endobj
145 0 obj
<</BaseFont/Helvetica/Encoding/WinAnsiEncoding/Subtype/Type1/Type/Font>>
endobj
86 0 obj
<</Ascent 699/CapHeight 653/CharSet(/three/o/A/parenleft/R/p/four/S/parenright/at/q/five/U/a/r/space/six/b/C/K/s/N/seven/c/D/comma/T/t/eight/e/G/hyphen/u/d/Y/F/f/I/nine/v/E/colon/h/period/J/w/P/i/semicolon/L/y/x/zero/M/n/one/H/k/O/two/m/l/g)/Descent -205/Flags 98/FontBBox[-169 -217 1010 883]/FontFile3 112 0 R/FontName/PMJGIJ+Times-Italic/ItalicAngle -15.5/StemV 76/Type/FontDescriptor/XHeight 441>>
endobj
112 0 obj
<</Filter/FlateDecode/Length 6444/Subtype/Type1C>>stream
H‰tTyPgïfèA`Ài¤‡t·Š‰(–Áˆ‰»*Š‚‚ŠxD.9f˜Aä#.ŠˆŠB,‚ŠfW‹D# ¸x®Êj6î–Q“¸yMU»ÙRµ[]õê«ïëwıŞûıHÂŞ IrÂšàåAÁï…ë“ãÍ>Aiº$}ìØıG’–<Ié;‰WHîöüğæh';IprÃ…˜üKñ/JŠ¯'ÿmµşj”ĞáãÏ{j£4E’ªšÆæ._ß9³|}?03MúmÛÓÄ±Şâÿù~3Çìo­ÿ˜õ÷ÇbâÅu™æ´ød³”k0&]Z|Ü,Q\œ”$†E0‹añæxSº|û¶bQoubšIŸ¬3%Š†q•>Å–iŒ/u)q³&Q/û™wÆ˜õqzIoş¯ï¯İ¾=ÿ¦}‚”?Â$œíˆñÄ$’ğr&æ*ˆ±DE¬R‹dèAD>ÑD\&†ÉwÉ]ä;?;‹]b"QñÒ~ƒı!ûaª–¦èhúª2L9¨Z¥ºéàæ°İÆp\êxÀIí´ßYë¼Ã¹_=O}ŞÅÇe—«Æ5Ñõùø:ÍM£a¢'0öO¸ÃêØoÜ|İªÜĞ=ÇıéÄ|éu¢ZT›G&g´eh:˜­0Øp±>íãzƒçY°ç™únğüòr÷%³5·†Â`œ½}ÑŸ[iÅi/q>/˜“A‚q@q
W°0ÁÀZÜŒ0! ø]Å”-¼a†ÈÍµ Sªù(t_½E¥‘…,òÖuE%²lÏÉÛ½}Ü¦Sú]±>W¦çÂ2råŞK^„´Ág,èœUiµ˜
²Š¿æ±ND}ÛáöÓ©¶äd“)1¾ÕR/¨O(O’Í÷áê}(À—}1(	à=lšŒ~x¹Äğ:Pñ’4°ßa&z €0¦ôxı'ì†Í¼ÚZ#ı\İ‘¡¹£LûE7h®¡?.Ûöéi®¶º½ò(S¤Zª¶²òh¶ …ä‚Hy­ì)§œ²&”ä”æ	ÈæåFÅ–®)òP[ïHÇo“’İ°Bòİ–e1i1¬’†p§À\Oœëã†Ö}7É„î%è»¯/¤NêøV{÷üê%kQDo0ÊP^‚‰”º°CzÕ©{Œc@ teÖ´]èÕv\4¯@…èé9Â^Å<y±ÿiŠj|ôz~İ«[´	ù™éQWr¾†¿Ãd)»À¦Ô*áS%3ğæóKmw¸G‹ÃE¯6ÉP@Ñª^iy†f¯dbŒĞE,n¯ ¡nQôbgÒà,-§bèQ¿Ñ€ŒÔĞLûf¤îÓŒñ<,¥^ÑêÂN©ç	?(`ô¼tÃ-
ĞS0…ÊV‚ÊôãNôáŞ_‚
o~½éJ”vWúîC“a6ş³`psÑÍ&Ø&yÎjJ>æZMÓ¨{Æ´I‡G–°øÕ.Á
ŒápşËáwaák©ƒÉÓ:—óL›%û“’léË.Í)Î),)Ÿxü¨a!,mP1mx«Ø;şsÖã"¤½­`o«={€ÔÕéÒ÷·ój†¤f€i—ZG¼Ø¢ƒ30êH/@ÏC{¨³­ÍƒZ0Ñå¥£ŠÑR7å~h4MıgïÏĞ®~æMÌa“ë‘¹	¸Ï†ïÅ^[4$0o®òÌìh	òy³×F[äµ`Ş\ˆ¿ß„S¹şRp¹bûLv|1ıDj0÷ŞBİzyã·áê}ÆIÙ¾®ëmó×ÂSù™ÃÖÓ6N]‘eç¤Kj›fà)T1²X¸|FŞòˆâ`Æ‡ñBtAW|‡g¢ãOººêlgùŠOò¶¢'~ŒÁIÀI³Ùçİ0¨—V$âŒ–©¦8~«a]V’vzÉ›fAm–I	Y Ğ\…|d0õÿzKÏÖÚæÔ)I¦Ô$™ÇfÍKøÇ[ŞÊ¦IÉ&ó¸Öl™·fx$ûÿpİ"»×Ÿ‘µùÓÿW¦^ŞöĞÿGºšù98´$vÂÉ.ĞÖÀ¸GàtKw–y,õI,óGsC—ê´ÛÇ¿§§ƒİóøTõNp¸‡mÈÍ;©Eüh™ ÿIõç5îå¿ª<w¡ê°ªœfï.kX{Cãú@û>Ä)0Wâ&Y>¼P@á¨ºÛßØÔ+ì>E¥†mLŸ«ÅÅ¨”5e¤Ê3TÁLş	½‘ò‹@•tewM…ğTR´ö[k!áŒôn¹IB…t­–][Yô‡İ7}¤Ş‰©4~1ZêâÒø=X]«ÜR‘[iãí«>ÔÈ÷ 5¦GÑ*Ï±æ”q±©EKx”)G= †o¨¢Êé2º«(5ôf“^!o€½yD1"Jñl;DPét~qÑî”´ĞãZÌÄe˜Šë1¦-“ëöìMW»uˆŠŒX¶)-:†?w˜şC$L9€œ¡\FŸ´6Iß6Yj5Ò°<H™+à62ı²ÄV¬ç2
’JóxtÍ
É.İ<ÖÆ>%\ ?(AÖğÃ,OÓ°r{¨¢¢¦GËZÑeZè¼†ı‘æ}-µÕ]Z„1¬Z »ªZÆRİ¯g¨G&±£E4s×¢K·Ë+ˆ-ÍÿM:©Bùg˜÷º«5¨©3Æ“°Û­g£pÒ=g­Şª»ºµÚU»êÔq-­J‰ ^ ‘†!rIÈ…ÜNá$ÜA	7QŠŠŠ·a©µUK—U¼·vİZ;ïI¿ìÎ~g§û£¿Ï7ßû<ïû>Ï÷­‡˜ñAÒN+İ“ä8Rîôõƒ–…F«5Òšµ¦|ºÚxò5Î¢Übu±.27£¤-°„“O@GT»ì.,ôuå,=Sc!FÇv¹í”Ç>r0‚bÔ
Ïšê-)”Æğ©I7‚C½×"ÓcÚ,'ÚeO¶wRûå®Zú2ä¥U–©×oNTfã5~{5ì–y+Zb-^çŞï¸"…m{×è,ºRİ >LÓí´˜TÏÂ>ÇG>Á(dYòY¾“ĞéT;ö|Ôò®¥£XÓš¤&´¼7Övö3=°ÖÛÈÙëŒäP•VtÎxĞœIiSÑŠL­È”Ê¤èıİ0áXô=XaË—ÏÓÑä2ÆgÆÌ¯‡Z.Là¦¬Za—ñ9ÒsJTô´ˆ@Âsç8Å¶:p‘­è´éŞ‡Ñÿ·¥œ(Îé8pa ÌĞ!üj¢SL[Jğ·NË¦:*/AŸá½ÂÙ{ÊÂÅ9V.†ğo
ô“ÀÌ	“X¹£™:ÈV»ğ#=_;z×µjE¿Dö‹ºâaÍ‘ÀX.¬ä‰€/‘pk…İ¦f|T¥ÏÂû€&wª’â]»¤ò¢ŠzfŸ­ÌEÕçÖîÉÌSdÄôe÷Âä£?şÔD¿àE¾şö3H,±Q\î@¢ ºS®7ºÌy”ü¯Ñ«h4-ªÄvÖùN³ş_kËšË'¡¶Ø8Ñ'.µ½ƒª`ËËšé>Èò”‚ÅåÊ†9•«´Ä–`±7r¢u®"[VZ" ”n¶µÁÏb8	Ö6şûP›úüôœ­ğ×¦À»D—`•ÊE ¨Õ1£qÒõ­'ö3e¡v¾£˜Ï%¨ùy¼ ğïĞ‹…è^PG˜…yVcº¥UyJª¸0£p;=%ÂU†­L'í¶ï`;)·ó [Eƒˆ_ŒsD_ĞOx…|8špÜ¦‹SäE¿šüzVeo§ªÙ*WÍ«©–Û{ËFû\¤ü›¨
íİ!$	¸¶©²h•gPcéE_Ç¨Ğ6^O Zá)sÖ›‚^.ˆHA“
‹6êÃG eÚ·9:)İçn ±1¾ƒ!á°£#|B˜Æ[[`[qµ"2$8?ÿXßK~ùKA`-¿XKĞØ[èu´
©Q&¶Íõ@m¼
¶ĞÁ#È(IÏáÄÛ¶òOH<İG‰h’¦ÖÑ£r¼ZF|³ôEH½…mó¸±ÉœBéŠ¶4úmpéÿüÃ’‰ÖŞBy­ÖòÏè^ˆ%ŒµæëRØ|Ä7ò	ÌF‹m‰4²	áƒ%åNwX
c'/Gï¡HëŠ½v‡Š­Üß•#•U/ÉA¾Ÿ“ÄÚµ­{[ç‚%¦:wı6ÓĞ2k*¾L+<YrĞ²ƒ*(N{åä¼¢²ĞŠš±:İ:¼¢«³¼›¾ ;¯a<$`†|‚Êqâó¹ûº¥/+,KYŠ¦eëmÎF¬iåƒş‰^ç»|Ş®ò‘wÈ!>O“tâ'I!ÔëRUË­f\š×VéÜ%›õ![4šÎwüiíÑÔ¦´÷æÌÛpûÇÆÚ<´ÊNÁ](Oî€Ó]İØr&õ)D^ÿñé€òè3ïÜ-8x’úüŒÿ<MÁ8Ç[ëmLH#ÿÏÖ0ş«
A`\ÈÂ›„Éh®ÏDÀøK§­0IŠ¦ë5«“L[M˜p'ZÆæÛQÎJO#o$Îov)ßÒ2ŞQ[>ÆÿÌ…ığPp½ÚÊ³ß”Hi¡}•³-^ÖüàÜS¸vàãhsŸdÃGÌà’±Ú’ºiê¢€9_Ş‡È£ôt´ÁçşşŠ]¨ğş¬àŞ˜³zO)·~ÕFÄ 4õê¦Í!¨Ç9ÑJVmk§šj®pçè¦AÔ5wî÷:€çcü`}–l*MEó·n s'Aä!ª¹Á~ÂIsH/ö$œáÅµ½ÿ Ù£—<Fªù0F’¸U%Ï—êK\î#á©£œ18òXŒÁl.J$,ÂFszCShZ‹¦g:æ?gÈî¾ŞÃ bì‚TkcŒ¹
*ÏºçxWKÛÍ>š<|­Lòğ!dÃošÕ	3g¢Œ)Ùé¾^Z\XÇOè­^Ÿjbİ=h¾K>ã# O²ğm”Š~¿ÙÚà~ùN"c®ì‹ÍÀ	H.•º
JW,7dÑèÍ …0‰r3za,†å0ÿFü©•óÖÌK§-6‚¼ÓÄ	ˆ©ı»‘ ŸÅÉ›JÂÅÃ…m<SvøÈ‡ğâ'ÉöÔÍÛÖJc>íüîX	“|ÕÆ|&/¿d¥¨ÔÕ××úÈO/D3)OA‘Cò«//İj®§Å{{e§ø7êF	TÃG_*É\XØ.‰±^ô>ú2`ìIk¢M˜‰Ö¿Í­Ğ{S’¬R¨¤Ezw%‡¯Şï‚Œ‘%È\Y¡Ì 3†ç‰Îr4ÈõYtú³ÅBÔšş8œ¡÷q0W³zˆ!•§/xaÌW#-ïÒ§™
Jé‘õ_=ùyIvó¿«;2ê§¬äAûµÁsÒú}j¥Şˆ=m[293$Û6%ïŠ•&ÇÕ]«f«Ù¦ÑIÀ»uOïÜ¦>Ë8(Ãlç£%hêšæ¥/Ÿ?zÌí§ÅKĞöşv3¨kÃşKu¹F5•]q\Š‰±Ö¸š3±p¯ŞëtU]­ÔaAgÆQ—TKä!>ÂC^y'B!áò„„7ğR AQèŒ#£KåYÔ±«ËvV§ç¶ÇN{Ò®ùĞu¿İ»ÖıïÿŞûüö>hë<óŞR`?³‰ÿœú&Œõiiâ%‹5õõ´Ù¤o$Úó¬ÊJêB…>µœ8];\ÔCÂÕÓx3ävÑàC`×zXhûš©zDZÊJiU‰^H¨js=­M.—Kî;ˆxñ(üı<*„ÍEç[à³f{ÙÖÂ«Ÿê]„Ûo
–Àcğ“ÅlãG²5j“IFƒÇ&i¾é<8'ĞÊÃŞ‚9Qx6'‹Ø‹-jjwŒ@EÄ\†pãâ­¯)ÌœùuÂÚÒi£¬¶2+	şõì/f]å.­“¾ÊÑÖ7‰üø„ä
´¢úe«¾s¸Ÿ2û:kÉúWiê&Ú©%àQ'sŒ¿="YÖëûjô¯#öœŠ«¾"1Ä5˜doóàğ’qä/“
WóS²Ädii…²æehê'îœ®îÜŒvÄgQ|	<êoü¸âXuœ–#_ÕQÅê­¬/*&ò(Õ9
á30Çî…<û”ï.§Ëõ²®’k	Nƒ·(å¹V‰gÆûÅä .ê
³ÂÑ.†à{ŞÄœ÷˜€ùÍ?q>G\Lª5õuËPµ~çÊı¬MÑ„ÉS+°èT½ND_ü U%Rı™+Ó£SŸ_¦À[nFƒok-²^AA¡$=½UÖŞëèqù›oR,b~ë€éìØÆDƒB0Á¼øñ9%R!™'ƒûÒ‚ÜKİLÆ£òU]zIzk{ÌYû^ÃÄû}ÆÇıè{DŸGT…ûÕğ!šcÃ##L¦†ìK¡–BÎñî¦ÂrÔ=øàz™¿ùÕ‡À=(ëøÇDóI…ŞV‹	i0Ñà5ÜÎÌûEîı¿ˆm~ã«3F¿¸<¾pÂĞÿo	ƒ'“<ø÷…'ó†%  ıÿ8„+˜”š—)!‹Ë4Ø–as1TØy!bO(âÂdÙ†ZÛˆQkêî_¡„lün&ùó›«Š-9Y‚u'ìØX8ê—GĞsìAÈuÍİä ÁPçüki²ês%‡QeŞ;ø£²oÏs&z<&-¦R¦ŠøCäÉ%”úô‘é«Ó×¨š:ÖMçxh®r¤7sÖoZ~¦˜¬Pì4HéşÔ{‰‘Â¶Óa!ˆŞŸ„cû¦úc;uRuò±İhP)DGPQbaıa¸Áê»Ç)Ó·Ÿ“ÎZ¥”îO÷£ò"Ç=v£ì««ìÍÌæ€Î'°ãI œe~ÏG[0@w¡­a¾Èï1­7Â¸n&ëâĞ¼åLÜ&LÄÏø#üé˜WÒ\tÎ?q2„W/æ}gƒöçx<¬ƒ3|´f'ŠDÜü|sÇå!¸¡ıKênÇgcWÈ;U'ri4ÿœßZÅj­rK	Ñæ7œ\´’Ê,ÕæÆ’rxÎ¾*/UïquÁŸ˜úèâV—®ÄmøÜCdşnxÔôÜ/Yæê2C9	–QˆÅE©MğÈufmK@ûSØbdHÍÏ©Œ©´ŒÀ0f6è [éê"?§×c£Qhã'Qß|¶¼p3zº¤LÎ/‹ñní*ÔùƒŸ?¼ìq‹’·¡(ã—é¢LnO³¾|ı»;)	·àÚõÃ0Øæ»ô€Üöú›0°‡·Ú¼¤y@?Ù—o/<¶­Ğ¥â
ÃLô—Ïš¬9^tJƒ‡‰Ál6šÉ¹R­Í(I£÷ ‹ëÁåùu+<›ïp€×p_ŒBY¶¹¶ºÁæ’t“Ó/Ûa ı5â~s›˜ğ˜Z(ÀÜi;UC;Ø.H³”ìR¶D–-nL&ßVîÍÂçé#¸f{!'Fï‘;ªñãfşÓ0-p‚ù˜¿—İõ¡¾Â¤©VÊÔeº‹é‰É™L}Q£U—ëôº*-g–}u±Êä’H‘İUâš¼<Š`Q+3?=ILªtõ&£ŞPeÄzÊzÂæª®Ÿº°5‰İbŞÈ"üpA,swú™ô‹éRUi®±[Gk]ôœdíg§lKØÏÆ¸Œc¿9KŠÊ›­Fúü·?kıñÅñj¼"(W;õ9tî>Ts†8ãT<Ÿ…?‡¬»”‘"ÃÅ»¥„Âæ»ÚÑñâ6¦QÄ„[Û1Ú7Ü‡\>À43[ù³u¹c'§á„½oCE&{“ëş|½ıp<ü-1XĞ!Ë•
êäˆ9…ˆß‹ÖD§²25p£öQ6
nÖUV–º¥ê Şcoc™=ÖVq3Z{Ù1Á²¹ª¼†­åã`SŒi—ñHuhR/°ÚëšáÇ¯(ßRÛH“‡c`»Ñ=–¼J¯4“f«s|ˆc7`Œû3á–w¦å¨¥2JàÕ] â>z'P 7"–¡R_£!µåeºrE£)Üâ ±©n”¾¦n””´¤:R^EcâOÅ,À©‡ÑÓiƒ¼\&˜˜-0Ÿ+N‘bM»£ŒÖ¶gÀM„ş.\ë¦@{K¬lkp6ÑÀÔ&´Hâ’"Ãã(Õë™T¡’™ê\TU+Xõ›ÑDvV+³Lt•®«	ô‹y2ÄH¥N!),–Êñ_
’Ş‹ÙÙHõÜŸéF?ŠµÚ•n²Õ­‡ìû8Jt~*æ1Ófmó˜õÿ— hÿ³˜¸šø$—’ŒšÄ˜`0¦œUµûCepaZrnci~‚{Xy~§mvzzv˜a¶ˆ“÷÷¬øf÷¯w¥fq€v}]Á–bV<û`Ew÷~ÖP÷G~Šy={ƒ[yù!œû†˜÷’÷ üt}™øV•÷^™ûnŒøs“÷‹	×øˆ÷ù ™}uå
endstream
endobj
96 0 obj
<</Ascent 699/CapHeight 662/CharSet(/trademark/c/O/quoteright/eight/e/Q/parenleft/R/f/nine/K/n/colon/S/parenright/h/x/semicolon/U/i/endash/asterisk/F/N/V/j/less/l/dagger/plus/k/equal/W/comma/P/m/greater/hyphen/o/Y/question/period/p/H/Z/slash/q/bracketleft/T/B/space/r/zero/C/g/d/s/one/D/brac\
ketright/two/t/G/three/u/quotedblright/I/a/four/v/quotedblleft/J/five/w/A/L/percent/emdash/six/y/b/E/M/seven/z)/Descent -217/Flags 34/FontBBox[-168 -218 1000 898]/FontFile3 113 0 R/FontName/PMJHBA+Times-Roman/ItalicAngle 0/StemV 84/Type/FontDescriptor/XHeight 450>>
endobj
113 0 obj
<</Filter/FlateDecode/Length 7556/Subtype/Type1C>>stream
H‰|T	PWîA„Q¦i„éM4QÁ[-F—Kq‚GŒ0\3Ìà "‡0rd E• ‡0
¢¸h"‰JLtUÆ‹eALD³ÙÒJ©[îß“G*ÛèV%[emu½ÿ½~õ¾¯şÿ{ïÿpL(Àp§B6¬\£tOLQëlÔ¤¨R'·—s2Œ›‰s®%8!'·sB>(õçİ?;‘l#ş«Éô6Ú‰¡}XzgÎ¢¥‰ã6õ­'z<<-ôğX±V£ÍÒ%Æ'¤+şó¡b‘çÊeó'ãŠ7Ñs2zz(”±šhµ",KŸ®NÑ+‚Rc4:­F§JWÇ.T(”ÉÉŠ“zÅFµ^­3ğ»oRU$ê*EºN«NQév(4qŠàÄTMz–V­P(T©±î"‘ÇéwFëcUºDµş¿Ø7e¾Yş¾lç?L„a6ÎØl'ÌK€­Æ°5.X"†ip,ÃJ1¬Ã"yİ0#±Ë¸ ÷ÄµÁr^P$hôS	%±Ÿà„Ë…µB ç’'Dö¢"³è–è…X*.¿°Ùc3:eÍ”¯lİlÛ§RS§VØM±·ûÚş=ûtû1É6Éğ´5Ó*§½œî7ıƒ—Ãn‡‡~i¤ô%¡öSĞIßsZæÔ7›ÑâL9ovt	p9Î¸1Ì¨ÌKvsæŸf^u%\s\+XœÍdMòy
‰BÂiMf¨é<|ZšÍÒ¿®¥ÒZ©óùV7NL#Á{Èq–¿9`ìG`¯ÖTÅËkwĞgÍñ[–û!ùÒõ¦+ŸõôAØs¹
~¤cE);¢Õ+d‘YuµÙrê×üºìœÚm2d;¹~0w ás ‡Áı_r¿±¤º¸İ[_SÜ-ëk«¯m’——¢—¿È^ÛOèØô†¯Ş‡ù–†Üììòı™ù»$ôF¶Ş¬DÏùA1Â “€<¶›
¡_s~´f®şŞryZ›®KÚÓµ§µª²¬¬‚-ÛWQV.«ª**ÈÌş$H%—è­+3ğŞÇôZWÒÈİİÍC¾b;Ö~¹–=fñû6¹æ°3Z¸	4/¨zvğ*û[gîOŸò²ø2À&l`ÕW‚î†ÈËv†Õ7!ÍU¹­R†°8Ê¹O0†G£eHïÀ¯(¬ÚEïpŸtşCkSåşÓlK›Ét±³Ìè|ğÏñÉŒîhÎ‘–º¦Ö¬©ı‰©W•i×›VŸ—5©i¾ê›ìuQ^XI¾ê¿¦ºÉ´éäÅ¥Ä­cÅd«øÒñŞãLmakš1ÅËnoÉõbrÅç—õ}"ÓîÕC»%?d$W„zu3ˆi4€Ö‚C¹…€rè¦‘&4Hk-h,HÚ ‘D±°•)xtSQÑ,šjüÿrSQ¿>ºwÃ§D7TÓÁğé±D‘~òyO9}"­5%E§Û¡îÌn”K|ªVÿ¼ ¾$à,O"”õ‹?y[$ÉiµJ[ñægPûŒ€
+Kƒc9ÚàSŠŒÈ9–BÁw·Ëa8Ê[…(X…2-²ïAéÁ=ö`«‚,—˜ê­òWšÈ?['h¯ùfê•sÏÅ…å(ĞƒÌ»b2ÕÈ:MiùÄf±2®4´”•˜†¸¦AÆœ\éÜJ286³$N†
Eà$Ï_{Í€pÑm%¶"·¶±ˆì;f“m‹û&ß¨EKÊ‘?
%ó8F,ÉéâÆ®IáŞˆz€ºà!}§¼¥¨+ÓæfRRÇøFû,dCÔW¶É²ÓšÈŠšaØıfƒóòSª£rê‘åÜñs}Ì_´ÿDtàâd4#†­/&Ûê{îÉ»>Úäî»Õ#•/²×ßäB3¤5gÁxŸÊä’!›Ã…n¡[¡äzèSŸ#ïa1•	Ş/Å(ğ&Œ"(€q²œı4÷ÍÜ]‚¸4l:h:X!?ó¤ ŠÜ_Ÿ&CjÂÑÒXR±w¿°bğû-eD¶Ğ^_/‹1¥î‰¿ Å x.OòÛ£.ÉCñ®³‘ä´qÂ/Àxï‡}?ÜF«/Š
Ñj´mgPÜËù`ş]°äoÀ¬šfÈK
g@òÈÀ¿ÍE£núµùƒ÷¹-2Ø7p|®U7WWË›[ºtÊ$µn|ÿŒS\„u=!eozÿH!y©ãh{¿RDhËÄ8Ù/‚ël’ÏÆ*i“^òÍğ!j Ÿ¦€Ø³'EÉø}¬
öÚÖ?ÌRãc½İ'[Yä¼èUO˜Îò‡¼:@xé–á[Ä<“SÃ}íz2C,ˆ\67b®×ÙÄQ%\¼”¡†psèŞ“—ÿ>|*"|IXœZÇÆ7-şæ>#i0@á9NØ†›Ÿ‚ñ9qu'U‡a.l„¼İ€DÓ“7Â‹çÈ˜¯.=}-/İ«ç}QŒ\+U’—»‡İePe%Éfí„)Cß7‚‹	E†ğ]Æ·!”!ıˆTÌ„ïêFª!á;»ô-À«·yİ”öß“æĞŞQ3Ò—©1äo-	3çüsHøÍ(3\Ò; bjxWIp×è‰UÁñƒ¼-¨D»ÈbnrânæÊîçDO”qe"Äß.~£i»Fğ(ØE^ç9ø‰ÿ[…"HÉ…ÿa»Ú£¢8¯¸ëº3xÒ<tº<f{f¬(¦jğHÁÑª1"©øÌ1>#È«°,³À²dawY^Êc—ex,Èû%‹à4¥¦L‰Dã3&ÚœšTkİ@sgómÚ~Ãš&=é™ÿæÌ÷»÷÷İßıİ;Â™æ™£ƒW`ÊFë­‡ÔSê1äA Ü|¿¡ç÷#ÍıWéYu	mLSÒ†¦ÅºWŞñ‹*ëi,³YÙÎCå'é¶ÁÆŞ›m¿Ùr€[§>ÀÄo’åh’Ö…ÓTQ)Z…ÙÙZ,MIõ1qIÊ˜C­˜ 1ò°Ó.,O‘Xœë¥ÎH^¾·@Svô2	W¼StĞ¥åöÆ¬Q&ú¨¹T}šÁƒƒ]<©Úcì-+0U°g`º,„}¬XSF6f88Nº2°Ë	àñy®z{ ¼‹ãg‚Ì:Ç
 ©«ÓKşi®Y»šv…“aÚÔ =>ÿ€¤Ú!±˜î‰às¯V±&üaÙ_jAJÃ"´Öü*ƒÚØ…¾?jÕe¶³Tò…´óÑA4¢ÑóY¶ª»Á<Íb2W3¥æüuzlœCÏ‰>]hÒô	_÷Hp~Rça»<’e*":;Ú¨KŞØ¶TVáİòy¤D&X½ –Ã÷a†)ŸUWÉbcÖ†¡h&zînÈ9}#§ºY{ï¥ê¼øqğìz÷½r]Âç"×q‡@€„Š©ô„.>¸;À”hHĞ1Õ”•#oæ”eN^ÀëÚ´•¹Âˆ¼ÚÈŸ…™C	ïœc>Úl[@£>d0nÚ­-iÇ½‡è†^;œèÆQ8ÀZ×f£R„¯ DOøíİ‹f(Ğ¯ŒùvòIğ×ß3X4åÁ>u®$ÂŞËLÂı!‘h/7Ö0  @Ú¶ÔÂÖyà+s5T'Gël9¿ó
UfmÂy¥pBùìÆª¹üCàãu½6ê‰„­c“«2Õ)A
4c7—Ö3ğ‹Ÿbßû/öëd6}U..zO†¤”BC<	sõŸl™e>ø.5=0\=3[f=>Ø@	ÎğW£ºjC ^#ß]§\ù‚6@1ÌşCMÀ¬/¯=ÉÖÙğ®,™ˆÏ‰Öe}»ÍO OŒìÕ~q+:ÒØ'
J€©àsÉÌÂÛäXƒ©¯q7Èù>èâ%ß8`È!å=¡…'BŠ2ùiØCh;¹*79@Ì¿…'İï…pr¬¼âF1Ã£¼cÆµE‘h"úówŸ!ÉÈ;§ñ Ò*Oà‰Õ¦¤Ò["Øú’køĞ GŞûQ§¼†×€VM·ğo|(Ì!…a@~İ\v«ÚÃ‘wuåš0Úu€Ü®IbÕ¶^—ËiŠÓ*Õ¬¶¬>£Wq~Y ‘n¹NÆ~É!–à†<¯çõ	tT\R¡½ì#¿ÇíâÈQ]í±guyw`Ş…ÚÊ«4l!jş9[ÖõhNœjˆ{ùOFètoüi ÀÏğ±«5,òá‘…tËø”ğT• gñTDáÕõƒô8¡ƒ<kd‰òŠØ”‹æ+Õù=¬KŞ®/kÕôŒ…¤O¨rHã"ÖnıÎeBi‚I†vqÄõÜšlœü|MQ¥¯Ôáô´<¹¦@Uû5-øšH0¹NËÌ”ÊL®mDP†›"–æ¦Bå‰›b5nÛŠ‡‹ÜÊÈR9gc3Ãñ–õQıÎíb@-‡5Ù˜H=Ğ“.JH–¡•ÑS©Ûig]›ÿ_`Û'¼áê—Y…:¦·—ˆğNö¯NI;}(RøN#ÇÚö/ˆ‚T€5?È¥¢(ğC^°íœ†¤s¿À;3Ò»HW %Ì]Š¤¬»mk{`@t¥8 »Òcên%®÷µceÚ0±¦kÊ€7áPSªåI½7Ø#UöÓ¬µ²Ï~‹Æ“‰B/]Dƒ¬¼&o+Ëoî?=òEm<¬JÉ7q"´‡…M?¦áÜŠ–É™"š÷t¥š#/dY=`JøCı?¬¦#5fÅø™Èœı­lé-ğŒZQQmÌ7³èKç%ù$95şÉÁä&IÇƒZ$ÍN°wB‡H_B†HÔ9—ï7%U%ŸDû¡Ø{°<m@Óà‚j–2¨‰ îräÕc–¬g=©Z!©™'ƒ3ù?Ó°“2Aº,ƒåõØµ[¸/o:QrÑ^yÈó¯0`WŞ‹æ´KÆîƒæ©Txÿ3¨ˆ÷ô:e|â¶ö-Š%‹ßBÄË#{F²0oyeT½í@D0Rì Ï³£$šÑY-QYj­ašÏGİP€ïè£ÏYØ‡TÃ|úOƒ-#K‚¬L=1Ù8Âß{%Õ5å€¨šŸ
;xy@–¥…ãï“0µQ¦Ö°6"Be®ËD
•Ùğ$ª=ÉÃTÅû®<bur±¨î~R[Ÿàä%ãø®Oê—S”ÎWsm©³hTG®ÈŒÎHföÄEQ 5F`GX¸&ºÙmÑÍğ¤¸¡3¿‡]î
¹ïtx™+7BøÌä„Õró¸(…R±Y$•Î©s³¿#ºõyûiUê>}ƒæ¹¤hüU¦TÛ-t+o=çÈ³ú*­}1\g¼-$
—šo˜Íç
ğdøÌYôí2é·"&îğö¼Üƒ´*;6[Å è!ò†¯dé§´µVºóŒ©CVsäEƒ%§-°-È{ê@s„ŸÉt9V3İP]ÜoÂ_è9ò:s\k`÷¼qÔ5ˆ^ñÀı…àÓHò):Üáëc!>€mw ú#xÓ|ªÒ|ş?lWyTT×/¥3—Ô#¯/è<û¶jÔV96Æ5Q¢`”àÆ.¢"²…™afÄa†™A¶á±/2¬‚ .ˆ"¸këXEGTj“›˜¨ßó\rNï`kşé9ïŸwÎ÷İßïŞoû}.?÷Ğk¤õltITˆ›âÒ²Ò³28’!2<v‹2­{+‹%¶zÓqR«ËæõÏñ‡à7MÅ+Ğr}òGÛ<_‰š4å·$djÀl]Ùš×7Í÷CÂƒCN…ÂCgá&xÓ+Rk°;ƒ‹Ä‚·ğRÄ×"9^.: ¾j-ù;Ì` I<î;şR¤.¢:²ºîÁê_Ö;=v†¾×Sèz,ıé<Hëÿ‚BŒ]%ÜëE¨ÔØtŒ}kK‡Û°;½¤¯ÏcéîQÔkÜ‘Îı´¥ãÃY×GÚ³ “W[ÇãU`ö¼]0™×§Ç©Y]fœ&…‰Jhî!*®­øÌ=ÉNgfh´2&ÁØØÈA º`üÏa©o±K˜÷UIbóÊšj®PÇó’æC­M=+Y?D½À‹¿X3KâÓÕ?pº«µƒ]iéÎ©`ÊšM½İœ«¶E˜t>æÊİ®ÛAş˜!«ì}6ïJEóÏö™òUaF»½­¹Å*:êÅW'aİyğ{µ~wyÀúä}¬Ä:³ˆU†¤…j\TÈ”_dÌgeñ¹í-AÔèTÇYø ĞA1Q+™Å«†‰Öõ´¹ã´%5¾€ËOÉO)O:`Öd.«¬•Thšã«Ù²İá¼”!›’‹£Ãy¾ZsoäoG@ÜOh÷Ë„_ÛŞo¹:ÿzNK÷FîÙÆø®<s`úµŞ3=½±«÷sTÌÅ´ÎXuX"\A®§\ƒ'¸¼åŠ Æ]ñ¥şÕ<Œ°;€òÎÁ¢¨ıÄyz•pºòxÙ‰rr­ëĞ¨İ©şº³0ìQÉ«=ßOÃçé\ƒ{†wß|æ¯ø=?¼0¼„,m3ÏÁôæ"ßƒyôã²Î†æn‘Oè~ˆ^˜ÕÛlN?Øá’@ãÉà"î°ô°=–O»™ªZkcÛÖ†ØÇˆ?ßÈ-‰½¯Š—)3}õ¬¬<ú³9çÀE	\WäŠÎÂ‡·É`n=ìê´ØÜl7x]€ ;6jĞƒ:âñl!İTQİÜÁ’ßmñk½Ë ¡×.	X½¿Ã,–v5sÔ`D¿àM_í¬m-Ã’Äİg«—&=¹ËR÷=àæqºsR¥šdÄĞƒß‘RÍ,ŸŠ'­oÛr>‰£nW{z5JIâôKyIÃ¶Œ¡­ÏÇà“3 ²¥zXXjä!¦óEñ¦ĞÜZIU×á*3›ß®+aÎüĞ	¿8™Y©­å\Éó0ıoâ}Û~vjDPñtp¡ÖBFn(êÊIxò—!±ÁÑoÒ1÷¿é>âÜ·!E+´Y›³È£Åñ(Ä¢°Ü‘À>tâp'ßÈÔDúp8-SèBtÄ"¹zàÉÅrøıs·<ÿÈN½ k‰–¯ÊÓ•A(;7P¤TNS#³Õj.eÊ*sü9¬FK•ûÖéYjê%á'²J*JcÛ›jjm)µñÑêX2ë½pB›0TÒ?qôÓ‰£Á)œ^bÜÌJµ"…Lu\ÑôáïáNØ‚t¹òÀÔ@Õ42óo±¨©J8õ!÷yXYJí¾º³ÿ}Ğğb¹I´ËœRpX¾D¿±x­¨DY˜™%Ñhô{Y…xñWæÈıAWğ|˜ÚØ 7`lÆÓ#ÒPwÁŞŒÌ½ê4nGŒÿ&iœÁ<UX„²IE	Ê€´7Uh²2ùªpn\†6ï5ød°ùÊÁä™ê¨~2xñú\eÁ9‰ğõ„û÷÷€	÷’Ÿİ“Ğ¦T?ûÂâïnÍêsµÃZÇ÷ÛéTïèCÚ'Ş°#‡Äj7¢M»Ì½8ˆ,Çû¯÷•Gú²8­IÖ‡;J$™GÛMq¹Ã° ¶š6Ry·LşA–¢/T†à}Ä"‘GIfÑÖı¦¦²© Á´gxù}¹GÆvgÄu¯a6o÷ç†P!;²E¦Ó¸(‘¹ èMÖNä¨»U;àvÏŞvêØ½1Ú_­	s€Gó(07­¬Um¨ãPsUs¾BêÇáhy’.ÊaI’1/ï‘@*‚ÉŞ[üwFo	aïNÀİqÀ…OÀå¿…ÓÚO›Sã”9ƒAˆ ±d	vÂ“136h˜w¸Ãæ?Âî\ù¸“kè»üô1{ÏğÙÄ¹âø
Xß"¸ğ™Ü†ì2J‘Ù‘-óÕ±JĞU •ªb"^¢ØV[FÜMğ ½{ÚòûË¶„$Ê8ƒYtí#4¿U„*CÕ™ƒ¹Ê5b×Ó‡òÏØÚpµà’ñŠ…Š]›ÂÔ:°ËaÃEaŠ-[îV7
*;ÑÉãÂRº&2ÙÄà)sğ/1‹çy?¹x£»©œ³`?qpZò§zB,£…¥æN@2(/K/ZĞ9±FU Â%+UiP3‘ß<åÈ™ïößùÆäèØyøî™oIæe·a;uqØNoTé7iI ²xdÉ».¡¬‚Z¬c©‹uEÑ™ºÒÊúVyuÌÎ¹wgx21ëCäÁ©!*rWsañÿ*ÑµE[c‘	ëj3ån§.ùY!æF¨•: ×à*MeÃïDbª)[¯ËÊTÆUme>ŒğİøÙ@Ô¥hj8·KÔ’Zµ'V²!L3Gñèt:«S;ñ+¢
óórK“íˆâse¤û?”W[oWev7¡‰SÅ1$»Ò®€Š‚
…Ò‚*@ª ‚J…Vj9n¹'6;v|ÛÛ±³k;k;‰!×!@
­PKD+© ¨TÑ¢ŞfÃá¡kªş ^æeæÌœotÎ|ó=şúèØ¾4£M£‚o±Ã	û¸DÆ³×§/˜—%”ŸfùR.>£º«ğH@á‘å
<>}x7k:TWh2™ìİ¤“wònú*º†¿6e¸2sq"7Bw…°®Sµ×só4Ù¿	åF· /ÊæÂûÊ“VT—ñ²n—Ë•<GÂS´öq×å5×’Ú¨›¨·Y¬½´ÉĞÔÙDí°Ş¸–wi××.ùˆ%?§b³Şl–Îå°ïÂ´í£Ÿ×„Bß,*ª†åjµÜœç>†ÅSî„µ•<²­9¶’^AÌ°‹a2•èáiíe	É-ÙÅ¦s[Ÿ"väÃÂŞ¤üÁä©åğÃÈMäl~éUùÍpÕ›EU|~½ZşNÉÏ#}’ÃHvÛ=-ô›¨å]¨Wv^{(F§ú'|Jşı,1Õ²e¶UUè¡ü#ĞN’cIo2_};K¤\.©
(ô{Å1ÁgñS¾Ğ˜zØ~E=Ø·¨€w0a€†?ÅŒo0î¯	eL@Ú¬P™**TÃõ{:o_¸›%ÍVGc~éEâgàİ@å°·â†ÒéW)¢µ,u'İf²Çnİ¹n?x+FÆS|L¹P-KLpaÏÔÎßĞÒ
„£úN—ÁYÉÂ2%ŸÙs1!!>¤ïC)¦,ßùGË¹F›‘ç[N±ø.bi'­]½	µ 0§ß"OMrIN)s°“rö…[ Gî
¡qv5K¬EôZkèjŒ(½ëÑfš“—œ¾äZÑ«D…Ó‡øJÍcOZ&Óªëµü6Pº/¶é¤½q	…hò
LDN´‹á×üŞ³÷( q4ü|…²Š—šÇò6(@àğ´•å²uÀ<Éí”v;¬VdcqA“eã­ä†]ÉÔ„˜ûâÈ`³­ÏívÒn‡Óí¢l6_p8ráÎyFû‡_"^úK*ìTCÿ‚}²ó’¢ş>ˆ¡Mö„D´BÇ)M…Ò8géšœçéi8>CÅ’ÁÉÓ­á}o½k=ã†’Œ2°R¦„±Ùlj©Ê8Ü¨„æ×÷Nè©ÖîÆ£Ikl&06ğˆÑ{VÖ £uITÄ£R•V¼@ïPĞ”¥©Ë>Éí'ÚøWò6Jzğç;säƒ‡Z[êÙµç,£~ÇõÓœ·Ÿã)¿¿ÏÚ~²zG£u‚½ı%â5ó‹_€Æ¾ ÿŒUÀÏ«!$É’*-AÑI€Â÷sj°Î/Ò]Æ§¢‡ƒŒôúc„g‚ÑÓç©Kè¼Š÷ì±Óm°E"öğYRŞ²EÂaÜÂxÄâUıÿù7ÿï‡ 1Mó´´”@o¡Ûè¸¡’6||¬­)Ì Øß{b¿C9²X"ª½½Ñió„¦S˜]@æA0zpÏYèäİƒP-¢Ï8Ù€W=Ec¾";Ëa^÷¯  ²½6«
endstream
endobj
116 0 obj
<</BG2/Default/OP false/OPM 1/SA false/SM 0.02/TR2/Default/Type/ExtGState/UCR2/Default/op false>>
endobj
176 0 obj
<</BG2/Default/OP true/OPM 1/SA false/SM 0.0200043/TR2/Default/Type/ExtGState/UCR2/Default/op true>>
endobj
177 0 obj
<</BG2/Default/OP false/OPM 0/SA false/SM 1.0/TR2/Default/UCR2/Default/op false>>
endobj
178 0 obj
<</A 179 0 R/Border[0 0 0]/Rect[466.77 15.0 541.0 27.0]/Subtype/Link/Type/Annot>>
endobj
179 0 obj
<</S/URI/URI(http://www.jrheum.org/)>>
endobj
170 0 obj
[180 0 R]
endobj
171 0 obj
<</Length 11904>>stream
1 g
/GS0 gs
0 792 m
0 792 l
f
q
13.5 787.5 585 -783 re
W n
q
0 792.03 612 -792 re
W n
BT
0 0 0 1 k
/GS1 gs
/T1_0 1 Tf
-0.00011 Tc 0.18851 Tw 10 0 0 10 66 734.8264 Tm
[(When might someone wish to use the F)73.9 (ACIT)-420.7 (Fatigue)]TJ
0.1077 Tw -1.2 -1.2 Td
[(scale in RA)-302.9 (over other available instruments? )17.8 (The evalua-)]TJ
0.103 Tw 0 -1.2 TD
(tive performance of the 3 instruments across these 2 trials)Tj
0.0589 Tw T*
[(was very comparable; ef)17.7 (fect sizes for treatment dif)17.7 (ferences)]TJ
-0.0018 Tw T*
[(were similar)39.7 (, regardless of instrument choice. )17.7 (Thus, as eval-)]TJ
0.108 Tw T*
(uative instruments measuring group change, all performed)Tj
0.00011 Tw T*
[(well. However)39.7 (, the 13 item F)73.9 (ACIT)-232.4 (Fatigue showed a broad-)]TJ
-0.01579 Tw T*
[(er coverage of the fatigue continuum in RA)-179.4 (patients than the)]TJ
0.082 Tw T*
[(longer \(16 item\) MAF)79.7 (. )17.7 (The shorter \(4 item\) SF-36 )17.7 (V)59.8 (itality)]TJ
0.1678 Tw T*
[(scale, while it has the advantage of brevity)64.8 (, was tar)17.7 (geted)]TJ
-0.0237 Tw T*
(toward the healthy end of the fatigue spectrum, suggesting it)Tj
0.1086 Tw T*
(would not be ideal when planning studies with patients in)Tj
0.01109 Tw T*
[(the moderate to severe fatigue range \(Figure 1\). )17.8 (T)69.9 (wo instru-)]TJ
0.1815 Tw T*
[(ments \(F)73.9 (ACIT)-413.8 (and SF-36\) of)17.7 (fer normative data from the)]TJ
0.0761 Tw T*
(general population)Tj
0 Tc 0 Tw 7.5 0 0 7.5 129.4553 570.1265 Tm
(9,29)Tj
-0.00011 Tc 0.076 Tw 10 0 0 10 142.5803 566.8264 Tm
[(. )17.7 (The F)73.9 (ACIT)-308.3 (Fatigue adds to this the)]TJ
0.02499 Tw -8.858 -1.2 Td
(availability of normative data on patients with cancer)Tj
0 Tc 0 Tw 7.5 0 0 7.5 268.7164 558.1265 Tm
(9)Tj
10 0 0 10 272.4664 554.8264 Tm
(.)Tj
-0.00011 Tc 0.28461 Tw -20.6466 -1.2 Td
(Fatigue is a highly prevalent symptom of RA)Tj
0 Tc 0 Tw 7.5 0 0 7.5 266.7157 546.1265 Tm
(18)Tj
-0.00011 Tc 10 0 0 10 279.5614 542.8264 Tm
(and)Tj
0.0349 Tw -22.5561 -1.2 Td
[(af)17.7 (fects patients with all levels of RA)-230.1 (severity)64.8 (. Patients have)]TJ
0.1817 Tw T*
(identified fatigue as the most problematic aspect of their)Tj
0 Tw T*
(disease)Tj
0 Tc 7.5 0 0 7.5 82.8721 510.1265 Tm
(19)Tj
-0.00011 Tc 0.1033 Tw 10 0 0 10 90.3721 506.8264 Tm
(, and it may represent an even greater burden for)Tj
0.1017 Tw -3.6372 -1.2 Td
(some patients than pain. Fatigue may be especially salient)Tj
-0.008 Tw T*
[(for patients with recent-onset RA)-187.2 (and lower disease activity)64.8 (,)]TJ
0.1163 Tw T*
(because as disease activity increases, other features of the)Tj
0.259 Tw T*
(disease, such as pain, depression, and functional losses,)Tj
0.1414 Tw T*
(become more prominent)Tj
0 Tc 0 Tw 7.5 0 0 7.5 154.5682 450.1265 Tm
(8)Tj
-0.00011 Tc 0.14149 Tw 10 0 0 10 158.3182 446.8264 Tm
[(. Despite this, fatigue in RA)-336.6 (has)]TJ
-0.01601 Tw -10.4318 -1.2 Td
(been relatively neglected in the arthritis literature. Fatigue is)Tj
0.0356 Tw T*
(not included among the outcome measures proposed by the)Tj
0 Tw T*
(ACR)Tj
0 Tc 7.5 0 0 7.5 74.5591 414.1265 Tm
(24)Tj
-0.00011 Tc 0.0405 Tw 10 0 0 10 84.964 410.8264 Tm
[(and the Outcome Measures in Rheumatoid )54.8 (Arthritis)]TJ
0.02499 Tw -3.0964 -1.2 Td
[(Clinical )17.7 (T)35 (rials \(OMERACT\) Committee)]TJ
0 Tc 0 Tw 7.5 0 0 7.5 216.6812 402.1265 Tm
(43)Tj
10 0 0 10 224.1812 398.8264 Tm
(.)Tj
-0.00011 Tc 0.16721 Tw -15.8181 -1.21 Td
(In contrast, fatigue has now achieved recognition as a)Tj
0.2229 Tw -1.2 -1.21 Td
(prominent and distressing symptom among patients with)Tj
0.03059 Tw 0 -1.21 TD
[(cancer and is one of the prime tar)17.7 (gets of symptom manage-)]TJ
0.1221 Tw T*
(ment therapies)Tj
0 Tc 0 Tw 7.5 0 0 7.5 113.8056 353.7265 Tm
(44,45)Tj
-0.00011 Tc 0.12219 Tw 10 0 0 10 130.6806 350.4265 Tm
[(. )17.8 (These data on fatigue in patients with)]TJ
0.03059 Tw -7.6681 -1.21 Td
[(RA)-225.8 (allow the degree of fatigue suf)17.7 (fered by these patients at)]TJ
0.136 Tw T*
[(baseline \(pretreatment\) assessment in the ST)79.7 (AR to be put)]TJ
-0.01849 Tw T*
(into perspective. For example, the mean score of 29.2 on the)Tj
0.01241 Tw T*
[(F)74 (ACIT)-244.7 (Fatigue scale indicates patients with RA)-207.6 (are roughly)]TJ
0.0321 Tw T*
(0.5 SD less fatigued than are cancer patients with moderate)Tj
-0.0204 Tw T*
(to severe anemia who are about to begin erythropoietin ther-)Tj
0 Tw T*
(apy)Tj
0 Tc 7.5 0 0 7.5 68.4385 269.0266 Tm
(9)Tj
-0.00011 Tc -0.01711 Tw 10 0 0 10 72.1885 265.7265 Tm
[(. However)39.7 (, this score of 29.2 is more than 1.0 SD worse)]TJ
0.0153 Tw -1.8189 -1.21 Td
(than the scores of nonanemic patients with cancer receiving)Tj
0.0874 Tw T*
(outpatient therapy for their disease and 1.5 SD worse than)Tj
0.0849 Tw T*
(the general population of the US)Tj
0 Tc 0 Tw 7.5 0 0 7.5 188.4771 232.7266 Tm
(9)Tj
-0.00011 Tc 0.08479 Tw 10 0 0 10 192.2271 229.4265 Tm
[(. )17.7 (This places the average)]TJ
0.2012 Tw -13.8227 -1.21 Td
[(patient with RA)-396.4 (beginning this trial below the 10th per-)]TJ
0.03169 Tw T*
(centile of fatigue scores \(i.e., worse fatigue\) in the US pop-)Tj
0.13989 Tw T*
(ulation and below the 15th percentile of fatigue scores in)Tj
0.24001 Tw T*
(nonanemic patients with cancer)Tj
0 Tc 0 Tw 7.5 0 0 7.5 187.5316 184.3266 Tm
(9)Tj
-0.00011 Tc 0.24001 Tw 10 0 0 10 191.2816 181.0266 Tm
(, suggesting that greater)Tj
-0.0334 Tw -13.7282 -1.21 Td
(attention to this debilitating symptom is warranted in the RA)Tj
0 Tw T*
(population.)Tj
0.2607 Tw 1.2 -1.2 Td
[(The significance of fatigue for patients with RA)-456 (has)]TJ
-0.00909 Tw -1.2 -1.2 Td
(apparently failed to capture the attention of many clinicians.)Tj
0.01489 Tw 0 -1.2 TD
(Nearly 90% of rheumatologists do not assess fatigue during)Tj
0.0948 Tw T*
(their clinical encounters with patients, and only 4% assess)Tj
0.03571 Tw T*
(fatigue at least 75% of the time)Tj
0 Tc 0 Tw 7.5 0 0 7.5 181.0863 100.1266 Tm
(46)Tj
-0.00011 Tc 0.03571 Tw 10 0 0 10 188.5863 96.8266 Tm
[(. )17.7 (W)79.9 (olfe and Pincus)]TJ
0 Tc 0 Tw 7.5 0 0 7.5 264.7662 100.1266 Tm
(47)Tj
-0.00011 Tc 10 0 0 10 275.1229 96.8266 Tm
(have)Tj
0.06619 Tw 4.2877 63.8 Td
[(ar)17.7 (gued for the collection of patient-reported fatigue data to)]TJ
0.004 Tw T*
[(better identify patients with RA)-199.2 (who require or would bene-)]TJ
0.075 Tw T*
(fit from intensive symptom palliation. Formal, quantitative)Tj
0.0011 Tw T*
(information would also allow clinicians to track fatigue lev-)Tj
0.0703 Tw T*
(els and response to therapy over time. In addition to meet-)Tj
0.2467 Tw T*
(ing formal measurement requirements, self-report instru-)Tj
0.01311 Tw T*
(ments must also possess clinical relevance and feasibility)Tj
0 Tc 0 Tw 7.5 0 0 7.5 548.0001 666.1265 Tm
(47)Tj
10 0 0 10 555.5001 662.8264 Tm
(.)Tj
-0.00011 Tc 0.0768 Tw -23.75 -1.2 Td
[(The F)73.9 (ACIT)-309.1 (Fatigue scale is an example of such an assess-)]TJ
-0.034 Tw T*
(ment tool that is psychometrically sound and places minimal)Tj
0.125 Tw T*
[(burden on patients to answer and clinic staf)17.7 (f to score and)]TJ
0.1162 Tw T*
[(interpret. )54.8 (A)74 (vailable computer)19.7 (-administered assessment and)]TJ
0.14011 Tw T*
(scoring programs make its routine use in clinical practice)Tj
0.02499 Tw T*
(highly feasible.)Tj
0.1113 Tw 1.2 -1.2 Td
(This study has provided evidence of the validity of the)Tj
0.0314 Tw -1.2 -1.2 Td
[(F)74 (ACIT)-263.7 (Fatigue scale in patients with RA. )17.7 (The validation of)]TJ
0.14529 Tw T*
[(the scale in RA)-340.5 (expands the range of chronic illnesses in)]TJ
0.2095 Tw T*
[(which the F)73.9 (ACIT)-441.8 (Fatigue scale may have utility)64.8 (. It also)]TJ
0.0199 Tc 0.3586 Tw T*
[(expands fatigue assessment options in rheumatology)65 (.)]TJ
-0.00011 Tc 0.04739 Tw T*
(Although the importance of assessment of multidimension-)Tj
-0.0195 Tw T*
(al quality of life has begun to achieve recognition in RA, the)Tj
0.06599 Tw T*
(13 item Fatigue scale provides a brief alternative when the)Tj
0.02499 Tw T*
(clinical or research interest is symptom-focused.)Tj
/T1_1 1 Tf
0 Tw 0 -2.2 TD
(ACKNOWLEDGMENT)Tj
/T1_0 1 Tf
0.0562 Tw 8 0 0 8 318 450.8264 Tm
(The authors thank all patients who participated in this study in the set\ting)Tj
0.1956 Tw 0 -1.25 TD
[(of their severe disease. )17.7 (The authors also thank Hanadi B. Eltahir)39.7 (, MS,)]TJ
0.103 Tw T*
[(\(Abbott Laboratories, )54.9 (Abbott Park, IL\) and the 69 principal investigators)]TJ
0.02499 Tw T*
(and their study coordinators.)Tj
/T1_1 1 Tf
0 Tw 10 0 0 10 318 396.8264 Tm
(REFERENCES)Tj
/T1_0 1 Tf
0.02499 Tw 8 0 0 8 325 386.8264 Tm
[(1.)-875.1 (Stone P)110.7 (, Richards M, Hardy J. Fatigue in patients with cancer)54.8 (. Eur )]TJ
1.675 -1.25 Td
(J Cancer 1998;34:1670-6.)Tj
-1.675 -1.25 Td
[(2.)-875.1 (Piper BF)79.7 (. Fatigue: Current bases for practice. In: Funk SG,)]TJ
1.675 -1.25 Td
[(T)69.9 (ornquist EM, Champagne MT)73.9 (, Copp LA, )17.7 (W)39.8 (iese R, editors. Key)]TJ
T*
(aspects of comfort management of pain, fatigue and nausea. New)Tj
T*
[(Y)99.8 (ork: Springer Publishing; 1989:187-98.)]TJ
-1.675 -1.25 Td
[(3.)-875.1 (Hjermstad MJ, Fayers PM, Bjordal K, Kaasa S. Health-related)]TJ
1.675 -1.25 Td
(quality of life in the general Norwegian population assessed by)Tj
T*
[(European Or)17.7 (ganization for Research and )17.7 (T)35 (reatment of Cancer Core)]TJ
T*
(Quality-of-Life Questionnaire: the QLQ-C30 \(+3\). J Clin Oncol)Tj
0 Tc 0 Tw T*
[(1998;16:1)36.9 (188-96.)]TJ
-0.00011 Tc 0.02499 Tw -1.675 -1.25 Td
[(4.)-875.1 (Swain M. Fatigue in chronic disease. Clin Sci 2000;9:1-8.)]TJ
T*
[(5.)-875.1 (Ahlber)17.7 (g K, Ekman )17.7 (T)74 (, Gaston-Johansson F)79.7 (,)-0.1 ( Mock )17.7 (V)128.9 (.)-0.1 ( )54.8 (Assessment)]TJ
1.675 -1.25 Td
[(and management of cancer)19.7 (-related fatigue in adults. Lancet)]TJ
0 Tc 0 Tw T*
(2003;362:640-50.)Tj
-0.00011 Tc 0.02499 Tw -1.675 -1.25 Td
[(6.)-875.1 (V)110.8 (arricchio CG. Measurement issues in fatigue. QOL)-238.2 (Nurs Chall)]TJ
0 Tw 1.675 -1.25 Td
(1995;4:20-4.)Tj
0.02499 Tw -1.675 -1.25 Td
[(7.)-875.1 (Denbur)17.7 (g SD, Carbotte RM, Denbur)17.7 (g JA. Psychological aspects of)]TJ
1.675 -1.25 Td
[(systemic lupus erythematosus: )54.8 (A)-220.1 (cognitive function, mood and )]TJ
T*
(self-report. J Rheumatol 1997;24:998-1003.)Tj
-1.675 -1.25 Td
[(8.)-875.1 (Huyser BA, Parker JC, )17.7 (Thoreson R, Smarr KL, Johnson JC,)]TJ
1.675 -1.25 Td
[(Hof)17.7 (fman R. Predictors of subjective fatigue among individuals with)]TJ
T*
[(rheumatoid arthritis. )54.8 (Arthritis Rheum 1998;41:2230-7.)]TJ
-1.675 -1.25 Td
[(9.)-875.1 (Cella D, Lai JS, Chang CH, Peterman )54.8 (A, Slavin M. Fatigue in )]TJ
1.675 -1.25 Td
(cancer patients compared with fatigue in the general United States)Tj
T*
(population. Cancer 2002;94:528-38.)Tj
-2.175 -1.25 Td
[(10.)-875.1 (Freal JG, Kraft GH, Coryell JK. Symptomatic fatigue in multiple)]TJ
2.175 -1.25 Td
[(sclerosis. )54.8 (Arch Phys Med Rehabil 1984;5:135-7.)]TJ
-2.1381 -1.25 Td
[(1)36.8 (1)-0.1 (.)-875.1 (Jones EA. Fatigue associated with chronic liver disease: )54.8 (A)-220.1 (riddle)]TJ
2.1381 -1.25 Td
(wrapped in a mystery inside an enigma. Hepatology )Tj
ET
0 0 0 1 K
53.964 76.5 m
558.972 76.5 l
S
0 0 0 0 k
52.822 69.665 64.178 -15.665 re
f*
BT
0 0 0 1 k
/T1_2 1 Tf
0 Tc 0 Tw 8 0 0 8 53.8216 56.7343 Tm
(818)Tj
ET
0 0 0 0 k
356 69.665 203 -15.665 re
f*
BT
0 0 0 1 k
/T1_2 1 Tf
-0.00011 Tc 0.02499 Tw 8 0 0 8 424.3613 56.7343 Tm
(The Journal of Rheumatology 2005; 32:5)Tj
ET
0 0 0 0 k
/GS0 gs
103.631 82.583 407.5 -10.833 re
f*
0.5 w 
/GS1 gs
103.631 82.583 407.5 -10.833 re
S
Q
Q
q
0 0 612 792 re
W n
BT
0 g
/GS2 gs
/T1_3 8 Tf
108.828 74 Td
(Personal non-commercial use only.  The Journal of Rheumatology Copyright\ \251 2005.  All rights reserved.)Tj
ET
Q
BT
0 g
/GS2 gs
/T1_4 1 Tf
10 0 0 10 540 17 Tm
( )Tj
0 0.48627 0.77255 rg
/GS2 gs
-7.22298 0 Td
(www.jrheum.org)Tj
0 g
/GS2 gs
-18.00796 0 Td
(Downloaded on December 3, 2023 from )Tj
ET

endstream
endobj
60 0 obj
<</BitsPerComponent 8/ColorSpace 66 0 R/Filter[/ASCII85Decode/FlateDecode]/Height 99/Length 646/Width 76>>stream
8;Z\6$^/CM#ke05j>oA^ne4hSAuE6S-CqT%H+X@h!5/#tXE:=W37#4e^I?>U:%6lQ
!k$t:GYY$H'bCV\+Mb9%pUg,K#e(+H?4=PKj!Lsn=FXZ;@qp`:"+F22O[ef0T?:Y)
6rT]q?EQ?IV+q:]/U58Tg0-g0j)eu:lWS^5A*ePLUO=etnX(1aX1T4P*gMi&p>cB/
53^Y7.\Ea^_<VoekOj#L)-"N]"6cjm+YPMBm9O"K)mWC_`d)D"QP?"6Hmp:X=f_qL
*pe:gg$-UUJ&KJt3Gd$=H%ZZ#L@d\"apl:#pSlK^j8aBT&1/Hu4P!s,K1?/'YEAI:
g!6iVNFI+e8Lm5u"r7c"1)ebMY/C]4Kf5:0mhZ^F^q.M<MT4>+H*%FFCSWc)"WnrT
F.7M)O_4/R#5M+Vb%ejrW%.o#N=G/c@uhRZ,a.)]`e1].gD9K=SCYd]77qDI0.o_l
Z/BogZ"I^nWDIFF9YqWEg5*Fj]uSP9Q"Q\j/??%;Ru$HHN\7)ha$:6F8E4.nF:6bu
R'C'DGnj>,m'D]pD^QC'U5%Q0]_U1olpOgkZFkEUZJm66^gB%mJ1S@gd:bWS.f!Dp
X/eD#"#jt=."&nO#oKMX6.pG]'X)&</Mp^/4aZQRc[H&uM[#!E~>
endstream
endobj
33 0 obj
<</BaseFont/PMKJDM+Times-Bold/Encoding/WinAnsiEncoding/FirstChar 32/FontDescriptor 36 0 R/LastChar 181/Subtype/Type1/Type/Font/Widths[250 333 555 500 500 1000 833 278 333 333 500 570 250 333 250 278 500 500 500 500 500 500 500 500 500 500 333 333 570 570 570 500 930 722 667 722 722 667 611 778 778 389 500 778 667 944 722 778 611 778 722 556 667 722 722 1000 722 722 667 333 278 333 581 500 333 500 556 444 556 444 333 500 556 278 333 556 278 833 556 500 556 556 444 389 333 556 500 722 500 500 444 394 220 394 520 250 250 250 250 250 250 250 250 250 250 250 250 250 250 250 250 250 250 250 250 250 250 250 250 250 250 250 250 250 250 250 250 250 250 250 500 500 250 250 250 250 250 747 250 250 250 250 250 250 250 570 250 250 250 556]>>
endobj
36 0 obj
<</Ascent 699/CapHeight 676/CharSet(/A/W/L/M/H/O/C/N/R/D/T/S/G/F/U/I/E/space/K)/Descent -205/Flags 262178/FontBBox[-168 -218 1000 935]/FontFile3 37 0 R/FontName/PMKJDM+Times-Bold/ItalicAngle 0/StemV 139/Type/FontDescriptor/XHeight 461>>
endobj
37 0 obj
<</Filter/FlateDecode/Length 1974/Subtype/Type1C>>stream
H‰\TkPWqè¾°š‰¡£=Ú3åª5X*âŠá¡l" ¾‰»J„!ŒÌ{x
¾‡™™DAEŒJ+È+DELR¢.»«fU\+[Ñ¬céêºÆ¸9=Ùr»ÁÖÖí:ÕuëŞóï;ß=JEĞ0…R©]º81aáâ°•F³Á6-ÎjÊw#D­B§Ç9•8*HÔQhyQôbÅR¾,+Š#}ºŞê¼)TA)•Áû…ã'ÃÃgLŸ³ÀšSÈ?ÍÊÕ¿“>E?cnäì©rœ3çÊqn¸>6ÃºÎ _QhË5˜múE–t+ŸcåÓrÓõúX“I¿\Î`Ó/7Ø|¾´;X©ŞhÓ§ésù´ƒ9ÏÖ[3õIF‹5·0Ç }_ŸfÉx×ÊëÒ=[Ş:›1Ã˜Æ¶Wwe–ƒ¯‘V(¥¥˜ PL¤Sƒ3UŠH…b”$‘"HAiŠåX¥GùÓ°Ìa7To¨JU×ƒŞÚôˆÊ Ò³èı$,¥–¾2bNˆ(PîöG©üñ‚f{SëG¿ M<2ÆJ#è2ÇWíËÃÇ1z×ø¾`kkO5ôsGïËnÍa×–..áxø–\°UóœOÑI©í=şåYˆ#•LÕLŒ1Ï×š¢ö÷§é2/9õ±0ÿLƒÉ@ÿCfµqlÎ¡ùmÛós6¼wv†3q"†ãÇ¸B1ŠaÔßÿòıT3ß&şÜÊ¡!ö@cÚ7®ÒPQ
‡$¦‡C¶px‘fğä„³ÓÌ¶‘ÌKÇ˜À-~£9\Z*\ÒBÌ4†ã™‰´f{İIzµ”¾	¾j…fág	!â(ĞSÀ|^ë×iÎ¸:Ü‹Ø€,6¹–;8¦€o““AIj…%MÚ0E›`¯éÔA	yò•ßªÑ…ûè"¹zC˜'ŠÈéºò^Ğ^çqÂ‰pjào´Z/uáÂk€Ó õÌæ{°Ûuêu@‰÷¥{¯°PL ´6nnµN€û<]<¯h!ô3O†PÎAÌ±¤_æê%K´ºÏŞA$-¡í_Cx¦Àˆ~'œÔà#¾êlv'²È'›Ì3q™¼×!æ$L…IóüU{tÿßr¿Ç8Âxğéñ.hZ{tÀÛõ¾?ïâÔ}³sİĞ$(ÿ#ñr@„Ê_&hRve•÷±¢\îòöq>àI§ëŒDÓÑéäÊo§¼ÿ#O:œ§İ	2ı¥Ù%);%ú?
$¥2³üO,ln$É™ÎY–D·Ë?-(’€DZĞ¬,O÷]’şÚãéöJ	ŸñäŒ«û•ÎU²oŸ¹ÌÁ{!r{M§Ø[T‡Eõˆ‚˜³Ï+ƒìàI¿s¯#—µoß“Ã¡-¬'­ŞŞr)÷}9÷«^%g;W:^;HV“c$`Uk¯Ú²™İTèJvKî‘!ÃùBèsˆ`rü¡P ±ĞH¥®ˆÄ0íyU=:ÑD~hò\“ù‰']ƒ L»cv­ØÉ19¼x“¨!ˆÅó±ŞU½˜&híÎó}ÇŠÉd Ù{^®±‚àÚ€	×Š&
+yúzI]ñ‡lÀJ–m.š/‹»Y ‘…õ×XÑà%àPÇhğ‰O)oÀC/²¸–È¤îé	æåûgHnít2]µ£¡@ c«òö³âD/aìâ²À	ªA {*ôï–³yrËQ³~	‹çİÿ-FSø)Oï­uıî¼é
XÈ"ëÎ%;9Ù¦ş1-Ê6É£¿@¼JëŸ¬};.ÄÉ³¸£1Ú[îÂävXz]K®ÂÙ8-˜	Sp¤Ik
L‚L°àl«äy§šáKùu-Ù0¢™[Ìchkš*¼Õ½ÚïN}2G˜‡o—êÄD¼¡ÙRä©+Öa*|A;ğ¬	Şd™[…YUñŞäéÎ&÷l6L~[àz‡$É}i«HÇ+¤ÑjŒÈ°M¡m ”Ü?|éqæh­0›‰½¤¤(×²¶e–ù—›p\rjÙlˆ«û&›ºlê¶}Àn.yGpÌd–õ´@gÁ²Fº¶¼¢îPS—ñŸZHºoü Êè‹Æ:üÍŠ¹1§Ã~ø{¹÷ø×ğ«>$ñuœl/ñe³²å¬’¸¯lP‰’Ác+lŞ;¬XO®:Ÿ•|†³‚i7¤RÇ´S©Fú3˜õ¬âZyp Ì±¹ãä®û‰Ú~Ö¯”ÿ‚™p³Så_æÔ`O8kŒÉ,^$‰nœ&õibp8¸+{öŠoèaœwuÏañ.AÅÑ¬Ónùå‡Nmßİƒç¾Ôutí»÷GúÉ•#Õ½UœÚ*óıÓ…Ğƒ/RŠ¹Ã\}a”±xºÕİVºÍwnumãP…(7­‡ÊqpG}ÛÚèœ&—yÒã®Şº7¯-l†àEé‡ÿRÎjWu5ÛŞàı\>Õ-ÍÇmÖ@VàÉ˜Ä,jQ,ÙôkÅ'5í‡ëÛ|cÕöƒşÈı¸±††C»y>R¼OLÙíF‹G´UÁÈ²îĞ‚Â·_İpÏµ?s”æ ›05ì
endstream
endobj
172 0 obj
<</BG2/Default/OP true/OPM 1/SA false/SM 0.0200043/TR2/Default/Type/ExtGState/UCR2/Default/op true>>
endobj
173 0 obj
<</BG2/Default/OP false/OPM 0/SA false/SM 1.0/TR2/Default/UCR2/Default/op false>>
endobj
180 0 obj
<</A 181 0 R/Border[0 0 0]/Rect[466.77 15.0 541.0 27.0]/Subtype/Link/Type/Annot>>
endobj
181 0 obj
<</S/URI/URI(http://www.jrheum.org/)>>
endobj
166 0 obj
[182 0 R]
endobj
167 0 obj
<</Length 4860>>stream
1 g
/GS0 gs
0 792 m
0 792 l
f
q
13.5 787.5 585 -783 re
W n
q
0 792.03 612 -792 re
W n
BT
0 0 0 1 k
/GS1 gs
/T1_0 1 Tf
-0.00011 Tc -0.0043 Tw 10 0 0 10 53.468 253.6616 Tm
[(moderate to lar)17.7 (ge ef)17.7 (fect sizes. Similar results were observed)]TJ
0.02499 Tw 0 -1.21 TD
[(for the SF-36 )17.7 (V)59.8 (itality and MAF measures.)]TJ
0.1055 Tw 1.2 -1.2 Td
[(The comparability of the F)73.9 (ACIT)-337.8 (Fatigue scale with the)]TJ
0.0385 Tw -1.2 -1.2 Td
[(SF-36 )17.7 (V)59.8 (itality and MAF was further examined setting each)]TJ
0.05431 Tw 0 -1.2 TD
(of the 3 fatigue measures as a reference to create 5 distinct)Tj
-0.007 Tw T*
(groups of patients based on the guidelines of 0.2 and 0.5 SD)Tj
0.15581 Tw T*
(units following Cohen)Tj
0 Tc 0 Tw 7.5 0 0 7.5 146.0205 184.8617 Tm
(41)Tj
-0.00011 Tc 0.15581 Tw 10 0 0 10 153.5205 181.5615 Tm
[(. )17.7 (These 5 groups were then com-)]TJ
0.1801 Tw -10.0052 -1.2 Td
(pared to one another using the other 2 fatigue measures.)Tj
0.00281 Tc 0.3721 Tw T*
(Regardless of the instrument used to classify patients)Tj
-0.00011 Tc 0.0779 Tw T*
[(\(T)69.7 (ables 4 through 6\), the results consistently conver)17.7 (ged on)]TJ
0.0425 Tw T*
(the conclusion that each instrument supports the validity of)Tj
0.0537 Tw T*
(the other and produces comparable estimates of an MID or)Tj
-0.03619 Tw T*
[(change score. One notes, however)39.7 (, that SF-36 )17.7 (V)59.8 (itality scores)]TJ
-0.02251 Tw T*
[(and, to a lesser extent, F)73.9 (ACIT)-209.8 (Fatigue scale scores increased)]TJ
0.0706 Tw 26.4 15.61 Td
(among the patients classified as unchanged by other meas-)Tj
0.0833 Tw T*
[(ures. )17.7 (This requires further study to determine the extent to)]TJ
0.1781 Tw T*
[(which one instrument\325)54.8 (s change relates to that of another)54.8 (.)]TJ
0.2094 Tw T*
[(Nevertheless, each instrument shows excellent reliability)64.8 (,)]TJ
0.3036 Tw T*
[(concurrent validity)64.8 (, and responsiveness to )54.8 (ACR clinical)]TJ
0 Tw T*
(classification.)Tj
0.0663 Tw 1.2 -1.2 Td
[(The MID values for the F)73.9 (ACIT)-298.6 (Fatigue scale were con-)]TJ
-0.02699 Tw -1.2 -1.2 Td
[(firmed in a second sample of patients with RA)-168.2 (that produced)]TJ
0.0376 Tw T*
[(nearly identical values. )54.8 (A)-232.7 (3 to 4 point change in the F)73.8 (ACIT)]TJ
0.12309 Tw T*
[(Fatigue scale can be considered clinically significant. )17.7 (The)]TJ
0.07069 Tw T*
[(F)74 (ACIT)-303 (Fatigue scale was comparable to the SF-36 )17.7 (V)59.8 (itality)]TJ
0.13091 Tw T*
[(and MAF in its psychometric performance, of)17.7 (fering clini-)]TJ
0.1006 Tw T*
(cians and investigators another choice in the measurement)Tj
0.02499 Tw T*
(of this important concern of patients with RA.)Tj
ET
0 0 0 1 K
53.468 76.5 m
558.468 76.5 l
S
0 0 0 0 k
494.29 69.365 64.178 -15.665 re
f*
BT
0 0 0 1 k
/T1_1 1 Tf
0 Tc 0 Tw 8 0 0 8 545.468 56.4344 Tm
(817)Tj
ET
0 0 0 0 k
53.532 70.501 203 -16.591 re
f*
BT
0 0 0 1 k
/T1_1 1 Tf
-0.00011 Tc 0.02499 Tw 8 0 0 8 54.532 56.6447 Tm
[(Cella, et al: F)128.8 (ACIT)-257.3 (scale in RA)]TJ
ET
0 0 0 0 k
/GS0 gs
103.631 82.583 407.5 -10.833 re
f*
0.5 w 
/GS1 gs
103.631 82.583 407.5 -10.833 re
S
Q
Q
q
53.532 742.5 512.968 -481 re
W* n
q
/Fm0 Do
Q
Q
q
13.5 787.5 585 -783 re
W n
q
0 792.03 612 -792 re
W n
BT
0 0 0 1 k
/GS1 gs
/T1_1 1 Tf
-0.00011 Tc 0.0463 Tw 8 0 0 8 113.532 342.0293 Tm
[(Figur)36.8 (e 1.)]TJ
/T1_0 1 Tf
0.0462 Tw 4.027 0 Td
[(Item coverage of the fatigue continuum at baseline of ST)79.7 (AR \(n = 625\). )17.7 (The fatigue measure for each person)]TJ
0.0289 Tw -4.027 -1.25 Td
[(on each questionnaire was transformed to a common interval scale \(y-axi\s\) using item response theory)64.9 (. )17.7 (The location of)]TJ
0.013 Tw 0 -1.25 TD
[(each item reflects the relative probability that a problem will be endor\sed. Because items perform best when tar)17.6 (geted to)]TJ
0.02721 Tw T*
(people at the same location on the continuum, one can directly compare t\he distribution of items on the right with peo-)Tj
0.0063 Tw T*
(ple on the left. )Tj
/T1_2 1 Tf
0 Tc 0 Tw [-0.3 (\002)]TJ
/T1_0 1 Tf
-0.00011 Tc 0.0063 Tw [0.2 (: individual item location on the fatigue continuum \(average item respo\nse category is plotted\); ST)79.7 (AR:)]TJ
-0.01311 Tw -0.0001 -1.25 Td
[(Safety )17.7 (T)35 (rial of )54.9 (Adalimumab in Rheumatoid )54.9 (Arthritis; F)73.9 (ACIT)49.7 (: Functional )54.8 (Assessment of Chronic Illness )17.8 (Therapy; SF-36:)]TJ
0.02499 Tw T*
[(Short-Form 36; MAF: Multidimensional )54.8 (Assessment of Fatigue.)]TJ
ET
Q
Q
q
0 0 612 792 re
W n
BT
0 g
/GS2 gs
/T1_3 8 Tf
108.828 74 Td
(Personal non-commercial use only.  The Journal of Rheumatology Copyright\ \251 2005.  All rights reserved.)Tj
ET
Q
BT
0 g
/GS2 gs
/T1_4 1 Tf
10 0 0 10 540 17 Tm
( )Tj
0 0.48627 0.77255 rg
/GS2 gs
-7.22298 0 Td
(www.jrheum.org)Tj
0 g
/GS2 gs
-18.00796 0 Td
(Downloaded on December 3, 2023 from )Tj
ET

endstream
endobj
58 0 obj
<</BitsPerComponent 8/ColorSpace 66 0 R/Filter[/ASCII85Decode/FlateDecode]/Height 99/Length 427/Width 76>>stream
8;Z]"CD)7B%#"BS(X."_<<?Ui&KjoNllR=oI.!j;8@5d)'#5lJlRtg-YX\+;,?fY)
+M4f2p>'[ICj"qp\f\qJS&12\gA7WWn]=.QT]p6+#*LWaR/Y&r-S&Q#,Xnec]Okq_
C44<FX,h%(l&ADHjU0PF?8!ap]Zuc7YXZ$'&!C5Ff<ib&WE3$Mb5>:,cWHrK0*lpq
Et/;_43+1bEM7X`Ir'Rpgia6]!si$*>mfbMF+Lfbc6]9eMQP>d.#nG^2o$[(CP&TQ
kQcd3cn<;SkPm.)+9]?XO?j[3N$<-OhgBrNPbqi^Y9r;`g7)ZTpnF]pN-4.B%V;cG
/f)F)CIN>TC;tWt9bRjOUF9t1l\rg'-N,i7'WaXK:GU'M/<b1W?T6&.RO=E"Cej;t
gN&95k_nWX^4##dFrOXaoGIYr%^1i~>
endstream
endobj
26 0 obj
<</BBox[104.532 347.31599 517.91499 742.5]/Filter/FlateDecode/FormType 1/Length 103/Matrix[1 0 0 1 0 0]/OPI 25 0 R/Resources 24 0 R/Subtype/Form/Type/XObject>>stream
H‰Ì1@@FáÌşZbììÌ°Ûµ(@DîŸyí—w‘`¹²kDc‘.‘sPZÜMªúQ°>tÁDYÓ§Ã—fgš!Áş…ZÃ¦µ`ŞQu» =1Ğ@¯  w	Ş
endstream
endobj
25 0 obj
<</1.3<</Color[0 0 0 1(Black)]/ColorType/Process/CropFixed[0 83.33701 6890 6670]/CropRect[0 83 6890 6670]/F 21 0 R/ImageType[1 1]/Overprint false/Position[104.532 347.31599 104.532 742.5 517.91499 742.5 517.91499 347.31599]/Resolution[1200 1200]/Size[6890 6670]/Type/OPI/Version 1.3>>>>
endobj
24 0 obj
<</ExtGState<</GS1 116 0 R>>/ProcSet[/PDF]/XObject<</Fm1 23 0 R>>>>
endobj
23 0 obj
<</BBox[-0.25301 -0.87801 1.228 1.12399]/Filter/FlateDecode/FormType 1/Length 86/Matrix[1 0 0 1 0 0]/OPI 22 0 R/Resources 20 0 R/Subtype/Form/Type/XObject>>stream
H‰*ä5TÈTàÕ5Ğ342V0Ğ³´´T0Ô321TĞR†f
E©¼áZ
y¼
 h¨Í«ïl¨^Ì[Ô
‘É¹¼ú¹†
.ù¼@` 	ÏÔ
endstream
endobj
22 0 obj
<</2.0<</CropRect[0 83.33701 6890 6670]/F 21 0 R/IncludedImageQuality 1/Inks[/monochrome(Black)1]/Overprint false/Size[6890 6670]/Type/OPI/Version 2>>>>
endobj
20 0 obj
<</ExtGState<</GS1 116 0 R>>/ProcSet[/PDF/ImageB]/XObject<</Im1 19 0 R>>>>
endobj
19 0 obj
<</BitsPerComponent 1/DecodeParms<</Columns 1722/K -1>>/Filter/CCITTFaxDecode/Height 1648/ImageMask true/Length 11757/Subtype/Image/Type/XObject/Width 1722>>stream
ÿÿÎİ•&y•FvgnËAâ§åR;PR4×°ƒ<™e"8ELMfÃÿF» ÁF ÓÖÑğd°7Áé'Ú,¥€CXkIÁ‚Ñ9’”ÉN;ËöL&ˆW'í¢M0²T˜I5“®QüvÓ±Qµu¼?UŞ—okéjëıÚ®Úë¶×^µö×ZµÖg“Éš#¢Î©J2C:#ÙVáù™©Qä¥‘ùŞ’z÷Â"Aì»òãDvG-Â|`ˆ&œağNa A„BáªçØD#°MÉÙ0GˆØÂ!,´ ØL0D>´ByÉÁ,$‚+"ÒEØÓ
šu÷ASTénÁV5Ópé„ÂĞ}**i…øtpËñ‡·Á—:60ÈÇÍŒb)#dFÆ°f™³ü×^âİÁ—Ôlqh»`Ë]v"æ¿ß}“tòxÿt m&ûöğÖÛ'ŸéÁÒ|2Nƒ¢Vÿ+a‘İïzM†K	e/¿¿CÓÿ«u«øKûK¯ßıö‡iÿzxN­ÿW
½ÿİOÿ]?|WÿÓ÷ÿÿ«ÚÛıõKí?ìßıo­øB¿ıö?Óÿ[úÿqÿc×o¯¿ıõ_“	ô¿‡û÷ÿşº}õşøßÿı×Ğ/Ë«ì=xÿúÿúòëûÖ}ÿÿöÿè¸ı~ëaş¿ÿßıÿÛ®ÿÿÿïô÷ûƒïÿÿÿ_Ğnşßÿÿ}Ú_÷á½vÿ×şºşŞıl?Kÿ_ıZ¿ëõ“úïÖÿÿï¿ÿr…ôİW<Ÿıß¯¯¯¶ı½½wÿ¯÷ı¿^×öıkôÿëµ¯WõiUgúÒÎ/ÿşî—Òş×óÉøJÛókõµÍ­º»n»×6¶ÂWØ"¾—^–ºN—·KàŠ†ÿ®]Õ…ûJÁ8ûIUµ¾Áî>5ãmp—Ô‰Õ°‘æïû_+ûèBX¦)4á¥"I†+¶)4Ø¦“kN¢„œ5i=†R á±JÃK¶ÒOiı;XAPL ÃÂ¦mM „Õh Âª œB „Šj¨& ƒ6)0‚0ƒŠÕ{+(„FPÀŠFl¯ˆ`„ÍÁyÕ‚FòuàÂ&{SZÊ@L¨l$\f÷›! aOjXı‚–ÃÿÿÿÿÿÿÿçzŸÊ”]˜ŒFó».Ë³ˆÄn1Œ2ñ†b1f#‹¯Úéİªß~·uwëö¶ªê¿kzì¢ƒïS‹œ\âç8´¶JƒuÉBÿş·¯ÿÿß÷åqsÚÿşºÿÿ÷ÿÿş¿ÿíˆ´õñ¹h+®#áÿÿùG@Ìçâ°¼(rLÃŸŠ²œãšÆ‡ü´Š/•Ê÷ı®¿ßß¬³¯ÿïÿ¥ëùÉB%(‹ä]•Ö×´Èµ[ÿÿşş¿ıÿÿÿÿÕÿÿ÷®úõııw]¿ÿÿ×ıïÚé¦«^[™çfoı…ÿ„ş‚ïZ]n’ïİ×¯U¿ÔÂ×ñÿ¿ö‹çş¿õÓ².ëD¡tJQ(WÿÓ"ú­¦¿ş»ÿêë÷×ÿ½ÿïÿ¾«ıİ6·ıÿÿ¬í_ÿı†–-k»ï«b¿Õ}W†¼E¡zØşÿ_ïÿ_Ö¾Ÿ~®¿ıÿ¯÷¯÷ş¿ÿ"ÑŞ¹È¾J(]¿È½~šÿ¯ëÓû_ÿ×ÿÿ¯ZÿÚÿïÿ{÷½ÿëÿûı«ıW_ßÚªi¥ªâ"#÷ş¿ÿõ¯÷÷ş¿ÿïı{ÿ__ïò.‰J;×%”"P¿é¦EıSNÿíõÿ¿ÿÿ¯ß_ÿúÿ¿µÿı}oÿÿİÿİ¯ÿï–éo¯ÿÿıòƒ$fˆ£¤TÑ¤]DqMÆÙ„#™ÈùŒò0Ì]—ÍÈû.\ß\"`ÖŸÿ×ôïù›“ªÿİÿëÿ¿ÿÿî³°qZızWÿ½&ÿé5ş¿ÿªÿı*ÿÖ—şÿÍfyŸFêÿzJ
Ÿ¯ZEÃz¿ÿÖ‚l:µÿ¯Òÿ_ßª^Ú¯ÿëKÖ¿×ÿò‡«^½õTµêïäj*#²–U­üN¸«K­ò!ƒ	ÿK¯ûÔ±Ø/®ºU_éÒI°¿J“}Wÿ¤·÷×At¿»^Ãß„)Šª×8ıÿÑ1Ókÿ(v–OÙ®ş¼DDûø@Áxé—‹w¾ëÿih·¢ŞØB/¿ÿÖ¯õurPßÖ·¿Ö¶½dŸ×ıÛ_ïñï¾×ÿ×_ÿ[OÿHWÊ ‚q¼o÷µÉÕô×®ºõ_á²1ÂßÿúíxIüE•ÿûÿ¥øù»ûÿêßÿIş¿ö»7Úû}÷şûí/W¯÷şnmHÇiÜU³!¥_ñÃÂkÃA©!ß• bÿYnNŞÿÿ.’?ÿ÷ Õÿ¿ëZÿÿŠÿÿôÿúDFq>27õûüöÓ.A\¨/ÁïÿõF…ĞE¸µÑŸş«Ğ¤¶:A„ª‚¿ÿú^µRŸKÿ¿æÊUÒXúIkÿ÷ô¿K¤–ı~•%ş–’„¿ŞEÓ02±Pé6–±
ŸÕ¢.¥L'ı*\RU¿é'ÍQ¬4ª×°µ‚ëú»A‡(¢ãõ®”á×¯ßO¶:O	ïõÈşGÕQÇ‚)Ùí^ûıÓ~¶hTT8¤;Wşëo[´äQÕpëbUû¾ò€#ÿĞm4Ô$„Âkıö;wÓş""!‹•ÿoÚş¾Å/Õÿ«iÛÿT¾ÒJ¿°ü¨½ÿuK÷†üœ3úi{’_á¿#¯é/(Wıúş¼GşFÓzı%õê×¯õÿŞßimé{¥ªKºAß_Ûô·Trÿúa$%™ÚHÿb„vÅ%ÿò*RÇ$Ih0¦ÿÿËrwÿõÿÿ×ßÿÿğ¿ßïÿ¯ÿÿızÿÿÿ´ıÿÿüì&z2ËÿM£)È*geÈ—‚kß´íV“	zú Úí#[TZŸıÿŠV/ş÷êî“ÿızúúÿŞ¿õ3"qGÆz.d€Î½Wÿçw;Âj&¿íL/ÿúóãF‹¼Š;$ıê!ıÛ­m''Ğkÿıu
“¿uıÉİ÷ÿ·Ká¥ÜıUÿÿÕæâÂdâıÓış÷¯ü"Çê÷ÿÿúíô¿ZÿÿÛßè*ğÂßÿ]W™¯×ñë¿ëßûk_¶¶ëëÿ~×Uïÿÿ¿WÒ±M§Úût{î½¯é½¼]±oI4ÛKÿz ƒal›«V)ÂlRıü*hE£RS=ÃÖµE¹;ıß¿ªûÿé÷şºşßÿŞß¿ÒıWÿûÿÿÿ¯şÙeõ÷ş’ÿÿÿı—_¿ÆB¹œˆäPåD‡rPg-ÊrÜ¨=•dQË‚,äÎC¹‡&äxaÊs «;•åĞ—ÿò`Ô2¿ÿì¨;<ÿ"ùŞ¹Èº%ÿô""9RÍæãÌŞo7›Íæó™¼Üc7Œg3ˆÜqÍÿÇM5M4Õ4ÓL&ši¦°Ó	ØM4ÿ÷ÿ÷vºvŸúú_[B"ÓD4""-4á Ğ¸¸şò¸¸ı¿ÿÿÿÿÿ×ûş¿×ÿ×"èíg"è”,®W_²Q‘NÈ¿Oõí¿ÿOş¿ÿÿÿÿ_şõûÿõÿ]ÿï¾ş¿ÿèvšş""?ÿÿÖ¿ûw¾—T¯ÿßÿÿÿ¾¾vf¿á>ı.—"è”£½Q(È¾EÕ×ôì‹éıêïÿ×õ[ÿÿÔãÿÿ½ú__ÿ®×ÿûÿUÿÿşÒÿş«ú^½ªİÿıùn¶Ié~ıÄ_ûõÿ³´·ş¿ÿ×ÿıwÿ_ÿõëÿü”#º³°òQ‘uşÓ"öE«Óúûÿ¿ÿşëÿÿÿÿÿÿÿÿWş¿ş¿¯ù…ıöŸv±ş´[¥ïÿ÷ş¿úÿ–ê€ûëuÿış÷õ¯÷÷§şEòQ’Œ‹d_%×¯~¿ÿûßßıÿúÿ¯×ı×şÿzïêÿıÿ×ÿëïßû^Ó_õËuPÿÿÿïş¿¯ÿÿÿÿÿÿÿßÿÿş¿ä_%(”dZ"Ù(È¿ÿµÿÿÿÿÿëûÿıÿ_ÿÿÿÿÿÿÿÿÿÿÿıÆšk§ş[ªÿÿÿÿÿ÷ÿÿ_÷ÿÿÿ¯ëÿÈ¾wVEÑ(D£"ëıä£´ÓÓÿ__ÿÿÿıÿûÿÿııõÿÿ¯ÿÿÿ¯û¯¯ÿÖ"ïMÄDGÿÿàÿÿÿïÿş¿ÿÿÿÿıÿ¯ù(D¥„J(D£"ıÿMSM?¯ÿ¿ÿÿuÿÉ „1ÅÈ„ÉvgGA‰d&PÎÄò¢;*eB$¿ım$Âa8°¡A$!0šëÿÿ ‘nÁBaĞ@¡B-Ø<$[°P‰»ÿıô“j‹‡ĞP»v©aRÿÿÿü'¿m/­¿oõı¿Ş¾> á¯ÕpÿÿÿzİUÿİÎ?ÿùn°§<Ğ#æİN=y9šªõç–ON»í_~šqC^ú¯Ü&<t?ÿÂ Ï@Èqr7¯W_ıı;F‹h_ávëE»™ÛiÿíÖ‹„[¸´"ëØ¯ÿii:Ü“şì ıVµy'ÿşºW¶É>şëÿ¿÷}cı÷ë¹.®ÿo÷^¶EÀ¾ŸÿéÿÕİ/ş¬GÿÒûÿı¿·èmöïĞõş¿ıúÓÿñ\–½Ê9 Ÿ^Å=
ôC?ö)i¥ò€Îh'Ú,¯ß ºëûô²z¿Oÿù=ßÒMûş½?Ù.¿ß¿„½¯şºßıÓú_ûKñÿÿE¿Çßß´[õ[ÿõº_‹ÑË®»Kÿë¯Kº/kßïÙÅúyçïºıçÎÿ}×îôş—ş×_z½4ºìß¯éíÿÙÏ_}?ÿêÒlTCíµÖ)_cˆv»^’Õ±Qş—¶—ı Ú’zk´¤6™!ë„lRnƒ©áª·XM´½‘tJQ(Èº%”d]~3ü0ƒ	…+'°í(`±Ã	„Ô«Úm&Òb¡¦š»SH6+Òª¦º~ZB÷ÿµÿÿşÿÿê¿ÿıÛÿûßı×úÿûÿÖqÿº~«j¿Ğˆ‹ˆ¯üÿÿKÿÿûÿùØÁ‘ó`„‘’ñÌ‚Ù !%eZ:æUÄùØù(¿ÖàÂf á0ˆ[MB!,‚êAAÿô^C/ƒ™Ú¢á£d2nÑ¡ª„]Ã5Oÿ¤ømŞ•«´f{kÓlÓs[Ñpş—ï¶º7ªzöÒÕR|6–´ÿÿöû¯Õ÷Võëm+T¿ÿû«cßûu£ïï¿¯ØöNWZ¶şH‰ß~?}ıÿî½½ïÖêÇ´-t½Û²pÏÚ^ß¯Ø~ÿ¶“{×¥¥Ãú]uşEòQ’Œ‹d£"ùA/oÅzb˜~?º[qúëÿöº°ÿÕ¦úK[oú_şõÿı¿*×öÿI×aÿÿÿßşá¿'>l?'?ÒÃù8éÿıxğßïèÎÃıúKá¿¿Kÿÿïû~T^©;~>„4 Û½É8ÿê—ó½SéÖÛûÕïJ"ô…ßÿîÿÿúUÌŠ;Òù÷2¢~½İ/ÿ×ıúWûíi^!‚!İéyÿõõ»ÿêé/ş¯_uí¤ı|D\F—ºÂ_OV¶–«ş—íÿûJÁÚG®û¥	6‘ëí%	:G¯Kÿ„Åi1QALWò(ø…jÚ_\ìAÊÂÖ°Œ‚‡Öü§‚ÖìWü²£%\CMkş"">Â0ÿ×ÿKÿÿëıÿõÿ×ú_÷_è‹çu"Pˆ¾J2.¿şJ;NôÿıëÒÿû¯­Ü%ÿÿõÿÿşÿşÿ½õı×„¿ÿ×ÿş…ÿkÿe¸•ş³‹ş£ÿ¯ıÿ¯_í~ÿş‚ÿ×ÿåMæ#qŒÜmÍæóy¸Şo7›£q>n7›ÿÖ§z	¦šié¦š„óši‘Qû…õû[õıı5êº÷˜MBhZˆ†„E ÓB#¿\®./²-|”"/‘|”d]%ş½?Óÿÿß÷ÿ¯ıˆ_ûú¿úßı~÷ÿş¿ÿİõş¿éRÊå’ö…¡İ}øˆµÿ’kõø_zışº	ëß¯ı/]¥ïÿúfiHG®ßôWšFò/|”dZR/%ÿõ«õÿÿéÿºÂûïúø^—ÿûÿÿî“ÿşşúÿõöımWêv°?Ùo–ƒÿëúKFÇüéÿuÓüè.´µ_ûO^ôzëzÿı.øAkÖ¡p»û¥×]d[%(‹Ä["ù(ĞZ_íÒÒ3_¯ÿÕ ¿ÿüÁhy7Sÿõıiëÿõÿß=ş¿ä’uÿÿúÅ§Òÿâ"(/Oÿ¯´¿¾‚ôÿ_u¯ÿ‚^ŸëïÚú^’ö¿ïßízı¯Áõö¾JİH‹ä_	/¦EôûA_¯ÿë_Oÿø_×ÿú/Oßş¿ÿ÷úúÿÿûÿş¯÷ÿşÿ¯´-;„«ëâ"0Cøí}ú^Ö/ÿíÚ&À_2K‡Ñn²Eg¦v›f"dˆDH¿é„ï_	…¦š^Öª½ÑvåÃë%_õN‚{sh¨ÈkÓYxÿ¾ŞØM3¤0@ÏŒØÍx"ÇŸˆøP´şH~)wšh0ªzd€Åä äÇÿíI;Ó¤Ó·­>gÏüG¶©l(O//œ¾.Üİ—v¢ñ¸ã®È¶wR"ÿÿîŞõzMStÿÓõ¬”iòCöş•Wı
ÿıu¥ïøö?ßÛøëıõõÿ»é}ıôNz_ÿË1VûKÿÿëî°—¿üÊ¤–•ÌæÓÿ1¥ÿı2Ğ¢ÿı.³;ÿñô½}È£şÕµ{»\Îí[?{gëĞ_ê£ö**ê¯°¶ÚÚÿöµ¥÷|"´ğîâ˜­Šb—‡ìyûC,DEM¦UMm4ıû]éù
?LA„îÔÎa4ÂaS»[®¼~"#–úø"c’ÃÎ?Oõ$2C$2r(gL¡æˆë“&tD6CGTv’İkü@äGÃA„M0ƒ3˜Dsf3Aš&h0™˜¦b™Šf3AšÌf‚‚"Ì‹23‘Ğ•3 ÌÆh3AšĞfƒ4"q™ŒĞf„N3B4¾Gv¶ıéé¦ši§êškké¦ŸjİÚiªiÃM~ù!È#ıë¯ÿıö¯ÿÿ~ÿÕoïõşµÄtÕ;NÓ´›NÓMS]4ïO»ôí=;»ÖínîÕcÁdQóJ’Ê¨ƒ	®‹ ûÈ,A¤ğX~K×ãëşü‹Ä¡„Eğ—´[/ªz x´ŸşÖ?¿ß@‚ı}W×½ûßyÁqı%ÿÂÇöMÂ×­t
@ğÖµ§ïãÓıUãAzä×á(ôş/şúÿYÃh{ÿ£Úú
E‡ÿ_	}‚úõ Ô?¾×AH,ßñùn«—EòDkÎÉc‹‘|î¤$)~Ò øBañ…v™Y"'%hÇ×­-i¨Aû­ÿªKñĞjŸıËsJZ?ÉTHw÷Á/ß¤ó.É3Š\Ñ Aø ÿ^¿´AÂág‚ ËØDiËsÕoıWé)ôM;ü&Hm¯ÿ²@ÿâ
NÛ$ô\:EÃDİ«úzëOÿArô­ªá6‚/Â/æë
¹cÛ_ûñü»}=?ôé7¿ûcéÚv‚_¤Âÿë_ı/Òíxˆ CøÿúñÿñŞ–Çùr
ëıÓÿ×şN_¿;+‰
Î#R>Ë™v„y•J¯ûY÷Èƒ¯ÿ¿B&?r İrÊy?ı|Úyƒó¶¸úõÓ¯ıºÌÿÿÇ¬ß_í[_ïÌşÓÌïşÏŞFV»_¨«ı+	í¤Úÿí«/~¤ ä9±È`~ğş6++áüq›¶+ÄD°Ÿé­„×ß´××d(äô»Ìè0°Ği§&†¶„zˆˆvM†´#©ÀÀäãôÔD|G§ş¯îš¿%
@ğ.=îº’±÷²ü·&¿¡ŞŸù‚Èä0?ÿÜDÿÈûıGÒÿğÕÿı{C!éñkÿ¯ú¾¿ş¬·1ğ]£ROè›÷¿ÿIõ÷ixE÷¯ëĞºÿ†GE#:">NÎ‘B)ÑGhÍY1iô¸†f*Z‹0ÌÆh3Aš Í™4˜¦c4 ÍĞfƒ4"pnNDäh3B'#A“™9¡9‘¡‘9’Ê>=şšj©ªzpÕuM4ôÓTÓNÓMƒNĞi¦šh4á§õÿëşûÿõ¿ïÑÿ¿]S[ï×^EòR‚]=S^ôíSTí4ûõ½5´×½mS»½uî¿µ~uêEq¦v¡ˆ°De8@Ó	•	Zõş9nÊ‹ú]¹]i*t¿ıªûşéÂø¿­P^×ÿúşõÿÜA/¯Œ/kéôƒö—uéôÿôŸÖC Ç÷ôwä5Gÿê=/¥ïõÿİj×ª÷úRãŞ¾±Õ|‹áLr ƒ÷ÿñğ¿µû×ûş‚ä5G!œr†0ıïŸü)«×®FØ*¶£üË^ÿZùÀÜr
 Ò9Á@õNüDFıùÀœrãÎ>õ:ˆiã²XİXˆÖé0ƒ?gaV§c‘/òãõzAúøO	øİ;˜ãÚşF9
9ãÎ9€Î?¿›ú.ØT]¿,/pƒË™×.F„f‹³„hfhÛSvféÖ›úw¤¿Ğ´L Ğ¸~d€ÇªUıjDåı§¦şÖæ~>ClsaÌ=­ïÃ
]¹;¢íËÂí¢ñÉÅ…¼»oXùsñoÓÓĞz ôôõè'â“…Ã˜r†qÌ9‡#¯6?ÿm/Úúoşÿ¿ ¶
«–Sh_ış/QBÿÖ_åçÈiF9·¯ÿÿÿ÷Œ£6GOúoÄF­5}ÿ]ÿ¨BÁÿùĞä2L}VF*ëûæÓËşÌ#úÿˆßi=¿ÿ÷kş·k§ıÈeC$(ı«¿KÿÍŸ¬Í§™¡ÿõûM„¡…şÒl'Úè=oík¶–äC<2Çªkı…†»a¥ÿ¶“yqê#+‹Vš‡ñLWÇì=ã¤ö¼ğÿ°Âa?Ó[A…¿«Mj×Œ©fóˆâ9›ÍäùÄqÄqÑäQè<D8µ,t!0CNÓA„[†mši ÓM2í4Ó0Âa™ˆÃA„Ë´Ë³‡éˆå¸a¿ÿÿÿ×½÷şšá4ÓM4ÓBÓXi§iİ…×Iÿ+‹®¼†Hjõ¿ÿMxı?Ó_ıü®Wmıúÿ×ûş´Âû»´ÿÒ¯÷_í_ú_ı™Qi°Ÿï¯ôÒMïşkF¤@‘tCTë^E˜3ALÅY˜Í>) ó1LÆf)˜¦b™Œœ‰ÈĞdäh3Aš9Ğ‰ÈĞfƒ'"r4"r(3B'¡9”eò†Pe!Ä;42‘’DtŸ~ítîî×OûM4Âiªiª4ÓM4a4Õ0š0ƒ@ÂxLÌPƒ4E˜3â™Š¿¯õW_ışşÿõÿşõï»îõ^ïÿµ´íSW¿¿îõ_Uõ½ß_UÖ×ûı²¶¶ÄYZÂeB `ƒ0ƒ=Aˆ0ˆ3aqÂa0ƒ	 Á4Ê¡ÓM4í4ÓM0šiªiªiÿâ¥•,!•ûM¯¦šÿk¿úi/ï»ò£Èqû»^#¦îF9±çkF%ê#N»OÈ*@ğÎ9Á@ä(äF†ØwüDDi7K×>ŒrÇ¯µ\î‹ˆ¯Úx¯¿T¿_A÷r/™‚Ø/ê­êÛ¾¿!Ç  r
ãË†F?ÒNÿÄDGîšÿh…†@gŒrcúOoüDDZä8ä1şí'uı¥«Èdäcşê¯Än´÷ùãÓÒ´õâ?úü†@,aÈQí¥ïÖ"6×¦»È…†@`|Sº_ˆŒ4šÿ?XñjØCâ=_û¿Ô&ŸqÌ9ˆ¯ˆ‡dYGLíc7yÇ Ò9€SõR0`…œ“;
ÓÎİšîEøˆOO]}L < xeA˜}é§Öµ„İ?ÄGµh»s‘¬|ÖˆäŸä‡ x3kZu¼ŞAçL„‰¢ñˆiÄ{Wú!‚ø¡3áeìùÿ¥AıÈ8äÇõ´úİ Ô&ƒOğƒ$)×¿Q½
È˜v´šwúĞ×äáœrr‚ôÂzM¤_dî‹Ç/™»'vÍÙŸé/â">ô¤ÇÂzoWJÚöÄÿ!¬9qşÒ°¾¾ş¨w÷ô¿I.1Ó¤/÷¼ÿÆ·¥ä3!G ®9qÈ1È9
?ÒA_ßÿöhP7Ò	y°]rËM»¿ëëÿ«¿ÒòÈ‘È,úHŸúş`üÁÿæ.¿Òñ«N•­~—æÿâ=*ÈqÈ#Î91øéiwwæu6gzşg6•%â"=íşÖÂİ¤ÚûûmV¿´ˆ=¨Ålqü?3–ˆ"¯¿´ÿMm5÷í4½ÿÜ\4ÔÃ¦ša[øaÒUö„Dsµxˆ‹NKşA˜r#ÔqÄä	 N9qÈCş±ùã‘û‘~#ÇûÿëÈ7ŒsC ÇÙÙœHe©~"#‘fEò'‘fE™d_"Ì0ƒD_ÌS1š
f3AšĞfƒ4˜Íh3B4Ìfc4Ğf„h2r'#B49‘9“ŒĞfc'#B(2r'#Gù¡Ì9ÂC8ä	Ç p?ûµ[½{MSNÓUM5O»ÓNÓ	§i¦ƒµ´ÓAÚw~Al\³şÿ[İ{ÿw÷ÚÚ}ÿªÿzÚ§kù!È#<0şšiªvŸÚİö©¦©İ§§¦©¯kwş·İªÄDG:ãaˆ†Q Eza0ƒ4h4Ö«RÇ!G xÇ©j™øÄGùñÈQÈQÈkA¤{Ş""5òƒWá¶=üDyfU rÇ Î9äÇ!¶9aÌ?S-;È-‚ë–{ò†ãSáœr1Ègõë ¶®Y¿ú}õÿ½ı›
¡ÉBù+¯ÔÊñHá–Gˆã#†r8ÈàÛ§şC 5—+¯~@ğh†ĞÿZ‘|”d_A›ÿÛôÇÿÿÿ@ğhßü7eWÿùÃ@ıkı°ãÿşÈÎ?¶¿ïé×Ş ä¡û¿n=7íHmAL~µøß² ~v=~½µÌ•†@kë]ûëùøø÷ş×úÿÿı.EòQ‘ÿ÷íıÿş×¿úõûå Iª;%Œ?üáÈÎJ„J„J„LäÉÌÉÑ:d6HdˆgDHdˆ†ÈyÕ¤HÔ&~ÎÂµÎî òsÿÆšiªi Âv©„Ğ†0˜A„fƒ0ƒ	‚Ğfc4 fb™Œœfƒ3 Íf3AšĞfƒ4¡‘ Íœ‰ÆhF†êú¨Aÿÿ´õõ´ÖÓON×»M;TôÓ[Õ4ôÓ´ÓTÓTõ_ÚÕSûÔ†@ƒşªßß¿ëÿşïÓõşïÕeÛüuY1ßætÓNÂ¦šj©éª¦©ÚÚi÷ki§­¦šwi¯ë}Ö<ÄjFâC!ç™C:^g(Tå¡Øı8†„0A Âp(A˜°ƒ:ªÿ<‡ã;ÒîîƒNípšÌ?¡ãû'DßHœQw“‹OËwÂyâ—÷¦äñÂæà› İ;¤ƒd*8/ûß®´¿zêşéÇëÿşûæÔSúúïÛÿëÿÇÔ_ş†ø7yÁ ÿõÿÿù ` _n±ıÿÿõÿÕ¯şAr
ãş¿ï›O6ŸîYu^ïûúû™ßÿˆ®Ÿÿ´¿û?w¶~ıw?{õıøi6½­¯ıZı„¼ ÿ¨ÅlSpûcÏÛãè5O´×Mû]«ò/’Œ‹Ëˆ»\±Ó
ƒL*wi¦îÂÿøˆÑ’Â¿ïØÿÿ¯èá¦?ÿñÿÿÚÿøßöC \Zâ2ƒÿÑ€ƒ£ÿıÿü¯[;pmı¹ãÿqü7!Çÿğşá¹ãú¼yi/~Ÿ"ù(È¾Eò/†O×ïVÿÿëß}ü÷ı÷ûÿ×ÿ_ûö÷ÿöÿªÿÿÿÅªh0}7ÿ¯ì;şßıëïÿPÁÿÛ¿ÿúH[ûıÿÛÿƒÿşEóµ„JE8ß%í;ë÷ıWõëö÷ÿöı_¿ûÿïÿıüÿÿ¿ÿ_ı¡zkaÿÄDD?ş¯ûÿn¿òwÿûşı<†PÿíÇı¹9‡ÿXön?õÇû¹ÿ‘tv²‰B%?é’„J;Oyÿîÿxÿı/·"Bÿÿ[qe­ÿŞşBÿÿÿŸşÿoÿ_¯ß§íúv·ÿå¸fH/û×ú«ÓöÜ†ZÅëÿïğı?·!GÿøÊâÂÿäsÿ@ÜE(Äa—f#ˆÄb0Ë²ìÄb0Ë²ìÄb1f#‡µï»¿íSÿM?Ó»Ó¿kÿUUÓµµNÓM4íU;M5ÿƒÊâÂ¿ßèÉMŞ‡Ñ‰FEò-l”o•Êçÿÿò:ëÿ¿ñ{_ÿû¯ÿı÷ïÿ¿ùïÿ¯àˆôÿúöAÇãÿ×ø¿ÿÿÿËp0Òÿ"ÿ¡ÿïşBÿşAÿ÷ş¯ü‚¿ÇûÀşµşDŞÈ¶JQ(Èº"ù(Èº_w§éÿ¯ÿzÚõÿÿûşÿïÿ×ÈQÌ?ÿÿñ^¿¿AæP»ÿøÂ¾ĞíWZ¢ÜhÑvõò9‡Â~¼E×·ñÿï¥ÿ¿¯ú­ş¿¾ºÖvH*_ôëÿIk÷K½â»ZÒ?ÿ"ù)D£"Ùˆ¾E×_~ï¿¼!ëÿëí-¯ÿùÚÿÿÿ£#¯ÿ÷¯ÿÿï×ÿÖïúûÿşĞí5Uuü·ïo¯×^ßûÿ÷ïúı?¯ÿıÿÿÿÿ¯÷ÿ{şJİH‹çzä]õ%*ì‹z}wîşşş¿_î÷ÿ¿­.¿ÿıÿÿÿÿ¿×ıw×ïşÿÿÿÿûhvºvÿåº¯ş¿ıÿßÿÿúÿßÿÿÿÛªÿßÿÿÿÿÿ_%íeê‰Bûúd_%d[´í?ûşçp¿××ÕcÿûÖÛÿßûÿş«ıÿëßê­×û_ßïş×ûõ÷qzş"?ÿëúß÷ÿÿÿûÿüÈš¯ùØ”GØB¿ú[U~ı Âaßõ
©?ş«½Wôºkşıb¿ÉB;«"è‹ä¡a/¯êJVºdZZU?–mÿÿÿZ Pˆ$Sÿßß½HÇ‡FÄ¡ıõúÅRUHÏ¿ßWÿHºu¨…×é/úúúU¯÷ÿŞ½/T¿êÿÿU¯ªÿµûıWM„«ş"-µş¬R¯ñT¶c¯ÿ~¨‘ëá¦±_Uàê¾ş8H…¼/ï¾Ò3±kë¸ˆ¤}ßÒuÿïÿí_ûm„¿û¿Ä¶'ş?÷ùÉJ%È¾Eò/ÿûíoÿÚûÿÿ®¿ÿí÷}ÿëúÿÿ]}ggÌds;Q¯ûı÷B ÿ÷]ë«5oúÿ¯f¢O_–éoÈE¿÷K_ş¸¨ïÿïş§‘C/œgÙ>S¿ÿJÓ‚ Î0Oşú¢á¢àz-ßıb]:LÏ¤ÿÕ*ê³×T¿ù³Zé*ª¯ÿİz_ªI/ş¾½u®	RÿªJ—l$•!·ÿ~+X]_¤˜ZÁWÿT—œŠækşEòS‘|‹d_"ñŞHë#êG×PŠªÿµïıb8¨¨r1ÆÅ%şŸşğƒ‘ºªƒªªÿı}*°©¦‚Âh4•ÿ¯ÿlˆ_¿ÿÒKÿ÷ú_ê–ÿïKÿ½u[a$¿n;ïìR_¢İ-†
üG¯÷ÿÿïı÷ÿ¯×şÿÿÿÿ{ú%íe|”-k©)D£]2-}ıë×ßÿö×ßúú_Kÿû~ïû¿ş×ÿÿ¯ş¿÷ÿÿö†½¯ş[¥½µÿşŸúÿëûÿõÿÿÿÿ¯ÿıò/’”J2-l‹ä_úöŸ]ÿş¿ÿşÿÿÿÿÿÿÿÿı?ÿÿÿÿÿÿşĞĞüDÿÿ¿äB¯ãÿÿÿÿÿÿÿÿÿÿÿü”#!¥¯Ô”d£"İ‘|‹ø/ïÿü¡‘¤y~Ÿÿä	A¾Ò§;È8ä50ˆä^)Êr°­«ÿÿùh+.¿¯ó%µ[úºü…²ìÄ]˜Œ2ñˆÃ.ÌF#Äb1ŒFvb0Âf$A‡#¾@Ïëßwêºªéúk«&ÊPåANTÊr9G {…rëû»]4Ó»Ó»í4ÓM;ÈT¼®.Èædƒ2™iy…I§6„ø©•sŸƒF0­	ÙÌ²¬‹ç™B¸§÷kjdu‹ˆˆĞ‹h\DXB/şºş¿üï¿}ÿßªşÿÿÿÿÿÿ¾ÿ¯şş±a4Óÿ×şñfÿñ;õ[òÂØnw¯¸ÿ–©ª;ËQ,Càg ÆKYÄò<kÊ²(ĞÛA„ŠãYgLêg³ŠYÄ…A{!àƒuÂËèdşš&¸¡=8‹é‘lŠ™È¬EY(DU82Pğˆâ$ÒA´~ à°Üî‚‚2$0šdL“@Ú'i @íMÄùÓ{I6•¥²Ïÿwúï¤ım/ôé>÷»í5ZßIëßñ+_èğçŒñ4g¼ğç‡<?NŸ¯ßÒÿ~ôêû[­ïõâ«v8ßÒê?_ÿÿ÷¿´Ÿáfª§ÿÿ¯ëªÿß4S¿Ûô”İº0ôgÿÿÿëó-«şÃÕ(‡İ=^gÿÿşÿ¿ÂºêÃ;õ×ÿÿÿ×ÿëªW^ÃÊ±,võï¯õÿÿÿş=ÿ÷OVºW®´ÿÿÿUÒ¿Ã_ÈS{ë·ãˆQÅEGk'İÿíÖÒzäûwÚ}Ú¥§«ü?W{ïª½?»¾õÿA…ı¼wşÒ{ï»MoÓë¼}euú«İıå–¶]â›¾;ı¤²wC¯˜ÿÿÿcÑ‘¹İHíV%(Šçdké7”êöÿÒëşvq‘l‰²øA‘±‚d[
_Kıµõô›×tŸ¯}õû¶µÚ_Ö×İ_õ×ó"b%é[i}¥dÁ„›_÷¾D‡÷sÈØ¾©§~ÚWÅ'Å[J·Ğ"=hî9î‰¿‚#ıñÕa±Zl§l&éªkşõş?@”9² `›0•ÒĞƒ)X ĞBA„õNÿ®ïˆîî^"8ó;½sºÃÿ²ŸÎ8U™²×÷ıW‚#ş¿ïÿÿıb¸ïËTU~=~7AúøôŸÚàˆÿŞôş7ŞÁXŠb=¼{¶ñ]>÷ÿÿúûwÎõÚvšiÆX[ÿ-Ujvr"Ì‰¢;"dYnA‘c3©‘±™d lL·
N*…Oûåí5àÉ?‹µœ\âç3"tOjº"Dı´Å½5KöÿZ[şûİ_K]ÿtª·ßÈIJ½Ô£DN#DÓD.‰4`ˆg‚…œñ› ïÓA¹ÂÂv
cŸKH¸~ÈG	¯¢íƒ'”ƒ‡tkn¡ ËôøpËıuŞÒazMÚNûuïãßö½+Z×î½ßı×şë“è¯şñë¸*ûu§ÿı¿Â¿ëğŸõèµÌµ¨EÇöë¸DãúşÚú_ÿÅ^İ× »ö×¥ûû¥ÿ×ÿ¯r…ÿUì}+ùIı­_ßõúõÖÕëU_iúûu]„PíK§ì¿ü v_ä*Xİ66"ÓØÚ¦ÅE,‚ü ÚÓ©ÂA„ë‚Èİ46äW´Òm4Òh6ªË‹4×†™Ğ6å˜ˆ¥Pı%ZÑ6[%Ø2â¥bVòº|§"‘¸aA¶·Ûÿ¼›…2ª÷„ÂÎïoÛÑ>‡ÿ	şŞ¯öışßÿoÿ·Û”Aeı±	„{o†‹€Ñ­á·°ĞN¯Óö6¤Şœ0Õ­½/íĞ´¼^Üj!»áynSP"¸o¸ZC·&åI½o¥_§ŞÉÒı“ñ×÷÷M­}¥ûJ×a®ÒcÓ#üVI¨|SLĞAµ,éM0“)al7ËT×ñÿÿÿ€ €
endstream
endobj
21 0 obj
<</F(Volume A:RHEUMA.MAY.2005:2004-566.fig.1)/Type/Filespec>>
endobj
35 0 obj
<</BaseFont/PNBOGP+ZapfDingbats/Encoding 44 0 R/FirstChar 1/FontDescriptor 40 0 R/LastChar 2/Subtype/Type1/ToUnicode 45 0 R/Type/Font/Widths[278 788]>>
endobj
44 0 obj
<</Differences[1/space/a78]/Type/Encoding>>
endobj
40 0 obj
<</Ascent 0/CapHeight 0/CharSet(/a78)/Descent 0/Flags 4/FontBBox[-1 -143 981 820]/FontFile3 41 0 R/FontName/PNBOGP+ZapfDingbats/ItalicAngle 0/StemV 90/Type/FontDescriptor>>
endobj
45 0 obj
<</Filter/FlateDecode/Length 213>>stream
H‰TP=¯Â0Üû+<‚’2W]`é ï‰>ØÒÄ©"Q'rÒÿ’ò%[òÏ>[ìº}G.øe¯{L`ÆègÖ Ş‚q:=«%ëIYÜßcÂ©#ë¡i*qÊdL|‡ÕU»w4*Å\ƒøaƒœXıÕçKú9„NH	$´-´•ØT8ª	A|XØú¹ÜŒAidE#B#ëö‘Ì7÷RöQ~Z)·²­²âÅq¹êí@ÏÌÙÜrúâ«xp„ïïÊÊÕ¿  ÂmÉ
endstream
endobj
41 0 obj
<</Filter/FlateDecode/Length 322/Subtype/Type1C>>stream
H‰bd`ab`dd	ğsòwĞJ,HsÉÌKOJ,)‰›ÿaø!ËøCé‡óq–ò<b]¿•eş<Á*·€ñw7„äaÿ~JàûYşïg|ÿ%ÄÀÊÈÈÂ½ãäÕDs#=çü‚Ê¢ÌôŒdMCKSi&-À¤%ˆ´4WpLÉOJU®,.IÍ-VğÌKÎ/*È/J,IMÑSpÌÉQS¬”ZœZTôqV 9\ær…Ìb…D…¢ÔôL E©)
%E‰)©¹‰EÙ
ùi@‚y‰%™ùy‰9
!•©i‰É©
ÎP[€Â˜&¢„c)c;Ğ“ªßWñı\1©ìûŸòüåŒë~&3ÿ«ışçûŸß¾ÿV¾Ú™?=füş=ƒm9×Sn€  «Â‰h
endstream
endobj
168 0 obj
<</BG2/Default/OP true/OPM 1/SA false/SM 0.0200043/TR2/Default/Type/ExtGState/UCR2/Default/op true>>
endobj
169 0 obj
<</BG2/Default/OP false/OPM 0/SA false/SM 1.0/TR2/Default/UCR2/Default/op false>>
endobj
182 0 obj
<</A 183 0 R/Border[0 0 0]/Rect[466.77 15.0 541.0 27.0]/Subtype/Link/Type/Annot>>
endobj
183 0 obj
<</S/URI/URI(http://www.jrheum.org/)>>
endobj
162 0 obj
[184 0 R]
endobj
163 0 obj
<</Length 14048>>stream
1 g
/GS0 gs
0 792 m
0 792 l
f
q
13.5 787.5 585 -783 re
W n
q
0 792.03 612 -792 re
W n
BT
0 0 0 1 k
/GS1 gs
/T1_0 1 Tf
-0.00011 Tc 0.0807 Tw 10 0 0 10 54 302.6694 Tm
(along the fatigue severity continuum. Specific interest was)Tj
0.0407 Tw 0 -1.21 TD
[(in the question of which instrument, if any)64.8 (, was better \322tar-)]TJ
0.0972 Tw T*
[(geted\323 to this RA)-292.4 (population. IR)59.7 (T)-329.3 (allows determination of)]TJ
0.2312 Tw T*
[(which questions dif)17.7 (ferentiate people at low)64.8 (, middle, and)]TJ
0.2424 Tw T*
(high ranges of what is being measured \321 in this case,)Tj
0.0679 Tw T*
[(fatigue. )17.7 (The results in Figure 1 show that the 4 items from)]TJ
-0.0022 Tw T*
[(the SF-36 )17.7 (V)59.8 (itality scale tend to locate on the high end of the)]TJ
0.07561 Tw T*
[(fatigue continuum \(i.e., they dif)17.7 (ferentiate people with rela-)]TJ
0.1449 Tw T*
[(tively low fatigue very well, but they do not dif)17.7 (ferentiate)]TJ
0.0105 Tw T*
(people with moderate to severe fatigue as well\). In contrast,)Tj
0.0361 Tw T*
[(the MAF was tar)17.7 (geted in the middle range of fatigue \(com-)]TJ
0.07001 Tw T*
(pare in Figure 1 the range of MAF item plots to the distri-)Tj
-0.0349 Tw T*
[(bution of patients\). Finally)64.8 (, the F)73.9 (ACIT)-197.3 (Fatigue scale covered)]TJ
0.15041 Tw T*
(essentially the entire range of the distribution of patients,)Tj
0.1736 Tw T*
(with the exception of those with very little fatigue. Both)Tj
0.18111 Tw T*
[(F)74 (ACIT)-413.4 (Fatigue and MAF covered a wider range of self-)]TJ
0.2249 Tw T*
[(reported fatigue than SF-36 )17.7 (V)59.8 (itality)64.8 (, and F)73.9 (ACIT)-457.2 (Fatigue)]TJ
0.02499 Tw T*
[(covered a wider range than MAF)79.7 (.)]TJ
/T1_1 1 Tf
0 Tw 26.4 20.57 Td
(DISCUSSION)Tj
/T1_0 1 Tf
0.1499 Tw T*
(The goal of our study was to validate a brief measure of)Tj
0.00841 Tc 0.3665 Tw T*
(fatigue, originally developed to assess anemia related)Tj
-0.00011 Tc 0.04649 Tw T*
[(fatigue in patients with cancer)39.7 (, in a sample of patients with)]TJ
-0.01311 Tw T*
[(RA. )17.7 (The F)73.9 (ACIT)-219.2 (Fatigue scale, a 13 item measure of fatigue,)]TJ
0.3103 Tw T*
(showed good internal consistency in patients with RA,)Tj
0.0401 Tw T*
(which was comparable to that of 2 other fatigue scales pre-)Tj
-0.00011 Tw T*
[(viously validated in this population, the SF-36 )17.8 (V)59.8 (itality scale)]TJ
-0.0334 Tw T*
[(and the MAF)79.7 (. )17.7 (The baseline F)73.9 (ACIT)-198.9 (Fatigue scale scores were)]TJ
0.1563 Tw T*
[(strongly associated with scores on the SF-36 )17.7 (V)59.8 (itality and)]TJ
-0.03529 Tw T*
[(MAF)79.7 (, providing evidence of conver)17.7 (gent validity)64.8 (. Changes in)]TJ
0.0058 Tw T*
[(F)74 (ACIT)-238.1 (Fatigue scale scores over 24 weeks successfully dis-)]TJ
0.04289 Tw T*
(criminated between groups defined by levels of the clinical)Tj
-0.09081 Tw T*
[(endpoint, )-54.9 (the ACR20, ACR50, )-54.9 (and ACR70. )-37.1 (Thus, )-54.8 (patients )-54.8 (in)]TJ
0.06081 Tw T*
(ACR groups reflecting greater clinical improvement in RA)Tj
0.11909 Tw T*
[(also showed lar)17.7 (ger increases in their F)73.9 (ACIT)-351.5 (Fatigue scale)]TJ
0.02319 Tw T*
[(scores, indicating decreased levels of fatigue. Further)39.7 (, these)]TJ
-0.01489 Tw T*
[(changes in F)73.9 (ACIT)-217.3 (Fatigue scale scores were associated with)]TJ
ET
0 0 0 1 K
53.964 76.5 m
558.972 76.5 l
S
0 0 0 0 k
52.822 69.665 64.178 -15.665 re
f*
BT
0 0 0 1 k
/T1_2 1 Tf
0 Tc 0 Tw 8 0 0 8 53.8216 56.7343 Tm
(816)Tj
ET
0 0 0 0 k
356 69.665 203 -15.665 re
f*
BT
0 0 0 1 k
/T1_2 1 Tf
-0.00011 Tc 0.02499 Tw 8 0 0 8 424.3613 56.7343 Tm
(The Journal of Rheumatology 2005; 32:5)Tj
ET
0 0 0 0 k
/GS0 gs
103.631 82.583 407.5 -10.833 re
f*
0.5 w 
/GS1 gs
103.631 82.583 407.5 -10.833 re
S
BT
0 0 0 1 k
/T1_2 1 Tf
0 Tc 8 0 0 8 53.532 737.0293 Tm
[(T)91.9 (able 5. )]TJ
/T1_0 1 Tf
-0.00011 Tc 3.7608 0 Td
[(F)74 (ACIT)-257.3 (Fatigue scale and SF-36 )17.7 (V)59.8 (itality change scores \(baseline to )17.7 (W)79.9 (eek 24\) by MAF minimally important dif)17.7 (ference \(MID\)* groups.)]TJ
/T1_3 1 Tf
0 Tc 0 Tw 6.4689 -2.5 Td
(\004)Tj
/T1_0 1 Tf
0.02499 Tw 1.0988 0 Td
[(\3200.5 SD)-2287.3 (> \3200.5 to )]TJ
/T1_3 1 Tf
0 Tw [0.4 (\004)]TJ
/T1_0 1 Tf
0.02499 Tw 10.6057 0 Td
[(\3200.2 SD)-2110.2 (> \3200.2 to )]TJ
/T1_3 1 Tf
0 Tw [0.4 (\004)]TJ
/T1_0 1 Tf
0.02499 Tw 10.4286 0 Td
[(0.2 SD)-1799.5 (> 0.2 to )]TJ
/T1_3 1 Tf
0 Tw [0.4 (\004)]TJ
/T1_0 1 Tf
-0.00011 Tc 0.02499 Tw 9.1179 0 Td
[(0.5 SD)-2716.9 (> 0.5 SD)-2998.8 (A)74 (verage Dif)17.7 (ference)]TJ
0 Tc 0 Tw 6 0 0 6 545.4034 719.6693 Tm
(\240)Tj
-0.00011 Tc 0.02499 Tw 8 0 0 8 53.532 697.0293 Tm
[(F)74 (ACIT)-257.3 (Fatigue scale change scores)]TJ
0.75 -1.25 Td
(MID groups)Tj
/T1_3 1 Tf
0 Tc 0 Tw 9.0002 0 Td
(\003)Tj
/T1_0 1 Tf
-0.00011 Tc 6 0 0 6 136.4281 684.3893 Tm
(MAF)Tj
/T1_3 1 Tf
0 Tc 8 0 0 8 151.6286 687.0293 Tm
(\004)Tj
/T1_0 1 Tf
0.02499 Tw 1.0988 0 Td
[(\3205.9)-1854.6 (\3205.9 < )]TJ
/T1_3 1 Tf
0 Tw (\003)Tj
/T1_0 1 Tf
-0.00011 Tc 6 0 0 6 217.0626 684.3893 Tm
(MAF)Tj
/T1_3 1 Tf
0 Tc 8 0 0 8 232.2631 687.0293 Tm
(\004)Tj
/T1_0 1 Tf
0.02499 Tw 1.0988 0 Td
[(\3202.4)-2203.9 (\3202.4 < )]TJ
/T1_3 1 Tf
0 Tw (\003)Tj
/T1_0 1 Tf
-0.00011 Tc 6 0 0 6 300.4917 684.3893 Tm
(MAF)Tj
/T1_3 1 Tf
0 Tc 8 0 0 8 315.6922 687.0293 Tm
(\004)Tj
/T1_0 1 Tf
0.02499 Tw 1.0988 0 Td
[(2.4)-1893.3 (2.4 < )]TJ
/T1_3 1 Tf
0 Tw (\003)Tj
/T1_0 1 Tf
-0.00011 Tc 6 0 0 6 373.4353 684.3893 Tm
(MAF)Tj
/T1_3 1 Tf
0 Tc 8 0 0 8 388.6358 687.0293 Tm
(\004)Tj
/T1_0 1 Tf
1.0988 0 Td
(5.9)Tj
/T1_3 1 Tf
3.5342 0 Td
(\003)Tj
/T1_0 1 Tf
-0.0002 Tc 6 0 0 6 430.5945 684.3893 Tm
(MAF)Tj
0 Tc 0.02499 Tw 8 0 0 8 445.795 687.0293 Tm
(> 5.9)Tj
-0.00011 Tc -38.4921 -1.25 Td
[(\(n = 331\))-5117.9 (\(n = 73\))-6667.7 (\(n = 1)36.8 (10\))-5857 (\(n = 55\))-4917.6 (\(n = 62\))]TJ
0 Tc 0 Tw -8.9194 -1.25 Td
[(Mean)-7407.6 (10.73)-6647.3 (4.12)-8428.6 (1.45)-7367.9 (\3201.06)-5946.9 (\3204.22)-6928.6 (3.74)]TJ
0 -1.25 TD
[(SD)-8656.3 (9.15)-6897.3 (5.03)-8428.6 (5.19)-7617.9 (6.43)-6446.9 (7.09)]TJ
-0.00011 Tc 0.02499 Tw 0.9008 -1.25 Td
(p value)Tj
0 Tc 0 Tw 6 0 0 6 97.2333 649.6693 Tm
(\240\240)Tj
0.02499 Tw 8 0 0 8 140.6205 647.0293 Tm
(< 0.001)Tj
8.64739 0 Td
(< 0.001)Tj
10.5981 0 Td
(0.045)Tj
9.3679 0 Td
(0.301)Tj
7.7775 0 Td
(< 0.001)Tj
-0.00011 Tc -47.27699 -1.25 Td
[(SF-36 )17.7 (V)59.8 (itality change scores)]TJ
0.75 -1.25 Td
(MID groups)Tj
/T1_3 1 Tf
0 Tc 0 Tw 9.0002 0 Td
(\003)Tj
/T1_0 1 Tf
-0.00011 Tc 6 0 0 6 136.4281 624.3893 Tm
(MAF)Tj
/T1_3 1 Tf
0 Tc 8 0 0 8 151.6286 627.0293 Tm
(\004)Tj
/T1_0 1 Tf
0.02499 Tw 1.0988 0 Td
[(\3205.9)-1854.6 (\3205.9 < )]TJ
/T1_3 1 Tf
0 Tw (\003)Tj
/T1_0 1 Tf
-0.00011 Tc 6 0 0 6 217.0626 624.3893 Tm
(MAF)Tj
/T1_3 1 Tf
0 Tc 8 0 0 8 232.2631 627.0293 Tm
(\004)Tj
/T1_0 1 Tf
0.02499 Tw 1.0988 0 Td
[(\3202.4)-2203.9 (\3202.4 < )]TJ
/T1_3 1 Tf
0 Tw (\003)Tj
/T1_0 1 Tf
-0.00011 Tc 6 0 0 6 300.4917 624.3893 Tm
(MAF)Tj
/T1_3 1 Tf
0 Tc 8 0 0 8 315.6922 627.0293 Tm
(\004)Tj
/T1_0 1 Tf
0.02499 Tw 1.0988 0 Td
[(2.4)-1893.3 (2.4 < )]TJ
/T1_3 1 Tf
0 Tw (\003)Tj
/T1_0 1 Tf
-0.00011 Tc 6 0 0 6 373.4353 624.3893 Tm
(MAF)Tj
/T1_3 1 Tf
0 Tc 8 0 0 8 388.6358 627.0293 Tm
(\004)Tj
/T1_0 1 Tf
1.0988 0 Td
(5.9)Tj
/T1_3 1 Tf
3.5342 0 Td
(\003)Tj
/T1_0 1 Tf
-0.0002 Tc 6 0 0 6 430.5945 624.3893 Tm
(MAF)Tj
0 Tc 0.02499 Tw 8 0 0 8 445.795 627.0293 Tm
(> 5.9)Tj
-0.00011 Tc -38.4921 -1.25 Td
[(\(n = 270\))-5117.9 (\(n = 78\))-6649.2 (\(n = 109\))-5838.5 (\(n = 55\))-4917.6 (\(n = 62\))]TJ
0 Tc 0 Tw -8.9194 -1.25 Td
[(Mean)-7657.6 (22.4)-6647.3 (10.83)-8178.6 (4.28)-7617.9 (1.64)-6446.9 (\3205.0)-7178.6 (6.85)]TJ
T*
[(SD)-8406.3 (20.89)-6397.3 (16.36)-7928.6 (13.31)-7117.9 (16.16)-5946.9 (19.12)]TJ
-0.00011 Tc 0.02499 Tw 0.9008 -1.25 Td
(p value)Tj
0 Tc 0 Tw 6 0 0 6 97.2333 589.6693 Tm
(\240\240)Tj
0.02499 Tw 8 0 0 8 140.6205 587.0293 Tm
(< 0.001)Tj
8.64739 0 Td
(< 0.001)Tj
10.5981 0 Td
(0.016)Tj
9.3864 0 Td
[(0.51)36.9 (1)]TJ
8.1785 0 Td
(0.033)Tj
/T1_3 1 Tf
0 Tw -47.69649 -2.5 Td
(\003)Tj
/T1_0 1 Tf
-0.00011 Tc 6 0 0 6 58.4265 564.3893 Tm
(MAF)Tj
0.0267 Tw 8 0 0 8 71.427 567.0293 Tm
(: MAF mean change score. * Defined as 0.5 and 0.2 SD of the change score\. )Tj
0 Tc 0 Tw 6 0 0 6 321.4085 569.6693 Tm
(\240)Tj
-0.00011 Tc 0.0266 Tw 8 0 0 8 326.1823 567.0293 Tm
[(A)74 (verage dif)17.7 (ference between adjacent categories in row)64.8 (. )]TJ
0 Tc 0 Tw 6 0 0 6 506.3045 569.6693 Tm
(\240\240)Tj
-0.00011 Tc 0.0267 Tw 8 0 0 8 514.5178 567.0293 Tm
(p value for 2-)Tj
0.02499 Tw -57.6232 -1.25 Td
[(tailed t test of Ho: mean change = 0. F-test of Ho: means are equivalent\ across categories and significant for both rows, p val)-3.1 (ue < 0.001.)]TJ
ET
53.532 729.855 m
558.468 729.855 l
53.532 709.855 m
558.468 709.855 l
53.532 579.855 m
558.468 579.855 l
S
BT
/T1_2 1 Tf
0 Tc 8 0 0 8 53.532 525.7339 Tm
[(T)91.9 (able 6. )]TJ
/T1_0 1 Tf
-0.00011 Tc 3.7608 0 Td
[(SF-36 )17.7 (V)59.8 (itality and MAF change scores \(baseline to )17.7 (W)79.9 (eek 24\) by F)73.9 (ACIT)-257.3 (Fatigue scale minimally important dif)17.7 (ference \(MID\)* groups.)]TJ
/T1_3 1 Tf
0 Tc 0 Tw 6.4689 -2.5 Td
(\004)Tj
/T1_0 1 Tf
0.02499 Tw 1.0988 0 Td
[(\3200.5 SD)-2287.3 (> \3200.5 to )]TJ
/T1_3 1 Tf
0 Tw [0.4 (\004)]TJ
/T1_0 1 Tf
0.02499 Tw 10.6057 0 Td
[(\3200.2 SD)-2110.2 (> \3200.2 to )]TJ
/T1_3 1 Tf
0 Tw [0.4 (\004)]TJ
/T1_0 1 Tf
0.02499 Tw 10.4286 0 Td
[(0.2 SD)-1799.5 (> 0.2 to )]TJ
/T1_3 1 Tf
0 Tw [0.4 (\004)]TJ
/T1_0 1 Tf
-0.00011 Tc 0.02499 Tw 9.1179 0 Td
[(0.5 SD)-2716.9 (> 0.5 SD)-2998.8 (A)74 (verage Dif)17.7 (ference)]TJ
0 Tc 0 Tw 6 0 0 6 545.4034 508.3739 Tm
(\240)Tj
-0.00011 Tc 0.02499 Tw 8 0 0 8 53.532 485.7339 Tm
[(SF-36 )17.7 (V)59.8 (itality change scores)]TJ
0.75 -1.25 Td
(MID groups)Tj
/T1_3 1 Tf
0 Tc 0 Tw 8.688 0 Td
(\003)Tj
/T1_0 1 Tf
-0.00011 Tc 6 0 0 6 133.9305 473.0939 Tm
(Fatigue)Tj
/T1_3 1 Tf
0 Tc 8 0 0 8 154.1261 475.7339 Tm
(\004)Tj
/T1_0 1 Tf
0.02499 Tw 1.0988 0 Td
[(\3205.5)-1230.2 (\3205.5 < )]TJ
/T1_3 1 Tf
0 Tw (\003)Tj
/T1_0 1 Tf
-0.00011 Tc 6 0 0 6 214.5651 473.0939 Tm
(Fatigue)Tj
/T1_3 1 Tf
0 Tc 8 0 0 8 234.7607 475.7339 Tm
(\004)Tj
/T1_0 1 Tf
0.02499 Tw 1.0988 0 Td
[(\3202.2)-1579.6 (\3202.2 < )]TJ
/T1_3 1 Tf
0 Tw [0.1 (\003)]TJ
/T1_0 1 Tf
-0.00011 Tc 6 0 0 6 297.9941 473.0939 Tm
(Fatigue)Tj
/T1_3 1 Tf
0 Tc 8 0 0 8 318.1898 475.7339 Tm
(\004)Tj
/T1_0 1 Tf
0.02499 Tw 1.0988 0 Td
[(2.2)-1268.9 (2.2 < )]TJ
/T1_3 1 Tf
0 Tw (\003)Tj
/T1_0 1 Tf
-0.00011 Tc 6 0 0 6 370.9377 473.0939 Tm
(Fatigue)Tj
/T1_3 1 Tf
0 Tc 8 0 0 8 391.1333 475.7339 Tm
(\004)Tj
/T1_0 1 Tf
1.0988 0 Td
(5.5)Tj
/T1_3 1 Tf
2.9098 0 Td
(\003)Tj
/T1_0 1 Tf
-0.00011 Tc 6 0 0 6 428.0969 473.0939 Tm
(Fatigue)Tj
0 Tc 0.02499 Tw 8 0 0 8 448.2926 475.7339 Tm
(> 5.5)Tj
-0.00011 Tc -38.5543 -1.25 Td
[(\(n = 54\))-5367.9 (\(n = 39\))-6649.2 (\(n = 145\))-5838.5 (\(n = 92\))-4667.6 (\(n = 244\))]TJ
0 Tc 0 Tw -9.1694 -1.25 Td
[(Mean)-7407.6 (\3208.15)-6397.3 (\3202.69)-8178.6 (7.34)-7617.9 (8.37)-6196.9 (23.98)-6928.6 (8.03)]TJ
T*
[(SD)-8406.3 (19.38)-6397.3 (15.43)-7928.6 (15.28)-7117.9 (17.26)-5946.9 (19.65)]TJ
-0.00011 Tc 0.02499 Tw 0.9008 -1.25 Td
(p value)Tj
0 Tc 0 Tw 6 0 0 6 97.2333 438.3739 Tm
(\240\240)Tj
0.02499 Tw 8 0 0 8 140.6205 435.7339 Tm
(< 0.001)Tj
9.06689 0 Td
(0.350)Tj
9.7591 0 Td
(< 0.001)Tj
9.36799 0 Td
(< 0.001)Tj
8.19699 0 Td
(< 0.001)Tj
-0.00011 Tc -47.27708 -1.25 Td
(MAF change scores)Tj
0.75 -1.25 Td
(MID groups)Tj
/T1_3 1 Tf
0 Tc 0 Tw 8.688 0 Td
(\003)Tj
/T1_0 1 Tf
-0.00011 Tc 6 0 0 6 133.9305 413.0939 Tm
(Fatigue)Tj
/T1_3 1 Tf
0 Tc 8 0 0 8 154.1261 415.7339 Tm
(\004)Tj
/T1_0 1 Tf
0.02499 Tw 1.0988 0 Td
[(\3205.5)-1230.2 (\3205.5 < )]TJ
/T1_3 1 Tf
0 Tw (\003)Tj
/T1_0 1 Tf
-0.00011 Tc 6 0 0 6 214.5651 413.0939 Tm
(Fatigue)Tj
/T1_3 1 Tf
0 Tc 8 0 0 8 234.7607 415.7339 Tm
(\004)Tj
/T1_0 1 Tf
0.02499 Tw 1.0988 0 Td
[(\3202.2)-1579.6 (\3202.2 < )]TJ
/T1_3 1 Tf
0 Tw [0.1 (\003)]TJ
/T1_0 1 Tf
-0.00011 Tc 6 0 0 6 297.9941 413.0939 Tm
(Fatigue)Tj
/T1_3 1 Tf
0 Tc 8 0 0 8 318.1898 415.7339 Tm
(\004)Tj
/T1_0 1 Tf
0.02499 Tw 1.0988 0 Td
[(2.2)-1268.9 (2.2 < )]TJ
/T1_3 1 Tf
0 Tw (\003)Tj
/T1_0 1 Tf
-0.00011 Tc 6 0 0 6 370.9377 413.0939 Tm
(Fatigue)Tj
/T1_3 1 Tf
0 Tc 8 0 0 8 391.1333 415.7339 Tm
(\004)Tj
/T1_0 1 Tf
1.0988 0 Td
(5.5)Tj
/T1_3 1 Tf
2.9098 0 Td
(\003)Tj
/T1_0 1 Tf
-0.00011 Tc 6 0 0 6 428.0969 413.0939 Tm
(Fatigue)Tj
0 Tc 0.02499 Tw 8 0 0 8 448.2926 415.7339 Tm
(> 5.5)Tj
-0.00011 Tc -38.5543 -1.25 Td
[(\(n = 52\))-5367.9 (\(n = 38\))-6649.2 (\(n = 139\))-5838.5 (\(n = 89\))-4667.6 (\(n = 238\))]TJ
0 Tc 0 Tw -9.1694 -1.25 Td
[(Mean)-7657.6 (8.19)-6897.3 (0.09)-8178.6 (\3200.76)-7117.9 (\3204.86)-5696.9 (\32013.24)-6678.6 (5.36)]TJ
T*
[(SD)-8656.3 (9.82)-6897.3 (8.88)-8428.6 (7.49)-7617.9 (6.05)-6196.9 (10.97)]TJ
-0.00011 Tc 0.02499 Tw 0.9008 -1.25 Td
(p value)Tj
0 Tc 0 Tw 6 0 0 6 97.2333 378.3739 Tm
(\240\240)Tj
0.02499 Tw 8 0 0 8 140.6205 375.7339 Tm
(< 0.001)Tj
9.06689 0 Td
(0.953)Tj
10.1786 0 Td
(0.332)Tj
8.94849 0 Td
(< 0.001)Tj
8.197 0 Td
(< 0.001)Tj
/T1_3 1 Tf
0 Tw -47.27709 -2.5 Td
(\003)Tj
/T1_0 1 Tf
-0.00011 Tc 6 0 0 6 58.4265 353.0939 Tm
(Fatigue)Tj
0.01961 Tw 8 0 0 8 76.4221 355.7339 Tm
[(: F)73.9 (ACIT)-251.9 (Fatigue Scale mean change score. * Defined as 0.5 and 0.2 SD of the chan\ge score. )]TJ
0 Tc 0 Tw 6 0 0 6 376.1777 358.3739 Tm
(\240)Tj
-0.00011 Tc 0.01961 Tw 8 0 0 8 380.8955 355.7339 Tm
[(A)74 (verage dif)17.7 (ference between adjacent categories in row)64.8 (.)]TJ
0 Tc 0 Tw 6 0 0 6 53.532 348.3739 Tm
(\240\240)Tj
-0.00011 Tc 0.02499 Tw 8 0 0 8 61.732 345.7339 Tm
[(p value for 2-tailed t test of Ho: mean change = 0. F-test of Ho: means \are equivalent across categories and significant for bo)-3.1 (th rows, p value < 0.001.)]TJ
ET
53.532 519.534 m
558.468 519.534 l
53.532 498.2 m
558.468 498.2 l
53.532 367.534 m
558.468 367.534 l
S
Q
Q
q
0 0 612 792 re
W n
BT
0 g
/GS2 gs
/T1_4 8 Tf
108.828 74 Td
(Personal non-commercial use only.  The Journal of Rheumatology Copyright\ \251 2005.  All rights reserved.)Tj
ET
Q
BT
0 g
/GS2 gs
/T1_5 1 Tf
10 0 0 10 540 17 Tm
( )Tj
0 0.48627 0.77255 rg
/GS2 gs
-7.22298 0 Td
(www.jrheum.org)Tj
0 g
/GS2 gs
-18.00796 0 Td
(Downloaded on December 3, 2023 from )Tj
ET

endstream
endobj
56 0 obj
<</BitsPerComponent 8/ColorSpace 66 0 R/Filter[/ASCII85Decode/FlateDecode]/Height 99/Length 555/Width 76>>stream
8;Z\7$aRYm#itt$j>q^Qa@?CjM'fqpbVUWcXp]-/,/3b>#%W39MN?M/p([5BF:Fm<
>/[\UJDBQWU^.UZ)4;Bb,7s/AHl78u!sPijUDs^5X\]=*k1<oeec:nF,[?G)dc1pt
TCG9iW*768Q?#8E%p0Cn1D;-`rfl6=0.oL1qU1f\SS0*LRP=A6n"W\%?/qaV)EPfP
7f>YSIemkfqcLuAPrU$jn#>5t6Dj!(9W&MhF+2DF7lV%4#,mlpF`(!K2*tXRn?F$B
,-Md6Vi3V:f3m];g6.(2Pr;+.FH3?Jrjg:@?W*Z*aH#onj#Yh(2)3Mt4[;$YXflE:
;d[=qQ-64$'*E)j/PJ2,3hbqA+DEI9"5\O!m.<V^1\:N;-NG?tor@Q^ZK@HWS%fN<
5-:,HcXYcB@sWoj`b<TAg?YSEN-M%:Y%$3-UU^\t[$m[@&Ym&+eJRu'Kjr79VGT'3
]oQjk1ub>8W3KSM_MZ4#)^>ru)"7[;rg$ZR:W@3c!-D.up.@NHRC#$+m\Y)pCCBYV
YCh>Q+J$E]F+*F5_`e/&\3P[2~>
endstream
endobj
34 0 obj
<</BaseFont/PMKJGP+Symbol/Encoding 42 0 R/FirstChar 1/FontDescriptor 38 0 R/LastChar 4/Subtype/Type1/ToUnicode 43 0 R/Type/Font/Widths[250 631 612 549]>>
endobj
42 0 obj
<</Differences[1/space/alpha/Delta/lessequal]/Type/Encoding>>
endobj
38 0 obj
<</Ascent 0/CapHeight 0/CharSet(/lessequal/Delta/alpha)/Descent 0/Flags 4/FontBBox[-167 -299 1063 827]/FontFile3 39 0 R/FontName/PMKJGP+Symbol/ItalicAngle 0/StemV 0/Type/FontDescriptor>>
endobj
43 0 obj
<</Filter/FlateDecode/Length 238>>stream
H‰TP±nÃ İı7¦ê 8V&‹¡Éâ¡IU·İm8[H1 Œÿ}B#uàéîw÷Ş±swé¬‰À>‚S=F˜ŒÕW·…0âl,ˆ´Q±dÕ2x`ÔÜïkÄ¥³“ƒ¶­Ø'×v8ôû2ºû+vƒ±3¾Ä÷ıæı´8H	§Šß¤riÍ¼(ÆÕ
Ã`g„–IĞH@«ÿ×ªæÑ1N´|ÍÀk.‰¨Sœáø&qÌ1A]óS"š2ˆS#+Zò7.íKæŸrÕ9ÉÊ&’lcñyDï|R™^õ+À Îís)
endstream
endobj
39 0 obj
<</Length 464/Subtype/Type1C>>stream
  PMKJGP+Symbol 1øûêüø  H‚ÿ‹‹  H‚ÿ‹‹÷÷÷’ø\ 
lessequalDeltaalphaSymbol   Da£ˆ‡    $ NB‰úúûşş”øòú”ş!›ù¯ù×ı¯)¡øÏúœøş@ıøú@İ÷ì^üÉú ˜üÊ`Èùq÷K^Nk=5I¯Õ^^Õuõ÷ ÷¢ñ»ÖÖ»Ì±İ×ÈlM»ºM²&©û hûAcû_K÷où§BûÈr÷`ßOÃÃO=§,û"[,32+_ûûû"¶û	á//á÷]÷àÕŸ´ÊÊ´ÆÍÁç£%¥G¦gg¥°y¹¶«°¡ °–Ä×¡d‡nt|zz|yƒump™©qq©r·uÇ ¹Ÿ»¾½›¿™ÁÙ÷ÆûSú ÷DşHûúH÷øÿ÷#şFû½ûúFû½÷#ıT÷oùT÷rúøÏ
endstream
endobj
164 0 obj
<</BG2/Default/OP true/OPM 1/SA false/SM 0.0200043/TR2/Default/Type/ExtGState/UCR2/Default/op true>>
endobj
165 0 obj
<</BG2/Default/OP false/OPM 0/SA false/SM 1.0/TR2/Default/UCR2/Default/op false>>
endobj
184 0 obj
<</A 185 0 R/Border[0 0 0]/Rect[466.77 15.0 541.0 27.0]/Subtype/Link/Type/Annot>>
endobj
185 0 obj
<</S/URI/URI(http://www.jrheum.org/)>>
endobj
158 0 obj
[186 0 R]
endobj
159 0 obj
<</Length 12563>>stream
1 g
/GS0 gs
0 792 m
0 792 l
f
q
13.5 787.5 585 -783 re
W n
q
0 792.03 612 -792 re
W n
BT
0 0 0 1 k
/GS1 gs
/T1_0 1 Tf
-0.00011 Tc 0.0849 Tw 10 0 0 10 53.468 735.6616 Tm
[(clinical anchors, does of)17.7 (fer a common unit \(ef)17.7 (fect size\) by)]TJ
0.0547 Tw 0 -1.22 TD
[(which various instruments can be compared. )54.8 (A)-249.9 (small ef)17.7 (fect)]TJ
0.00571 Tw T*
[(can be compared to a moderate ef)17.7 (fect within one instrument)]TJ
0.1084 Tw T*
(and across others. It is likely in most applications that the)Tj
-0.0274 Tw T*
[(MID of a given instrument lies somewhere between Cohen\325)54.8 (s)]TJ
0.05701 Tw T*
[(small \(0.2 SD\) and moderate \(0.5 SD\) ef)17.7 (fect sizes)]TJ
0 Tc 0 Tw 7.5 0 0 7.5 257.2015 677.9617 Tm
(41)Tj
-0.00011 Tc 0.03931 Tw 10 0 0 10 264.7015 674.6616 Tm
(. These)Tj
0.1871 Tw -21.1233 -1.22 Td
(distribution-based estimates of MID can be confirmed or)Tj
0.1236 Tw T*
(adjusted using available relevant clinical anchors by com-)Tj
0.1899 Tw T*
[(parison. W)59.9 (yrwich )-17.7 (and W)79.9 (olinsky)]TJ
0 Tc 0 Tw 7.5 0 0 7.5 187.901 641.3617 Tm
(42)Tj
-0.00011 Tc 0.2076 Tw 10 0 0 10 199.9768 638.0616 Tm
(suggest that the SEM,)Tj
-0.0278 Tw -14.6509 -1.22 Td
(computed as the SD multiplied by the square root of 1 minus)Tj
0.10941 Tw T*
[(the reliability coef)17.7 (ficient \(alpha\), of)17.7 (fers an advantage over)]TJ
-0.0135 Tw T*
(the use of the SD alone because it factors in the reliability of)Tj
0.1241 Tw T*
(a test and renders the estimate of MID to be less sample-)Tj
0.3273 Tw T*
[(dependent. )17.7 (Thus, the distribution-based MID in change)]TJ
-0.0248 Tw T*
[(scores for the F)73.9 (ACIT)-207.5 (Fatigue scale ranged from 2.2 \(d = 0.2\))]TJ
0.1019 Tw T*
(to 5.5 \(d = 0.5\), with the SEM suggesting an intermediate)Tj
-0.0251 Tw T*
[(MID value of 4.10. )17.8 (The range of potential distribution-based)]TJ
0.0728 Tw T*
[(MID values for the SF-36 )17.7 (V)59.8 (itality was 4.1 to 10.3, and for)]TJ
0 Tc 0.02499 Tw T*
(MAF was 2.4 to 5.9.)Tj
-0.00011 Tc 0.2695 Tw 1.2 -1.2 Td
[(As described \(see )54.8 (Analysis Plan, above\), to compare)]TJ
-0.0025 Tw -1.2 -1.2 Td
(fatigue change scores among groups defined by the range of)Tj
0.2402 Tw 0 -1.2 TD
(MID criteria, 5 distinct groups were created: those who)Tj
0.05611 Tw T*
(reported major worsening, those who reported minor wors-)Tj
0.3455 Tw T*
(ening, an unchanged group, those who reported minor)Tj
0.07449 Tw T*
(improvement, and those who reported major improvement.)Tj
0.0563 Tw T*
(Using each of the 3 fatigue measures alternately as the ref-)Tj
0.1223 Tw T*
(erence measure for purposes of defining these groups, the)Tj
0.0437 Tw T*
[(mean change from baseline to )17.7 (W)79.9 (eek 24 for each group was)]TJ
-0.02499 Tw T*
[(computed for the remaining 2 measures. )17.8 (Thus, changes from)]TJ
0.0137 Tw T*
[(baseline to )17.7 (W)79.9 (eek 24 in F)73.9 (ACIT)-246 (Fatigue scale and MAF were)]TJ
0.26421 Tw T*
(evaluated across 5 groups of patients defined by SF-36)Tj
0.0386 Tw T*
[(V)59.8 (itality change scores \(T)69.7 (able 4\), changes in F)73.9 (ACIT)-270.9 (Fatigue)]TJ
0.06779 Tw T*
[(scale and SF-36 )17.8 (V)59.8 (itality were evaluated across 5 groups of)]TJ
0.29739 Tw T*
[(patients defined by MAF change scores \(T)69.7 (able 5\), and)]TJ
-0.00031 Tw T*
[(changes in SF-36 )17.7 (V)59.8 (itality and MAF were evaluated across 5)]TJ
0.0952 Tw T*
[(groups of patients defined by F)73.9 (ACIT)-327.5 (Fatigue scale change)]TJ
-0.0007 Tw T*
[(scores \(T)69.7 (able 6\). For all 3 sets of analyses, all change scores)]TJ
0.0387 Tw 26.45 43.56 Td
(were consistent with the direction \(i.e., worse vs improved\))Tj
0.2529 Tw T*
(and magnitude \(e.g., 0.2 SD vs 0.5 SD\) of the defined)Tj
0.10809 Tw T*
(groups. Change scores across these 5 distinct groups were)Tj
0.0386 Tw T*
[(significantly dif)17.7 (ferent from one another \(p < 0.0001\) for all)]TJ
-0.0202 Tw T*
(comparisons. In addition, the order of means across adjacent)Tj
0.0535 Tw T*
[(categories for the 6 comparisons in )17.7 (T)69.9 (ables 4 through 6 was)]TJ
0.0997 Tw T*
(consistent with the classification according to the criterion)Tj
0.028 Tw T*
(instrument that determined group assignment. For example,)Tj
0.17841 Tw T*
[(F)74 (ACIT)-410.7 (Fatigue scale mean change scores in those SF-36)]TJ
0.05389 Tw T*
[(V)59.8 (itality\320defined MID groups representing the lar)17.7 (gest ef)17.7 (fect)]TJ
0.00369 Tw T*
(sizes \()Tj
/T1_1 1 Tf
0 Tc 0 Tw [0.1 (\004)]TJ
/T1_0 1 Tf
-0.00011 Tc 0.00369 Tw 3.5861 0 Td
[(\3200.5 SD and > 0.5 SD\) were lar)17.8 (ger than the change)]TJ
0.13429 Tw -3.5861 -1.2 Td
[(scores for MID groups defined by lesser ef)17.7 (fect sizes. )17.6 (The)]TJ
0.21761 Tw T*
[(average dif)17.7 (ference between means of adjacent categories)]TJ
0.0327 Tw T*
[(\(last column of )17.7 (T)69.9 (ables 4 through 6\) of)17.7 (fers an estimate of an)]TJ
-0.03439 Tw T*
(MID that, because they are based on the 0.2 to 0.5 SD ranges)Tj
0.0318 Tw T*
(for classifying patients, one would expect to be comparable)Tj
0.1219 Tw T*
[(to the distribution-based estimates. )17.7 (Thus, for example, the)]TJ
0.09241 Tw T*
(average distance between adjacent categories of the MAF-)Tj
0.05521 Tw T*
[(defined groups for the F)73.8 (ACIT)-287.5 (Fatigue is 3.74 \(T)69.7 (able 5, last)]TJ
0.1098 Tw T*
[(column\), which compares to the distribution-based F)73.8 (ACIT)]TJ
0.02499 Tw T*
(Fatigue MID range of 2.2 to 5.5.)Tj
0.0006 Tw 1.2 -1.2 Td
[(Agreement of the computation of MID in F)73.9 (ACIT)-232.8 (Fatigue)]TJ
0.1909 Tw -1.2 -1.2 Td
[(scale and SF-36 )17.7 (V)59.8 (itality change scores was further com-)]TJ
0.07269 Tw T*
[(pared between data from ST)79.7 (AR and )54.8 (ARMADA)-267.9 (\(MAF was)]TJ
0.0723 Tw T*
(not assessed in this latter trial\). MID values using both 0.2)Tj
0.19679 Tw T*
[(SD and 0.5 SD were compared between both trials. )17.7 (The)]TJ
0.27161 Tw T*
[(F)74 (ACIT)-503.9 (Fatigue scale scores associated with the defined)]TJ
0.07069 Tw T*
[(ef)17.7 (fect sizes were nearly identical between the 2 trials, with)]TJ
0.04131 Tw T*
[(the weighted kappa being 1.00 for the F)73.8 (ACIT)-273.7 (Fatigue scale)]TJ
0.02499 Tw T*
[(and 0.97 for the SF-36 )17.7 (V)59.8 (itality scale.)]TJ
0.34711 Tw 1.2 -1.21 Td
(Because the 3 fatigue measures performed similarly)Tj
-0.03101 Tw -1.2 -1.21 Td
(when comparing groups on average scores, additional analy-)Tj
0.2854 Tw 0 -1.21 TD
(ses were conducted to determine whether the 3 fatigue)Tj
0.02251 Tw T*
(measures were equivalent in their coverage of the full spec-)Tj
-0.00591 Tw T*
(trum of fatigue in this patient population. Item response the-)Tj
0.08389 Tw T*
[(ory \(IR)59.7 (T\) was used to examine how fully the questions on)]TJ
0.0473 Tw T*
[(the 3 fatigue scales measured patients\325)-223.5 (self-reported fatigue)]TJ
ET
0 0 0 1 K
53.468 76.5 m
558.468 76.5 l
S
0 0 0 0 k
494.29 69.365 64.178 -15.665 re
f*
BT
0 0 0 1 k
/T1_2 1 Tf
0 Tc 0 Tw 8 0 0 8 545.468 56.4344 Tm
(815)Tj
ET
0 0 0 0 k
53.532 70.501 203 -16.591 re
f*
BT
0 0 0 1 k
/T1_2 1 Tf
-0.00011 Tc 0.02499 Tw 8 0 0 8 54.532 56.6447 Tm
[(Cella, et al: F)128.8 (ACIT)-257.3 (scale in RA)]TJ
ET
0 0 0 0 k
/GS0 gs
103.631 82.583 407.5 -10.833 re
f*
0.5 w 
/GS1 gs
103.631 82.583 407.5 -10.833 re
S
BT
0 0 0 1 k
/T1_2 1 Tf
0 Tc 8 0 0 8 53.532 276.0293 Tm
[(T)91.9 (able 4. )]TJ
/T1_0 1 Tf
-0.00011 Tc 3.7608 0 Td
[(F)74 (ACIT)-257.3 (Fatigue scale and MAF change scores \(baseline to )17.7 (W)79.9 (eek 24\) by SF-36 )17.7 (V)59.8 (itality minimally important dif)17.7 (ference \(MID\)* groups.)]TJ
/T1_1 1 Tf
0 Tc 0 Tw 6.4689 -2.5 Td
(\004)Tj
/T1_0 1 Tf
0.02499 Tw 1.0988 0 Td
[(\3200.5 SD)-2287.3 (> \3200.5 to )]TJ
/T1_1 1 Tf
0 Tw [0.4 (\004)]TJ
/T1_0 1 Tf
0.02499 Tw 10.6057 0 Td
[(\3200.2 SD)-2110.2 (> \3200.2 to )]TJ
/T1_1 1 Tf
0 Tw [0.4 (\004)]TJ
/T1_0 1 Tf
0.02499 Tw 10.4286 0 Td
[(0.2 SD)-1799.5 (> 0.2 to )]TJ
/T1_1 1 Tf
0 Tw [0.4 (\004)]TJ
/T1_0 1 Tf
-0.00011 Tc 0.02499 Tw 9.1179 0 Td
[(0.5 SD)-2716.9 (> 0.5 SD)-2998.8 (A)74 (verage Dif)17.7 (ference)]TJ
0 Tc 0 Tw 6 0 0 6 545.4034 258.6693 Tm
(\240)Tj
-0.00011 Tc 0.02499 Tw 8 0 0 8 53.532 236.0293 Tm
[(F)74 (ACIT)-257.3 (Fatigue scale change scores)]TJ
0.75 -1.25 Td
(MID groups)Tj
/T1_1 1 Tf
0 Tc 0 Tw 9.0629 0 Td
(\003)Tj
/T1_0 1 Tf
-0.00031 Tc 6 0 0 6 136.93 223.3893 Tm
(VT)Tj
/T1_1 1 Tf
0 Tc 8 0 0 8 147.1266 226.0293 Tm
(\004)Tj
/T1_0 1 Tf
0.02499 Tw 1.0988 0 Td
[(\32010.3)-1980.1 (\32010.3 < )]TJ
/T1_1 1 Tf
0 Tw (\003)Tj
/T1_0 1 Tf
-0.00031 Tc 6 0 0 6 221.5646 223.3893 Tm
(VT)Tj
/T1_1 1 Tf
0 Tc 8 0 0 8 231.7612 226.0293 Tm
(\004)Tj
/T1_0 1 Tf
0.02499 Tw 1.0988 0 Td
[(\3204.1)-2579.4 (\3204.1 < )]TJ
/T1_1 1 Tf
0 Tw (\003)Tj
/T1_0 1 Tf
-0.00031 Tc 6 0 0 6 302.9936 223.3893 Tm
(VT)Tj
/T1_1 1 Tf
0 Tc 8 0 0 8 313.1902 226.0293 Tm
(\004)Tj
/T1_0 1 Tf
0.02499 Tw 1.0988 0 Td
[(4.1)-2268.8 (4.1 < )]TJ
/T1_1 1 Tf
0 Tw [0.1 (\003)]TJ
/T1_0 1 Tf
-0.00031 Tc 6 0 0 6 373.9372 223.3893 Tm
(VT)Tj
/T1_1 1 Tf
0 Tc 8 0 0 8 384.1338 226.0293 Tm
(\004)Tj
/T1_0 1 Tf
1.0988 0 Td
(10.3)Tj
/T1_1 1 Tf
4.1597 0 Td
(\003)Tj
/T1_0 1 Tf
-0.00031 Tc 6 0 0 6 431.0964 223.3893 Tm
(VT)Tj
0 Tc 0.02499 Tw 8 0 0 8 441.293 226.0293 Tm
(> 10.3)Tj
-0.00011 Tc -37.6793 -1.25 Td
[(\(n = 50\))-5367.9 (\(n = 73\))-6899.2 (\(n = 53\))-5838.5 (\(n = 136\))-4417.6 (\(n = 262\))]TJ
0 Tc 0 Tw -9.1694 -1.25 Td
[(Mean)-7407.6 (\3204.25)-6647.3 (\3200.1)-8428.6 (2.22)-7867.9 (3.9)-7071.9 (10)-7553.6 (3.56)]TJ
0 -1.25 TD
[(SD)-8656.3 (7.65)-6897.3 (6.19)-8428.6 (5.99)-7617.9 (6.93)-6446.9 (9.37)]TJ
-0.00011 Tc 0.02499 Tw 0.9008 -1.25 Td
(p value)Tj
0 Tc 0 Tw 6 0 0 6 97.2333 188.6693 Tm
(\240\240)Tj
0.02499 Tw 8 0 0 8 140.6205 186.0293 Tm
(< 0.001)Tj
9.06689 0 Td
(0.919)Tj
10.1786 0 Td
(0.045)Tj
8.94849 0 Td
(< 0.001)Tj
8.6165 0 Td
(0.001)Tj
-0.00011 Tc -47.69659 -1.25 Td
(MAF change scores)Tj
0.75 -1.25 Td
(MID groups)Tj
/T1_1 1 Tf
0 Tc 0 Tw 9.0629 0 Td
(\003)Tj
/T1_0 1 Tf
-0.00031 Tc 6 0 0 6 136.93 163.3893 Tm
(VT)Tj
/T1_1 1 Tf
0 Tc 8 0 0 8 147.1266 166.0293 Tm
(\004)Tj
/T1_0 1 Tf
0.02499 Tw 1.0988 0 Td
[(\32010.3)-1980.1 (\32010.3 < )]TJ
/T1_1 1 Tf
0 Tw (\003)Tj
/T1_0 1 Tf
-0.00031 Tc 6 0 0 6 221.5646 163.3893 Tm
(VT)Tj
/T1_1 1 Tf
0 Tc 8 0 0 8 231.7612 166.0293 Tm
(\004)Tj
/T1_0 1 Tf
0.02499 Tw 1.0988 0 Td
[(\3204.1)-2579.4 (\3204.1 < )]TJ
/T1_1 1 Tf
0 Tw (\003)Tj
/T1_0 1 Tf
-0.00031 Tc 6 0 0 6 302.9936 163.3893 Tm
(VT)Tj
/T1_1 1 Tf
0 Tc 8 0 0 8 313.1902 166.0293 Tm
(\004)Tj
/T1_0 1 Tf
0.02499 Tw 1.0988 0 Td
[(4.1)-2268.8 (4.1 < )]TJ
/T1_1 1 Tf
0 Tw [0.1 (\003)]TJ
/T1_0 1 Tf
-0.00031 Tc 6 0 0 6 373.9372 163.3893 Tm
(VT)Tj
/T1_1 1 Tf
0 Tc 8 0 0 8 384.1338 166.0293 Tm
(\004)Tj
/T1_0 1 Tf
1.0988 0 Td
(10.3)Tj
/T1_1 1 Tf
4.1597 0 Td
(\003)Tj
/T1_0 1 Tf
-0.00031 Tc 6 0 0 6 431.0964 163.3893 Tm
(VT)Tj
0 Tc 0.02499 Tw 8 0 0 8 441.293 166.0293 Tm
(> 10.3)Tj
-0.00011 Tc -37.6793 -1.25 Td
[(\(n = 49\))-5367.9 (\(n = 72\))-6899.2 (\(n = 49\))-5838.5 (\(n = 128\))-4417.6 (\(n = 258\))]TJ
0 Tc 0 Tw -9.1694 -1.25 Td
[(Mean)-7657.6 (5.27)-6647.3 (\3200.46)-7928.6 (\3200.72)-7367.9 (\3204.5)-5965.4 (\3201)36.9 (1.14)-6697 (4.10)]TJ
T*
[(SD)-8656.3 (9.08)-7147.3 (9.2)-8678.6 (8.36)-7617.9 (9.68)-6215.4 (1)36.9 (1.42)]TJ
-0.00011 Tc 0.02499 Tw 0.9008 -1.25 Td
(p value)Tj
0 Tc 0 Tw 6 0 0 6 97.2333 128.6693 Tm
(\240\240)Tj
0.02499 Tw 8 0 0 8 140.6205 126.0293 Tm
(< 0.001)Tj
9.06689 0 Td
(0.708)Tj
10.1786 0 Td
(0.626)Tj
8.94849 0 Td
(< 0.001)Tj
8.197 0 Td
(< 0.001)Tj
/T1_1 1 Tf
0 Tw -47.27709 -2.5 Td
(\003)Tj
/T1_0 1 Tf
-0.00031 Tc 6 0 0 6 58.4265 103.3893 Tm
(VT)Tj
-0.00011 Tc 0.0135 Tw 8 0 0 8 66.4231 106.0293 Tm
[(: SF-36 )17.7 (V)59.8 (itality mean change score. * Defined as 0.5 and 0.2 SD of the change sco\re. )]TJ
0 Tc 0 Tw 6 0 0 6 342.8721 108.6693 Tm
(\240)Tj
-0.00011 Tc 0.0135 Tw 8 0 0 8 347.5409 106.0293 Tm
[(A)74 (verage dif)17.7 (ference between adjacent categories in row)64.8 (. )]TJ
0 Tc 0 Tw 6 0 0 6 526.9272 108.6693 Tm
(\240\240)Tj
-0.00011 Tc 0.0136 Tw 8 0 0 8 535.0355 106.0293 Tm
(p value)Tj
0.02499 Tw -60.1879 -1.25 Td
[(for 2-tailed t test of Ho: mean change = 0. F-test of Ho: means are equi\valent across categories and significant for both rows,)-3 ( p value < 0.001.)]TJ
ET
53.532 269.5 m
558.468 269.5 l
53.532 250.5 m
558.468 250.5 l
53.532 119.5 m
558.468 119.5 l
S
Q
Q
q
0 0 612 792 re
W n
BT
0 g
/GS2 gs
/T1_3 8 Tf
108.828 74 Td
(Personal non-commercial use only.  The Journal of Rheumatology Copyright\ \251 2005.  All rights reserved.)Tj
ET
Q
BT
0 g
/GS2 gs
/T1_4 1 Tf
10 0 0 10 540 17 Tm
( )Tj
0 0.48627 0.77255 rg
/GS2 gs
-7.22298 0 Td
(www.jrheum.org)Tj
0 g
/GS2 gs
-18.00796 0 Td
(Downloaded on December 3, 2023 from )Tj
ET

endstream
endobj
54 0 obj
<</BitsPerComponent 8/ColorSpace 66 0 R/Filter[/ASCII85Decode/FlateDecode]/Height 99/Length 511/Width 76>>stream
8;Z]"!=m!i#XuH,"hDpA9`Z];7C8p0ad,[Rr.hX=JA8e=P%jaoW#"aL"VauGJt^B*
=>/=E#VrJFbECdo]WN:j4O$ud(_Q1Hm.cIFDU^((@mPPLSmbm/O5b_.q-(Ve$p2E6
p!WQpH:GEaKFgUp"W^sSM,?d1B6<s,A[EY.)4SG`@DkV_i`1qSEVC#TW-)'+=1_96
RYQZ<`)SL$i`jNr:ZW#33Le5I51q$W_XnZ5)]4Rf(GjqB<SAPpI5YS.Q_FGfY8*"h
C@a+t9@`!LN&Pj86g,M"s57j^0t"P(I7Ku[-c>D&DI0f'bt`]E/B?a#d8/Ir!+]E6
/!WY\PmZbLI,B!;BWNK#auAoqg)]k"C+.VR\r2J7>0a;3LuqXH;'!6dBk`L[6k$%K
ME*Kc.Bp+<XbfU/od)89#3<MBf2jn:,o:&KYpEb^mm=fU49\Uj.UB$<)-.p;XU;sm
=Lb!,r(1!qUD5k-e!]3%gu2?!_C]hO[DVk!h[Zs<!!p3<d/~>
endstream
endobj
160 0 obj
<</BG2/Default/OP true/OPM 1/SA false/SM 0.0200043/TR2/Default/Type/ExtGState/UCR2/Default/op true>>
endobj
161 0 obj
<</BG2/Default/OP false/OPM 0/SA false/SM 1.0/TR2/Default/UCR2/Default/op false>>
endobj
186 0 obj
<</A 187 0 R/Border[0 0 0]/Rect[466.77 15.0 541.0 27.0]/Subtype/Link/Type/Annot>>
endobj
187 0 obj
<</S/URI/URI(http://www.jrheum.org/)>>
endobj
154 0 obj
[188 0 R]
endobj
155 0 obj
<</Length 10271>>stream
1 g
/GS0 gs
0 792 m
0 792 l
f
q
13.5 787.5 585 -783 re
W n
q
0 792.03 612 -792 re
W n
BT
0 0 0 1 k
/GS1 gs
/T1_0 1 Tf
-0.00011 Tc 0.0464 Tw 10 0 0 10 54 217.2384 Tm
[(moderate, and around 0.8 is lar)17.7 (ge, the ef)17.7 (fect sizes for those)]TJ
0.1306 Tw 0 -1.2 TD
[(who achieved )54.9 (ACR20 were found to be moderate in size,)]TJ
0.20979 Tw T*
[(and the ef)17.7 (fect sizes for those who achieved )54.9 (ACR50 and)]TJ
0.0442 Tw T*
[(ACR70 were lar)17.7 (ge for all 3 measures \(T)69.7 (able 3\). )17.7 (The dif)17.7 (fer-)]TJ
0.1171 Tw T*
[(ence in F)73.9 (ACIT)-349.4 (Fatigue scale change scores between adja-)]TJ
0.08701 Tw T*
[(cent )54.9 (ACR groups \(i.e., did not achieve )54.9 (ACR20 versus best)]TJ
0.22749 Tw T*
[(response = )54.8 (ACR20; best response = )54.8 (ACR20 versus best)]TJ
T*
[(response = )54.8 (ACR50; best response = )54.8 (ACR50 versus best)]TJ
0.1118 Tw T*
[(response = )54.8 (ACR70\) at )17.7 (W)79.9 (eek 24 of)17.7 (fers guidance regarding)]TJ
-0.0181 Tw T*
[(clinical significance of change scores. )17.7 (The dif)17.7 (ferences in the)]TJ
0.0011 Tw T*
(change score from worst to best responders are 4.5, 3.8, and)Tj
0.18919 Tw 26.4 12 Td
(2.0, with a mean change between clinical groups of 3.5,)Tj
0.0433 Tw T*
[(which is equivalent to an ef)17.7 (fect size of 0.32 \(T)69.7 (able 3\). )17.7 (This)]TJ
0.0219 Tw T*
(suggests a reasonable starting point for a minimal clinically)Tj
0.02499 Tw T*
[(important dif)17.7 (ference.)]TJ
-0.02299 Tw 1.2 -1.22 Td
(Further analyses were conducted to determine the change)Tj
0.1586 Tw -1.2 -1.22 Td
(score for each measure that might be associated with the)Tj
0.00011 Tc 0.3748 Tw 0 -1.22 TD
(minimum change required to be considered important.)Tj
-0.00011 Tc 0.1338 Tw T*
(Using conventions in the literature)Tj
0 Tc 0 Tw 7.5 0 0 7.5 461.6389 135.7384 Tm
(38,39)Tj
-0.00011 Tc 0.1338 Tw 10 0 0 10 478.5139 132.4384 Tm
(, an MID in scores)Tj
0.09171 Tw -16.0514 -1.22 Td
[(was estimated by ef)17.7 (fect size \(based on a proportion of SD)]TJ
0.0387 Tw T*
[(units\) and by the score change equivalent to one SEM. )17.8 (The)]TJ
0.235 Tw T*
(Cohen convention)Tj
0 Tc 0 Tw 7.5 0 0 7.5 393.3913 99.1384 Tm
(41)Tj
-0.00011 Tc 0.23489 Tw 10 0 0 10 400.8913 95.8383 Tm
(, although limited by the absence of)Tj
ET
0 0 0 1 K
53.964 76.5 m
558.972 76.5 l
S
0 0 0 0 k
52.822 69.665 64.178 -15.665 re
f*
BT
0 0 0 1 k
/T1_1 1 Tf
0 Tc 0 Tw 8 0 0 8 53.8216 56.7343 Tm
(814)Tj
ET
0 0 0 0 k
356 69.665 203 -15.665 re
f*
BT
0 0 0 1 k
/T1_1 1 Tf
-0.00011 Tc 0.02499 Tw 8 0 0 8 424.3613 56.7343 Tm
(The Journal of Rheumatology 2005; 32:5)Tj
ET
0 0 0 0 k
/GS0 gs
103.631 82.583 407.5 -10.833 re
f*
0.5 w 
/GS1 gs
103.631 82.583 407.5 -10.833 re
S
BT
0 0 0 1 k
/T1_1 1 Tf
0 Tc 8 0 0 8 53.532 737.0293 Tm
[(T)91.9 (able 2. )]TJ
/T1_0 1 Tf
-0.00011 Tc 3.7608 0 Td
(Descriptive statistics for fatigue measures by assessment period.)Tj
0 Tw 17.7906 -2.5 Td
[(ST)79.7 (AR)-23243.5 (ARMADA**)]TJ
-21.5514 -1.25 Td
[(Scale)-9384.8 (n)-2395 (Mean)-3537.4 (SD)-2116.6 (Alpha*)-1920.5 (SEM)-1899.8 (Range)-3815.9 (n)-3393.6 (Mean)-1908.2 (SD)-1942.8 (Alpha*)-1463.8 (SEM)-1742.8 (Range)]TJ
0 -2.5 TD
(Baseline)Tj
0 Tc 0.0249 Tw 0.9008 -1.25 Td
[(F)74.1 (ACIT)-257.2 (Fatigue scale)-1805 (631)-1908.2 (29.17)-3082.9 (1)36.9 (1.06)-2245.7 (0.86)-2670.1 (4.14)-2329.9 (2\32052)-3593.2 (270)-2906.8 (27.87)-1453.8 (1)36.9 (1.00)-2071.9 (0.86)-2213.4 (4.12)-2172.8 (1\32049)]TJ
0.0072 Tw 0 -1.25 TD
[(SF-36 V)59.9 (itality)-4452.4 (631)-1908.2 (35.13)-3064.5 (20.83)-2227.3 (0.84)-2670.1 (8.33)-2329.9 (0\32095)-3593.2 (271)-2906.8 (33.20)-1435.3 (20.02)-2053.4 (0.81)-2213.4 (8.73)-2172.8 (0\32090)]TJ
0 Tw T*
[(MAF)-7982.5 (621)-1908.2 (26.79)-3082.9 (1)36.9 (1.94)-2058.2 (0.93)]TJ
6 0 0 6 260.032 659.6693 Tm
(\240)Tj
8 0 0 8 282.8925 657.0293 Tm
[(3.16)-2329.9 (1\32050)-3843.2 (\321)-3781.8 (\321)-2685.4 (\321)-3053.4 (\321)-2963.4 (\321)-3047.8 (\321)]TJ
-0.00011 Tc 0.02499 Tw -28.6701 -1.25 Td
[(W)79.9 (eek 12)]TJ
0 Tc 0.9008 -1.25 Td
[(F)74.1 (ACIT)-257.2 (Fatigue scale)-1805 (596)-1908.2 (34.38)-3082.9 (1)36.9 (1.36)-2245.7 (0.87)-2670.1 (4.10)-2329.9 (2\32052)-3593.2 (255)-2906.8 (35.39)-1453.8 (1)36.9 (1.29)-2071.9 (0.87)-2213.4 (4.06)-2172.8 (5\32052)]TJ
0.0072 Tw T*
[(SF-36 V)59.9 (itality)-4452.4 (597)-1908.2 (46.67)-3064.5 (23.54)-2227.3 (0.88)-2670.1 (8.15)-2079.9 (0\320100)-3343.2 (254)-2906.8 (50.46)-1435.3 (24.02)-2053.4 (0.90)-2213.4 (7.99)-1922.8 (0\320100)]TJ
0 Tw T*
[(MAF)-7982.5 (583)-1908.2 (20.99)-3064.5 (12.88)-2039.8 (0.95)]TJ
6 0 0 6 260.032 619.6693 Tm
(\240)Tj
8 0 0 8 282.8925 617.0293 Tm
[(2.88)-2329.9 (1\32050)-3843.2 (\321)-3781.8 (\321)-2685.4 (\321)-3053.4 (\321)-2963.4 (\321)-3047.8 (\321)]TJ
-0.00011 Tc 0.02499 Tw -28.6701 -1.25 Td
[(W)79.9 (eek 24)]TJ
0 Tc 0.9008 -1.25 Td
[(F)74.1 (ACIT)-257.2 (Fatigue scale)-1805 (578)-1908.2 (34.69)-3082.9 (1)36.9 (1.21)-2245.7 (0.86)-2670.1 (4.19)-2329.9 (2\32052)-3593.2 (161)-2906.8 (38.71)-1685.3 (9.73)-2303.4 (0.81)-2213.4 (4.24)-1941.3 (1)36.9 (1\32052)]TJ
0.0072 Tw T*
[(SF-36 V)59.9 (itality)-4452.4 (578)-1908.2 (48.06)-3064.5 (23.94)-2227.3 (0.88)-2670.1 (8.29)-2079.9 (0\320100)-3343.2 (161)-2906.8 (57.92)-1435.3 (22.31)-2053.4 (0.90)-2213.4 (7.63)-1922.8 (0\320100)]TJ
0 Tw T*
[(MAF)-7982.5 (567)-1908.2 (20.69)-3064.5 (13.32)-2039.8 (0.96)]TJ
6 0 0 6 260.032 579.6693 Tm
(\240)Tj
8 0 0 8 282.8925 577.0293 Tm
[(2.66)-2329.9 (1\32050)-3843.2 (\321)-3781.8 (\321)-2685.4 (\321)-3053.4 (\321)-2963.4 (\321)-3047.8 (\321)]TJ
-0.00011 Tc 0.02499 Tw -28.6701 -1.25 Td
(Early termination \(all visits\))Tj
0.9008 -1.25 Td
[(F)74 (ACIT)-257.3 (Fatigue scale)-2055.1 (\321)-2783.3 (\321)-4314.6 (\321)-3227.4 (\321)-3420.2 (\321)-3205 (\321)-4343.3 (98)-3156.9 (29.18)-1453.9 (1)36.8 (1.86)-2072 (0.87)-2213.5 (4.28)-2172.9 (6\32051)]TJ
0.00729 Tw T*
[(SF-36 V)59.8 (itality)-4702.5 (\321)-2783.3 (\321)-4314.6 (\321)-3227.4 (\321)-3420.2 (\321)-3205 (\321)-4343.3 (98)-3156.9 (39.96)-1435.4 (24.12)-2053.5 (0.90)-2213.5 (7.63)-2172.9 (0\32085)]TJ
0 Tw T*
[(MAF)-8232.6 (\321)-2783.3 (\321)-4314.6 (\321)-3227.4 (\321)-3420.2 (\321)-3205 (\321)-4343.3 (\321)-3781.9 (\321)-2685.5 (\321)-3053.5 (\321)-2963.5 (\321)-3047.9 (\321)]TJ
0 Tc 6 0 0 6 53.532 519.6693 Tm
(\240)Tj
-0.00011 Tc 0.1803 Tw 8 0 0 8 59.9741 517.0293 Tm
[(Cronbach\325)54.8 (s alpha for MAF computed for 5 items, based on scoring algorithm describ\ed in text. * Cronbach\325)54.8 (s alpha. ** )54.9 (ARMADA)-375.4 (did n)-2.8 (ot include)]TJ
0.02499 Tw -0.8053 -1.25 Td
[(Multidimensional )54.8 (Assessment of Fatigue. SEM: standard error of measurement, computed as S\D \(sqrt [l\320r]\), where r = test reliabi)-0.6 (lity \(Cronbach\325)54.8 (s alpha\).)]TJ
ET
53.532 732.5 m
558.468 732.5 l
53.532 700.5 m
558.468 700.5 l
53.532 530.5 m
558.468 530.5 l
S
BT
/T1_1 1 Tf
0 Tc 8 0 0 8 53.532 459.4544 Tm
[(T)91.9 (able 3. )]TJ
/T1_0 1 Tf
-0.00011 Tc 3.7608 0 Td
[(Change in fatigue measures by change in )54.8 (ACR20, )54.8 (ACR50, )54.8 (ACR70 status \(baseline to )17.7 (W)79.9 (eek 24\).)]TJ
0 Tw 30.9711 -2.5 Td
[(Pooled)-2588.3 (Change)-3199.5 (Pooled)-7510.9 (Standardized)]TJ
0.02499 Tw -8.5297 -1.25 Td
[(Baseline)-5338.2 (SD at)-3229 (Score)-3450.1 (Change)-8066 (Response)]TJ
-26.2021 -1.25 Td
[(Scale)-7552.3 (ACR Group)-4783.6 (n)-4286.6 (Mean)-3717.5 (SD)-3208.5 (Baseline)-2650.8 (Mean)-3061.7 (Score SD)-1490.9 (Ef)17.7 (fect Size*)-1798.8 (Mean)]TJ
0 Tc 0 Tw 6 0 0 6 536.7418 422.0944 Tm
(\240)Tj
-0.00011 Tc 0.02499 Tw 8 0 0 8 53.532 399.4544 Tm
[(F)74 (ACIT)-257.3 (Fatigue)-1261.1 (Did not achieve )54.8 (ACR20)-1898 (295)-4049.9 (28.6)-3744.8 (10.8)-3837.4 (1)36.8 (1.0)-4029.1 (2.1)-4864.6 (8.6)-4365.8 (0.19)-3834.8 (0.25)]TJ
T*
[(scale)-5748.7 (Best response )54.8 (ACR20)-2313 (150)-4049.9 (29.3)-3763.2 (1)36.8 (1.5)-9597.9 (6.6)-10480.3 (0.60)-3834.8 (0.77)]TJ
0 Tc 7.7469 -1.25 Td
[(Best response )54.8 (ACR50)-2562.9 (69)-4299.8 (30.6)-3744.7 (10.9)-9329.4 (10.4)-10230.2 (0.95)-3834.7 (1.21)]TJ
T*
[(Best response )54.8 (ACR70)-2562.9 (57)-4299.8 (30.9)-3763.1 (1)36.9 (1.0)-9347.8 (12.4)-10230.2 (1.13)-3834.7 (1.45)]TJ
-0.00011 Tc -6.2469 -1.25 Td
(p = 0.001 for linear test for trend in change scores across categories)Tj
-1.5 -1.25 Td
[(SF-36 )17.7 (V)59.8 (itality)-1635.1 (Did not achieve )54.8 (ACR20)-1898 (296)-4049.9 (34.0)-3744.8 (19.9)-3819 (20.6)-4010.6 (5.2)-4614.6 (20.0)-4115.8 (0.25)-3834.8 (0.27)]TJ
0 Tc 7.7469 -1.25 Td
[(Best response )54.8 (ACR20)-2312.9 (150)-4049.8 (36.2)-3744.7 (21.1)-9329.4 (14.5)-10230.2 (0.71)-3834.7 (0.76)]TJ
T*
[(Best response )54.8 (ACR50)-2562.9 (69)-4299.8 (37.3)-3744.7 (21.6)-9329.4 (23.5)-10230.2 (1.14)-3834.7 (1.24)]TJ
T*
[(Best response )54.8 (ACR70)-2562.9 (57)-4299.8 (37.2)-3744.7 (21.8)-9329.4 (31.4)-10230.2 (1.52)-3834.7 (1.65)]TJ
-0.00011 Tc -6.2469 -1.25 Td
(p = 0.001 for linear test for trend in change scores across categories)Tj
0 Tc -1.5 -1.25 Td
[(MAF)-5165.2 (Did not achieve )54.8 (ACR20)-1897.9 (286)-4049.8 (27.5)-3763.1 (1)36.9 (1.6)-3855.7 (1)36.9 (1.9)-3779 (\3202.1)-4364.5 (10.8)-3865.7 (\3200.18)-3334.7 (\3200.20)]TJ
7.7469 -1.25 Td
[(Best response )54.8 (ACR20)-2312.9 (143)-4049.8 (26.5)-3744.7 (12.5)-9329.4 (\3207.2)-9980.2 (\3200.61)-3334.7 (\3200.67)]TJ
T*
[(Best response )54.8 (ACR50)-2562.9 (68)-4299.8 (25.1)-3763.1 (1)36.9 (1.4)-9116.3 (\3201)36.9 (1.0)-9748.6 (\3200.93)-3334.7 (\3201.02)]TJ
T*
[(Best response )54.8 (ACR70)-2562.9 (57)-4299.8 (25.3)-3744.7 (12.0)-9079.4 (\32014.9)-9730.2 (\3201.25)-3334.7 (\3201.38)]TJ
-0.00011 Tc -6.2469 -1.25 Td
(p = 0.001 for linear test for trend in change scores across categories)Tj
-1.5 -2.5 Td
(* Change score mean divided by the pooled baseline SD. )Tj
0 Tc 0 Tw 6 0 0 6 240.1434 242.0944 Tm
(\240)Tj
-0.00011 Tc 0.02499 Tw 8 0 0 8 245.3435 239.4544 Tm
(Change score mean divided by the pooled change score SD.)Tj
ET
53.532 453.924 m
558.468 453.924 l
53.532 412.924 m
558.468 412.924 l
53.532 251.924 m
558.468 251.924 l
S
Q
Q
q
0 0 612 792 re
W n
BT
0 g
/GS2 gs
/T1_2 8 Tf
108.828 74 Td
(Personal non-commercial use only.  The Journal of Rheumatology Copyright\ \251 2005.  All rights reserved.)Tj
ET
Q
BT
0 g
/GS2 gs
/T1_3 1 Tf
10 0 0 10 540 17 Tm
( )Tj
0 0.48627 0.77255 rg
/GS2 gs
-7.22298 0 Td
(www.jrheum.org)Tj
0 g
/GS2 gs
-18.00796 0 Td
(Downloaded on December 3, 2023 from )Tj
ET

endstream
endobj
52 0 obj
<</BitsPerComponent 8/ColorSpace 66 0 R/Filter[/ASCII85Decode/FlateDecode]/Height 99/Length 497/Width 76>>stream
8;Z\6$aRYm#itt$j>sKH!obSZ_=UIBm5-\8f4?+&`.K-5]^YoG2)$mPGNf0HW]Mo:
E4NDMmMb^A5^f9T6!;2S2Btm1kSH4B2$jo$@]G<5TkFH!?2<:^M>P">l)D2jObB%W
nc!djeb(T/kFEhE`n?[L<U]DBMGr6s#!Q_+oV"Bf-:!R]V-"^);L]9h&s0/Q.i+tr
<5G:[.6Db_PR`e,C'kep:NC.))jI,1PN7C^CX14&2#,!;_kF$n5`)Z,!UJb_kq'ID
]UF.s*pgP1+`DG%WOlAG,bF%4#dA%R\`0<)M2W`d;-Z-#<MgSVaJk0@@ltrNihuAb
$$sqpCLVOW=NI7sX#p8A>Z$<WM;\,VadOe3B(:6/&W??jC59tcl1]5c['.([CKun)
5BZJ1h3`u%'VdaN46(2n<H`02eSQ[''3EeF#@jj:*=[.59rD<W55ICM\h5=Hdq')'
<O=<"`ctFKF%ZZs%,la+i8BU0!<AHM/tr~>
endstream
endobj
156 0 obj
<</BG2/Default/OP true/OPM 1/SA false/SM 0.0200043/TR2/Default/Type/ExtGState/UCR2/Default/op true>>
endobj
157 0 obj
<</BG2/Default/OP false/OPM 0/SA false/SM 1.0/TR2/Default/UCR2/Default/op false>>
endobj
188 0 obj
<</A 189 0 R/Border[0 0 0]/Rect[466.77 15.0 541.0 27.0]/Subtype/Link/Type/Annot>>
endobj
189 0 obj
<</S/URI/URI(http://www.jrheum.org/)>>
endobj
150 0 obj
[190 0 R]
endobj
151 0 obj
<</Length 14767>>stream
1 g
/GS0 gs
0 792 m
0 792 l
f
q
13.5 787.5 585 -783 re
W n
q
0 792.03 612 -792 re
W n
BT
0 0 0 1 k
/GS1 gs
/T1_0 1 Tf
-0.00011 Tc -0.0143 Tw 8 0 0 8 53.468 737.0293 Tm
(functioning \(10 items\), bodily pain \(2 items\), vitality \(4 items\),\ social func-)Tj
0.15109 Tw 0 -1.2625 TD
(tioning \(2 items\), mental health \(5 items\), general health perceptio\ns \(5)Tj
0.0134 Tw T*
(items\), role limitations due to physical problems \(4 items\), and role\ limita-)Tj
0.1167 Tw T*
[(tions due to emotional problems \(3 items\). )54.8 (A)-311.8 (high SF-36 score indicates)]TJ
0.01691 Tw T*
[(better health \(range 0 to 100\). )17.7 (The SF-36)]TJ
0 Tc 0 Tw 6 0 0 6 185.3338 699.2694 Tm
(30,31)Tj
-0.00011 Tc 0.01691 Tw 8 0 0 8 200.9692 696.6293 Tm
(and the vitality scale specifi-)Tj
-0.0002 Tc 0 Tw -18.4376 -1.2625 Td
(cally)Tj
0 Tc 6 0 0 6 69.0149 689.1694 Tm
(31,32)Tj
-0.00011 Tc 0.0759 Tw 8 0 0 8 85.122 686.5293 Tm
(have been found to be valid in studies of patients with RA. For)Tj
0.0361 Tw -3.9568 -1.2625 Td
[(purposes of this validation study)64.9 (, data from the 4 item SF-36 vitality scale)]TJ
0.0074 Tw T*
[(\(SF-36 )17.7 (V)59.8 (itality\) will be analyzed and compared with data from the 13 item)]TJ
0.02499 Tw T*
[(F)74 (ACIT)-257.3 (Fatigue scale.)]TJ
0.00079 Tw 1.5 -1.2625 Td
[(The Multidimensional )54.9 (Assessment of Fatigue \(MAF\) contains 16 items)]TJ
0.049 Tw -1.5 -1.2625 Td
(that measure 4 dimensions of fatigue: severity \(2 items\), distress \(1\ item\),)Tj
0.02029 Tw T*
[(timing \(2 items\), and degree of interference in activities of daily li\ving \(1)36.7 (1)]TJ
-0.0002 Tc 0 Tw T*
(items\))Tj
0 Tc 6 0 0 6 73.4602 618.4694 Tm
(33)Tj
-0.00011 Tc 0.0498 Tw 8 0 0 8 79.4602 615.8294 Tm
[(. )54.8 (A)-244.9 (Global Fatigue Index \(GFI\), ranging from 1 to 50, can also be)]TJ
0.11349 Tw -3.249 -1.2625 Td
[(calculated, a high score indicating high levels of fatigue. )17.7 (The GFI is the)]TJ
0.0708 Tw T*
(sum of \(1\) the total of MAF items 1, 2, and 3; \(2\) the average of it\ems 4)Tj
0.058 Tw T*
(through 14; and \(3\) item 15 after it has been converted to a 0 to 10 s\cale.)Tj
0.186 Tw T*
(This measure has been shown to be reliable and valid in patients with)Tj
0.0573 Tw T*
(human immunodeficiency virus infection)Tj
0 Tc 0 Tw 6 0 0 6 187.0217 567.9695 Tm
(34)Tj
-0.00011 Tc 0.05721 Tw 8 0 0 8 193.0217 565.3295 Tm
(, multiple sclerosis)Tj
0 Tc 0 Tw 6 0 0 6 254.1448 567.9695 Tm
(35)Tj
-0.00011 Tc 0.05721 Tw 8 0 0 8 260.1448 565.3295 Tm
(, cancer)Tj
0 Tc 0 Tw 6 0 0 6 285.468 567.9695 Tm
(36)Tj
8 0 0 8 291.468 565.3295 Tm
(,)Tj
0.02499 Tw -29.75 -1.2625 Td
(and RA)Tj
0 Tw 6 0 0 6 78.3301 557.8695 Tm
(21)Tj
8 0 0 8 84.3301 555.2295 Tm
(.)Tj
/T1_1 1 Tf
-0.00011 Tc -0.03661 Tw -3.8578 -1.5625 Td
(Analysis plan.)Tj
/T1_0 1 Tf
5.8249 0 Td
[(The focus of analyses for this study was data from the ST)79.8 (AR.)]TJ
0.1537 Tw -5.8249 -1.2625 Td
[(However)39.7 (, we have included descriptive statistics on the )54.9 (ARMADA)-348.8 (trial)]TJ
0.01131 Tw T*
(sample and measures for comparison. Patient and clinical data used for t\he)Tj
0.045 Tw T*
[(validation analyses included the pretreatment \(baseline\), mid-study \(\W)79.8 (eek)]TJ
0.3315 Tw T*
[(12\), and end of study \(W)79.8 (eek 24\) timepoints of the 24 week trials.)]TJ
0.13361 Tw T*
(Descriptive statistics for demographic and clinical variables and patien\t-)Tj
-0.0128 Tw T*
[(completed questionnaires \(e.g., F)73.9 (ACIT)-219.4 (Fatigue scale, MAF)79.7 (, SF-36 )17.8 (V)59.8 (itality\))]TJ
0.0603 Tw T*
[(at baseline were calculated for the ST)79.7 (AR and )54.8 (ARMADA)-255.5 (trials. )17.7 (The MAF)]TJ
0.02499 Tw T*
[(was not used in the )54.8 (ARMADA)-220.2 (trial.)]TJ
0.1718 Tw 1.5 -1.2625 Td
[(The reliability and internal consistency of the F)73.9 (ACIT)-404.1 (Fatigue scale,)]TJ
0.0215 Tw -1.5 -1.2625 Td
[(MAF)79.7 (, and SF-36 )17.7 (V)59.8 (itality at baseline and at 12 and 24 weeks were evaluat-)]TJ
0.29311 Tw T*
[(ed using Cronbach\325)54.8 (s alpha. Conver)17.7 (gent validity of the measures was)]TJ
-0.00281 Tw T*
[(assessed using Spearman correlation coef)17.7 (ficients calculated at baseline and)]TJ
0.02499 Tw T*
(at 12 and 24 weeks.)Tj
0.07159 Tw 1.5 -1.225 Td
[(W)79.9 (e calculated the change in fatigue scores from baseline to 24 weeks)]TJ
0.0976 Tw -1.5 -1.225 Td
[(for the F)73.9 (ACIT)-329.9 (Fatigue scale, SF-36 )17.7 (V)59.8 (itality)64.9 (, and MAF based on )54.8 (ACR20,)]TJ
0.2341 Tw 0 -1.225 TD
[(ACR50, and )54.9 (ACR70 clinical groups \(i.e., those who failed to achieve)]TJ
0.10609 Tw T*
[(ACR20, those who achieved )54.8 (ACR20 but failed to achieve )54.8 (ACR50, those)]TJ
0.0079 Tw T*
[(who achieved )54.8 (ACR50 but not )54.8 (ACR70, and those who achieved )54.8 (ACR70\). )54.8 (A)]TJ
-0.02139 Tw T*
(linear test for trend was computed using general linear model contrast c\oef-)Tj
0.0087 Tw T*
[(ficients for mean fatigue scores by )54.8 (ACR clinical group to evaluate whether)]TJ
0.1282 Tw T*
(fatigue scores showed a consistent linear increase across these clinical\ly)Tj
0.0153 Tc 0.3596 Tw T*
[(distinct groups. Pairwise comparison tests using )17.6 (T)35 (ukey\325)54.8 (s Honestly)]TJ
-0.00011 Tc 0.0192 Tw T*
[(Significant Dif)17.7 (ference were conducted to test whether mean change scores)]TJ
0.09219 Tw T*
[(were dif)17.7 (ferent between )54.8 (ACR groups. )17.7 (T)69.9 (o evaluate sensitivity to change of)]TJ
0.12061 Tw T*
[(the F)73.9 (ACIT)-352.9 (Fatigue scale, we computed the ef)17.7 (fect sizes and standardized)]TJ
0.145 Tw T*
[(response means of the mean change from baseline for the )54.9 (ACR clinical)]TJ
0.0762 Tw T*
[(groups. )17.7 (The ef)17.7 (fect size was calculated as the mean change score for each)]TJ
0.04539 Tw T*
(clinical group divided by the pooled baseline standard deviation \(SD\);\ the)Tj
0.08501 Tw T*
(standardized response mean was calculated as the mean change score for)Tj
0.0056 Tw T*
(each clinical group divided by the pooled SD of the change)Tj
0 Tc 0 Tw 6 0 0 6 243.6217 247.4698 Tm
(37)Tj
-0.00011 Tc 0.00549 Tw 8 0 0 8 249.6217 244.8297 Tm
(. For compar-)Tj
0.06171 Tw -24.5192 -1.225 Td
(ison, we calculated the standardized response means of the MAF and SF-)Tj
0.00729 Tw T*
[(36 V)59.8 (itality )-17.7 (measures.)]TJ
0.1667 Tw 1.5 -1.25 Td
[(Potential minimally important dif)17.7 (ference \(MID\) thresholds in scores)]TJ
-0.00999 Tw -1.5 -1.25 Td
[(between baseline and )17.7 (W)79.9 (eek 24, or the change score associated with clinical)]TJ
-0.03191 Tw 0 -1.25 TD
(meaning \()Tj
/T1_2 1 Tf
0 Tc 0 Tw [-0.1 (\003)]TJ
/T1_0 1 Tf
6 0 0 6 90.3164 192.5898 Tm
(F)Tj
-0.00011 Tc -0.03191 Tw 8 0 0 8 93.6519 195.2298 Tm
[(\), were calculated using \(1\) ef)17.7 (fect sizes of 0.2 and 0.5 SD units,)]TJ
0.0799 Tw -5.023 -1.25 Td
[(calculated as the dif)17.7 (ference between baseline and )17.7 (W)79.9 (eek 24 fatigue scores)]TJ
0.0415 Tw T*
(divided by the baseline SD; and \(2\) groups with 1 standard error of me\as-)Tj
0.02119 Tw T*
(urement \(SEM\) change, calculated as the SD multiplied by the square ro\ot)Tj
0.1203 Tw T*
[(of 1 minus the reliability coef)17.7 (ficient \(alpha\))]TJ
0 Tc 0 Tw 6 0 0 6 199.0359 157.8698 Tm
(38,39)Tj
-0.00011 Tc 0.1203 Tw 8 0 0 8 212.5359 155.2298 Tm
(. Five MID groups were)Tj
0.1071 Tw -19.8835 -1.25 Td
[(created using 0.2 and 0.5 SD cutof)17.7 (fs for each of the 3 fatigue measures:)]TJ
0.0331 Tw T*
(major worsening \()Tj
/T1_2 1 Tf
0 Tc 0 Tw [-0.1 (\003)]TJ
/T1_0 1 Tf
-0.00011 Tc 6 0 0 6 117.5346 132.5898 Tm
(F )Tj
/T1_2 1 Tf
0 Tc 8 0 0 8 122.5687 135.2298 Tm
(\004)Tj
/T1_0 1 Tf
-0.00011 Tc 0.0331 Tw 1.115 0 Td
(\3200.5 SD\), minor worsening \(\3200.5 SD < )Tj
/T1_2 1 Tf
0 Tc 0 Tw 16.0706 0 Td
(\003)Tj
/T1_0 1 Tf
6 0 0 6 264.9477 132.5898 Tm
(F)Tj
/T1_2 1 Tf
8 0 0 8 270.5479 135.2298 Tm
(\004)Tj
/T1_0 1 Tf
1.115 0 Td
(\3200.2)Tj
-0.00011 Tc 0.0394 Tw -28.25 -1.25 Td
(SD\), unchanged \(\3200.2 SD < )Tj
/T1_2 1 Tf
0 Tc 0 Tw 11.5632 0 Td
(\003)Tj
/T1_0 1 Tf
6 0 0 6 150.8685 122.5898 Tm
(F)Tj
/T1_2 1 Tf
8 0 0 8 156.5185 125.2298 Tm
(\004)Tj
/T1_0 1 Tf
-0.00011 Tc 0.03931 Tw 1.1275 0 Td
(0.2 SD\), minor improvement \(0.2 SD <)Tj
/T1_2 1 Tf
0 Tc 0 Tw -14.0088 -1.25 Td
(\003)Tj
/T1_0 1 Tf
6 0 0 6 58.3625 112.5898 Tm
(F)Tj
/T1_2 1 Tf
8 0 0 8 64.7087 115.2298 Tm
(\004)Tj
/T1_0 1 Tf
-0.00011 Tc 0.1264 Tw 1.3015 0 Td
(0.5 SD\), and major improvement \()Tj
/T1_2 1 Tf
0 Tc 0 Tw [-0.4 (\003)]TJ
/T1_0 1 Tf
6 0 0 6 195.4792 112.5898 Tm
(F)Tj
-0.00011 Tc 0.1264 Tw 8 0 0 8 201.8254 115.2298 Tm
(> 0.5 SD\). Each instrument)Tj
-0.0079 Tw -18.5447 -1.25 Td
[(served as a reference for the other 2 measures. )17.8 (Thus, the change from base-)]TJ
-0.02049 Tw T*
[(line to 24 weeks in the F)73.9 (ACIT)-211.7 (Fatigue scale and MAF was evaluated by the)]TJ
0.07159 Tw 33 80.2249 Td
[(SF-36 )17.7 (V)59.8 (itality MID group, the change in F)73.8 (ACIT)-303.9 (Fatigue scale and SF-36)]TJ
-0.0359 Tw T*
[(V)59.8 (itality by the MAF MID group, and the change in SF-36 )17.7 (V)59.8 (itality and MAF)]TJ
-0.0309 Tw T*
[(by the F)73.9 (ACIT)-201.4 (Fatigue scale MID group. )54.8 (Analyses using 2-tailed t tests were)]TJ
0.0258 Tw T*
[(conducted to determine the dif)17.7 (ference of the mean change from zero with-)]TJ
-0.0247 Tw T*
(in each of the 5 MID groups for each measure, and analysis of variance w\as)Tj
0.0475 Tw T*
(used to evaluate the equivalence of change score means across the 5 MID)Tj
0 Tw T*
(groups.)Tj
-0.00369 Tw 1.5 -1.25 Td
[(Finally)64.8 (, a confirmatory analysis was performed to determine the degree)]TJ
0.0674 Tw -1.5 -1.25 Td
[(to which classification of F)73.9 (ACIT)-299.7 (Fatigue scale scores using the MID val-)]TJ
0.02139 Tw T*
[(ues \(0.2 and 0.5 SD units\) calculated with ST)79.7 (AR data agreed with classifi-)]TJ
0.0898 Tw T*
[(cation of scores with )54.8 (ARMADA)-285 (data. Cohen\325)54.8 (s kappa)]TJ
0 Tc 0 Tw 6 0 0 6 492.2304 639.6693 Tm
(40)Tj
-0.00011 Tc 0.0898 Tw 8 0 0 8 500.949 637.0293 Tm
(was calculated to)Tj
0.196 Tw -22.9351 -1.25 Td
(determine the degree to which this classification scheme agreed across)Tj
0 Tw T*
(datasets.)Tj
/T1_3 1 Tf
10 0 0 10 317.468 595.0293 Tm
[(RESUL)91.7 (TS)]TJ
/T1_0 1 Tf
0.1368 Tw 0 -1.2 TD
[(Descriptive statistics for baseline, )17.7 (W)79.9 (eek 12, and )17.7 (W)79.9 (eek 24)]TJ
0.2524 Tw T*
[(scores for the F)73.8 (ACIT)-484.7 (Fatigue scale, SF-36 )17.7 (V)59.8 (itality)64.8 (, and)]TJ
0.0813 Tw T*
[(MAF for ST)79.7 (AR and )54.8 (ARMADA)-276.5 (are reported in )17.7 (T)69.9 (able 2. In)]TJ
0.03909 Tw T*
[(ST)79.7 (AR, the F)73.8 (ACIT)-271.4 (Fatigue scale \(alpha = 0.86 to 0.87\), SF-)]TJ
0.0125 Tw T*
[(36 )17.8 (V)59.8 (itality \(alpha = 0.84 to 0.88\) and MAF \(alpha = 0.93 to)]TJ
0.08279 Tw T*
[(0.96\) all had good internal consistencies at baseline, )17.7 (W)79.9 (eek)]TJ
0.1685 Tw T*
[(12, and )17.7 (W)79.9 (eek 24. Correlation coef)17.7 (ficients showed a very)]TJ
0.0536 Tw T*
(high degree of association among all 3 measures of fatigue)Tj
0.0815 Tw T*
[(at baseline, )17.7 (W)79.9 (eek 12, and )17.7 (W)79.9 (eek 24, ranging from \3200.68 to)]TJ
0.13741 Tw T*
[(\3200.88 \(p < 0.001\). \(Coef)17.7 (ficients of association with MAF)]TJ
0.0293 Tw T*
(are negative because high scores on that scale reflect worse)Tj
0 Tw T*
(fatigue.\))Tj
0.1246 Tw 1.2 -1.18 Td
[(T)69.9 (o evaluate the sensitivity of the F)73.9 (ACIT)-356.9 (Fatigue scale,)]TJ
0.0197 Tw -1.2 -1.18 Td
[(SF-36 )17.8 (V)59.8 (itality)64.8 (, and MAF to change in clinical status, analy-)]TJ
-0.002 Tw 0 -1.18 TD
[(ses of fatigue measure change scores by )54.8 (ACR clinical group)]TJ
0.2471 Tw T*
[(were conducted. Four unique )54.8 (ACR clinical groups were)]TJ
-0.0374 Tw T*
[(established: those who failed to achieve )54.9 (ACR20 status, those)]TJ
0.164 Tw T*
[(who achieved )54.8 (ACR20 status as their best response, those)]TJ
0.0193 Tw T*
[(who achieved )54.8 (ACR50 as their best response, and those who)]TJ
0.0724 Tw T*
[(achieved )54.8 (ACR70 status. Because the )17.7 (W)79.9 (eek 12 results were)]TJ
0.05389 Tw T*
[(very similar to the )17.7 (W)79.9 (eek 24 results, only the )17.7 (W)79.9 (eek 24 \(end)]TJ
0.1281 Tw T*
[(of study\) results are presented. )17.7 (T)69.9 (able 3 displays the mean)]TJ
0.1942 Tw T*
[(and SD of the raw baseline scores and )17.7 (W)79.9 (eek 24 change)]TJ
0.1227 Tw T*
[(scores for each fatigue measure as well as the ef)17.7 (fect size,)]TJ
0.3465 Tw T*
(standardized response mean, and statistical significance)Tj
0.05231 Tw T*
[(associated with the dif)17.7 (ferences in change scores among the)]TJ
0.0708 Tw T*
[(4 )54.8 (ACR groups. )17.7 (There was a significant linear trend toward)]TJ
0.13901 Tw T*
[(an increase in fatigue scores across the )54.9 (ACR groups \(p =)]TJ
0.0359 Tw T*
[(0.0001\). )54.8 (A)74 (verage change scores were significantly dif)17.7 (ferent)]TJ
0.0224 Tw T*
[(between those who failed to achieve )54.8 (ACR20 and those who)]TJ
0.1387 Tw T*
[(achieved )54.8 (ACR20 as their best response \(p < 0.0001\), and)]TJ
0.06351 Tw T*
[(between those who achieved )54.8 (ACR20 as their best response)]TJ
0.0499 Tw T*
[(and those who achieved )54.9 (ACR50 as their best response \(p <)]TJ
0.0029 Tw T*
[(0.0001\). However)39.7 (, the mean change for those who achieved)]TJ
0.15379 Tw T*
(ACR50 as their best response versus those who achieved)Tj
0.02499 Tw T*
[(ACR70 was not significantly dif)17.7 (ferent \(p = 0.5477\).)]TJ
0.1449 Tw 1.2 -1.2 Td
(In addition, for all 3 measures there was a gradient of)Tj
0.0069 Tw -1.2 -1.2 Td
[(ef)17.7 (fect size and standardized response means by )54.8 (ACR group,)]TJ
0.0004 Tw 0 -1.2 TD
[(with ef)17.7 (fect size and standardized response means increasing)]TJ
0.16679 Tw T*
[(as )54.8 (ACR status improved \(i.e., from )54.8 (ACR20 to )54.8 (ACR50 to)]TJ
0.04691 Tw T*
(ACR70\). Following the convention established by Cohen)Tj
0 Tc 0 Tw 7.5 0 0 7.5 549.968 111.1296 Tm
(41)Tj
-0.00011 Tc -0.01781 Tw 10 0 0 10 317.468 95.8296 Tm
[(that suggests an ef)17.7 (fect size around 0.2 is small, around 0.5 is)]TJ
ET
0 0 0 1 K
53.468 76.5 m
558.468 76.5 l
S
0 0 0 0 k
494.29 69.365 64.178 -15.665 re
f*
BT
0 0 0 1 k
/T1_1 1 Tf
0 Tc 0 Tw 8 0 0 8 545.468 56.4344 Tm
(813)Tj
ET
0 0 0 0 k
53.532 70.501 203 -16.591 re
f*
BT
0 0 0 1 k
/T1_1 1 Tf
-0.00011 Tc 0.02499 Tw 8 0 0 8 54.532 56.6447 Tm
[(Cella, et al: F)128.8 (ACIT)-257.3 (scale in RA)]TJ
ET
0 0 0 0 k
/GS0 gs
103.631 82.583 407.5 -10.833 re
f*
0.5 w 
/GS1 gs
103.631 82.583 407.5 -10.833 re
S
Q
Q
q
0 0 612 792 re
W n
BT
0 g
/GS2 gs
/T1_4 8 Tf
108.828 74 Td
(Personal non-commercial use only.  The Journal of Rheumatology Copyright\ \251 2005.  All rights reserved.)Tj
ET
Q
BT
0 g
/GS2 gs
/T1_5 1 Tf
10 0 0 10 540 17 Tm
( )Tj
0 0.48627 0.77255 rg
/GS2 gs
-7.22298 0 Td
(www.jrheum.org)Tj
0 g
/GS2 gs
-18.00796 0 Td
(Downloaded on December 3, 2023 from )Tj
ET

endstream
endobj
50 0 obj
<</BitsPerComponent 8/ColorSpace 66 0 R/Filter[/ASCII85Decode/FlateDecode]/Height 99/Length 912/Width 76>>stream
8;Z\7>B0fh%.jENW9\Pg`Nh0K]-^*6g<aPG+$l3GD$]VOIqY2i+(gS7a2N%4mFCgr
G_tT^ZoanS=:Ke*##(oj]_7'j',E<+1`Tk<+X"-s6_JkSY="0RUY[&FQbf`96IKOA
*!cCuIoX:@Sm_n:K2(@6>3BclL^@=b"$b#,Z%$J@9qasq"ACUkX36N^20TZCV98sH
OZ\U=7UA/.n_Ren,Xl`KOKFa==#QNH9K#GK:CK,d+\)@"ZNUm>_o-%6)GP,oP_>+u
3hJUm#jr8ibM%Op8d$_d5[99iX._@#C_DBr(k#RL>"p0F>d*o%p<l$WOqC?aE2UMf
A$!_>OC_PX(;udorI)\@=//#U'qC5J;9-BD]n?2KPAKd(j>C]Ee4TV#jQ_%;'9qrq
4VNcII]ZF-\su`IFdK20hOh\ZY\7,q_u6fi3ZQ*S)AhI(@PRns`XUobOjXQtYc0d`
";M]W?U;-YP=<\mF9VX>Kg$ae^a*rkX7\86@3*T3iB)c8J)i_CXE!*E7UDsg_sYu:
]r+_fBBY@4a=/jCVpX3X-^j:Cfl%lGNI;U4:U5l>WhO+`WD`03-J@=C9-r+F,5*nC
(qGB5YVkDTNLoJ+!*s0d]T7A_+c8J-?>5X@hcnB<`=q+V/[sW/:#\0gKI9.Pe-3VD
4;]3N^fbCs\[@IF/`QB%Ig(JM.!a;u.lSKlbk).]3Nk%'Mc_fD+B&eTjsBDB"r>7@
oX09?irQ(4e@5;>jf!HC/8"W@2V]4:>Ns0J,LW^tD.1l9Fu5Z!:O2+Amh4Mr9#a5q
Si&C*0Y-m`er=I5U$hdMSC(=MWK]9GDFV8j?E7IZ"`]9n.A0VOIWuoI]T7_ieNB;%
23&=/1e4.0nZ+_%Z0sI%VL!sk+toh:SI?>_fCaO358cZf!9&?$+9~>
endstream
endobj
152 0 obj
<</BG2/Default/OP true/OPM 1/SA false/SM 0.0200043/TR2/Default/Type/ExtGState/UCR2/Default/op true>>
endobj
153 0 obj
<</BG2/Default/OP false/OPM 0/SA false/SM 1.0/TR2/Default/UCR2/Default/op false>>
endobj
190 0 obj
<</A 191 0 R/Border[0 0 0]/Rect[466.77 15.0 541.0 27.0]/Subtype/Link/Type/Annot>>
endobj
191 0 obj
<</S/URI/URI(http://www.jrheum.org/)>>
endobj
146 0 obj
[192 0 R]
endobj
147 0 obj
<</Length 12458>>stream
1 g
/GS0 gs
0 792 m
0 792 l
f
q
13.5 787.5 585 -783 re
W n
q
0 792.03 612 -792 re
W n
BT
0 0 0 1 k
/GS1 gs
/T1_0 1 Tf
0.01981 Tc 10 0 0 10 54 734.8264 Tm
(crite)Tj
0.0049 Tc 0.4912 Tw [-0.1 (rion for remission by the )54.9 (American College of)]TJ
-0.01511 Tc 0.2778 Tw 0 -1.2 TD
(Rheumatology \(ACR\))Tj
-0.015 Tc 0 Tw 7.5 0 0 7.5 142.6738 726.1265 Tm
(20)Tj
-0.01511 Tc 0.2778 Tw 10 0 0 10 149.9488 722.8264 Tm
[(. Fatigue associated with RA)-458 (con-)]TJ
0.03661 Tw -9.5949 -1.2 Td
[(tributes to work disability)64.8 (, personal injury)64.8 (, inability to partici-)]TJ
-0.00259 Tw T*
(pate in rehabilitation programs, and strained relationships)Tj
-0.015 Tc 0 Tw 7.5 0 0 7.5 275.1876 702.1265 Tm
(19,21)Tj
0 Tc 10 0 0 10 291.5001 698.8264 Tm
(.)Tj
-0.00011 Tc 0.0251 Tw -22.55 -1.2 Td
[(Our objective was to validate in patients with RA)-220.4 (a brief)]TJ
0.0999 Tw -1.2 -1.2 Td
(\(13 items\), easy to administer fatigue scale that has previ-)Tj
0.0627 Tw T*
(ously been validated in patients with cancer)Tj
0 Tc 0 Tw 7.5 0 0 7.5 232.6963 666.1265 Tm
(22)Tj
-0.00011 Tc 0.06281 Tw 10 0 0 10 243.3237 662.8264 Tm
(and the gen-)Tj
0.26089 Tw -18.9324 -1.2 Td
(eral population)Tj
0 Tc 0 Tw 7.5 0 0 7.5 116.865 654.1265 Tm
(9)Tj
-0.00011 Tc 0.26089 Tw 10 0 0 10 120.615 650.8264 Tm
[(. )17.8 (The Functional )54.9 (Assessment of Chronic)]TJ
0.011 Tw -6.6615 -1.2 Td
[(Illness )17.7 (Therapy-Fatigue \(F)73.9 (ACIT)91.7 (-F\) questionnaire was origi-)]TJ
0.13319 Tw T*
(nally developed to assess the fatigue associated with ane-)Tj
-0.00031 Tc 0 Tw T*
(mia)Tj
0 Tc 7.5 0 0 7.5 68.9951 618.1265 Tm
(22)Tj
-0.00011 Tc -0.0061 Tw 10 0 0 10 76.4951 614.8264 Tm
[(. )17.7 (This questionnaire is part of the F)73.9 (ACIT)-226.2 (measurement)]TJ
0.3483 Tw -2.2495 -1.2 Td
(system, a comprehensive compilation of questions that)Tj
0.2213 Tw T*
[(measure health related QOL)-434.5 (in patients with cancer and)]TJ
0.00349 Tw T*
[(other chronic illnesses. )17.7 (The core of the F)73.9 (ACIT)-235.8 (system is the)]TJ
0.0554 Tw T*
[(Functional )54.8 (Assessment of Cancer )17.7 (Therapy-General \(F)73.9 (ACT)91.7 (-)]TJ
-0.00031 Tc 0 Tw T*
(G\))Tj
0 Tc 7.5 0 0 7.5 64.5469 558.1265 Tm
(23)Tj
-0.00011 Tc 0.0504 Tw 10 0 0 10 72.0469 554.8264 Tm
(, a 27 item general version of the questionnaire, which)Tj
0.1398 Tw -1.8047 -1.2 Td
(serves as a foundation onto which questions are added to)Tj
-0.0192 Tw T*
(address concerns or problems specific to a particular disease)Tj
0.1071 Tw T*
[(site, treatment, or symptom. )17.7 (Thirteen fatigue related ques-)]TJ
0.1727 Tw T*
[(tions are added to the F)73.9 (ACT)91.7 (-G to make up the F)73.8 (ACIT)91.7 (-F)]TJ
0.14281 Tw T*
[(\(available at www)64.8 (.facit.or)17.7 (g\). )17.7 (These 13 questions form the)]TJ
0.02499 Tw T*
[(basis of this validation study)64.8 (.)]TJ
/T1_1 1 Tf
-0.0298 Tw 0 -2.4 TD
[(MA)73.8 (TERIALS AND )-54.8 (METHODS)]TJ
/T1_2 1 Tf
8 0 0 8 54 448.8264 Tm
[(Sour)36.8 (ce of data.)]TJ
/T1_0 1 Tf
6.1881 0 Td
(The validation sample consisted of 636 individuals with RA)Tj
-0.03169 Tw -6.1881 -1.25 Td
(enrolled in a 2-arm \(equal sample sizes\), double blind, randomized 24 \week)Tj
0.028 Tw 0 -1.25 TD
[(clinical trial of adalimumab \(Humira\252, )54.8 (Abbott Laboratories, )54.8 (Abbott Park,)]TJ
0.33459 Tw T*
[(IL, USA\), a human tumor necrosis factor)19.7 (-)]TJ
/T1_3 1 Tf
0 Tc 0 Tw (\002)Tj
/T1_0 1 Tf
-0.00011 Tc 0.33459 Tw 19.973 0 Td
(antagonist, plus current)Tj
0.15669 Tw -19.973 -1.25 Td
(antirheumatic therapy versus placebo plus current antirheumatic therapy)Tj
0.2337 Tw T*
[(\(referred to as ST)79.7 (AR, the Safety )17.7 (T)35 (rial of )54.8 (Adalimumab in Rheumatoid)]TJ
0.11481 Tw T*
(Arthritis\), in which 40 mg of adalimumab was administered by subcuta-)Tj
0.0793 Tw T*
(neous injection. Our study analyzed the pooled data of the entire sample\,)Tj
0.06281 Tw T*
(without unblinding the data as to treatment \(adalimumab versus placebo\)\.)Tj
0.14661 Tw T*
(The demographic and clinical characteristics of this sample are summa-)Tj
0.08189 Tw T*
[(rized in )17.8 (T)69.9 (able 1. )17.7 (The study subjects had a median age of 56 years \(range)]TJ
0.091 Tw T*
[(21\32086\) and were lar)17.7 (gely non-Hispanic white \(88%\). )17.8 (The median level of)]TJ
0.05409 Tw T*
(serum C-reactive protein \(CRP\), an index of acute and chronic inflamma\-)Tj
T*
[(tion, was 9 mg/l \(range 4\320197\). )54.9 (At baseline, the median number of tender)]TJ
0.1692 Tw T*
(joints was 25 out of a possible 68 \(range 7\32068\). Of a maximum of 66\)Tj
0.02499 Tw T*
[(swollen joints, the ST)79.7 (AR sample median was 19 \(range 6\32066\).)]TJ
0.0679 Tw 34.5 54.671 Td
(One set of confirmatory analyses included data from a second sample)Tj
0.05659 Tw -1.5 -1.2375 Td
[(of 271 patients with RA)-251.7 (enrolled in a separate 4-arm \(equal sample sizes\))]TJ
0.0692 Tw 0 -1.2375 TD
(24 week, randomized, double blind, placebo controlled clinical trial com\-)Tj
0.02319 Tw T*
(paring adalimumab \(20, 40, or 80 mg administered by subcutaneous injec-\)Tj
0.0199 Tc 0.4312 Tw T*
(tion\) plus continued methotrexate versus placebo plus continued)Tj
-0.00011 Tc -0.03551 Tw T*
[(methotrexate [referred to as )54.9 (ARMADA, the )54.9 (Anti-TNF Research Program of)]TJ
0.1358 Tw T*
[(the Monoclonal )54.8 (Antibody D2E7 \(adalimumab\) in Rheumatoid )54.8 (Arthritis].)]TJ
0.0237 Tw T*
(This sample was also pooled across treatment conditions and doses for th\e)Tj
0.0629 Tw T*
(purpose of analysis. Demographic and clinical descriptions of this secon\d)Tj
0.0509 Tw T*
[(sample are also presented in )17.7 (T)69.9 (able 1. )17.7 (This )54.8 (ARMADA)-246.1 (sample was compa-)]TJ
0.03281 Tw T*
[(rable to the ST)79.7 (AR sample, with the exception of the baseline median CRP)]TJ
0.1133 Tw T*
[(value, which was higher than that in the ST)79.7 (AR trial \(22 mg/l vs 9 mg/l,)]TJ
0.02499 Tw T*
(respectively; p < 0.0001\).)Tj
/T1_2 1 Tf
0.06889 Tw 0 -1.525 TD
[(Clinical outcome measur)36.8 (es.)]TJ
/T1_0 1 Tf
11.5381 0 Td
(The primary clinical endpoint for this valida-)Tj
-0.03571 Tw -11.5381 -1.225 Td
[(tion study was the definition of improvement developed by the )54.8 (ACR)]TJ
0 Tc 0 Tw 6 0 0 6 534.2078 598.0342 Tm
(24)Tj
-0.00011 Tc -0.0535 Tw 8 0 0 8 540.2078 595.3942 Tm
(. This)Tj
0.13989 Tw -27.776 -1.225 Td
[(criterion is a composite measure used to categorize patients with RA)-335.1 (as)]TJ
0.04311 Tw 0 -1.225 TD
(\322improved\323 or \322not improved,\323 expressed as a percentage. For\ example, a)Tj
0.0602 Tw T*
[(patient is said to achieve )54.8 (ACR20 if he or she demonstrates at least a 20%)]TJ
0.1118 Tw T*
(improvement in both tender and swollen joint counts and at least a 20%)Tj
0.1953 Tw T*
[(improvement in 3 of the 5 remaining )54.9 (ACR core measures: patient and)]TJ
0.0025 Tw T*
[(physician global assessments of disease activity)64.8 (, pain, patient-assessed dis-)]TJ
0.062 Tw T*
[(ability)64.8 (, and an acute phase reactant \(i.e., )17.8 (W)79.9 (ester)17.7 (gren erythrocyte sedimen-)]TJ
0.1104 Tw T*
[(tation rate or CRP)-323.7 (level\). Comparable improvements of at least 50% are)]TJ
0.0267 Tw T*
[(referred to as )54.7 (ACR50, and improvements of at least 70% are referred to as)]TJ
0.0537 Tw T*
[(ACR70. Intended as a single primary endpoint for analysis, the )54.9 (ACR20 is)]TJ
-0.02341 Tw T*
(a standardized definition of improvement to allow comparison across tria\ls.)Tj
-0.0242 Tw T*
(Since its development, this measure has been incorporated into a number \of)Tj
0.0222 Tw T*
(clinical trials for RA)Tj
0 Tw 6 0 0 6 384.5038 470.6344 Tm
(25-27)Tj
0.02229 Tw 8 0 0 8 400.6781 467.9944 Tm
(and has been accepted by the US Food and Drug)Tj
0.0199 Tc 0.4019 Tw -10.3348 -1.225 Td
[(Administration as evidence of clinical ef)17.9 (ficacy of investigational)]TJ
-0.00011 Tc 0.02499 Tw T*
(antirheumatic drugs)Tj
0 Tc 0 Tw 6 0 0 6 381.952 451.0344 Tm
(28)Tj
8 0 0 8 387.952 448.3944 Tm
(. )Tj
/T1_2 1 Tf
-0.00011 Tc 0.0159 Tw -8.744 -1.525 Td
[(Patient-r)36.8 (eported fatigue instruments.)]TJ
/T1_0 1 Tf
15.1007 0 Td
[(The F)73.9 (ACIT)-248.2 (measurement system is a)]TJ
0.064 Tw -15.1007 -1.225 Td
(comprehensive compilation of questions that measure health related QOL)Tj
0.158 Tw T*
[(in patients with chronic illnesses. )17.8 (The F)73.9 (ACIT)91.7 (-F)]TJ
0 Tc 0 Tw 6 0 0 6 477.1827 419.2345 Tm
(22)Tj
-0.00011 Tc 0.158 Tw 8 0 0 8 486.4466 416.5944 Tm
(includes the 27 items)Tj
-0.0322 Tw -21.0558 -1.225 Td
[(from the F)73.9 (ACT)91.7 (-G \(described above\) plus 13 additional fatigue related items)]TJ
-0.022 Tw T*
[(\(F)73.9 (ACIT)-210.2 (Fatigue scale\). High F)73.9 (ACIT)91.7 (-F scores represent better QOL)-191.2 (and less)]TJ
0.0174 Tw T*
[(fatigue \(range 0 to 52\). In patients with cancer)39.7 (, the 13 item F)73.9 (ACIT)-249.7 (Fatigue)]TJ
0.0782 Tw T*
(scale showed excellent internal consistency and stability \(test-retest \relia-)Tj
0.09911 Tw T*
[(bility\) and predicted group dif)17.7 (ferences in hemoglobin level and perform-)]TJ
0.10159 Tw T*
(ance status)Tj
0 Tc 0 Tw 6 0 0 6 353.6843 360.4345 Tm
(22)Tj
-0.00011 Tc 0.1017 Tw 8 0 0 8 359.6843 357.7945 Tm
[(. )17.8 (Thus, the 13 item F)73.9 (ACIT)-333.9 (Fatigue scale has strong psycho-)]TJ
0.11211 Tw -5.2105 -1.225 Td
[(metric properties and utility independent of the core F)73.9 (ACT)91.7 (-G in patients)]TJ
0.02499 Tw T*
[(with cancer)54.8 (.)]TJ
0.24471 Tw 1.5 -1.2625 Td
(The Medical Outcomes Study Short-Form 36 \(SF-36\) is a generic)Tj
0.07919 Tw -1.5 -1.2625 Td
(instrument that assesses well being and has been validated in normal and\)Tj
-0.033 Tw 0 -1.2625 TD
(medical populations)Tj
0 Tc 0 Tw 6 0 0 6 382.3863 310.5346 Tm
(29)Tj
-0.00011 Tc -0.033 Tw 8 0 0 8 388.3863 307.8946 Tm
(. Designed to assess functional status, well being, and)Tj
0.1987 Tw -8.7983 -1.2625 Td
(general perceptions of health, the SF-36 includes 8 subscales: physical)Tj
ET
0 0 0 1 K
53.964 76.5 m
558.972 76.5 l
S
0 0 0 0 k
52.822 69.665 64.178 -15.665 re
f*
BT
0 0 0 1 k
/T1_2 1 Tf
0 Tc 0 Tw 8 0 0 8 53.8216 56.7343 Tm
(812)Tj
ET
0 0 0 0 k
356 69.665 203 -15.665 re
f*
BT
0 0 0 1 k
/T1_2 1 Tf
-0.00011 Tc 0.02499 Tw 8 0 0 8 424.3613 56.7343 Tm
(The Journal of Rheumatology 2005; 32:5)Tj
ET
0 0 0 0 k
/GS0 gs
103.631 82.583 407.5 -10.833 re
f*
0.5 w 
/GS1 gs
103.631 82.583 407.5 -10.833 re
S
BT
0 0 0 1 k
/T1_2 1 Tf
0 Tc 8 0 0 8 125.532 276.2053 Tm
[(T)91.9 (able 1. )]TJ
/T1_0 1 Tf
-0.00011 Tc 3.7608 0 Td
(Demographic and baseline clinical characteristics of study samples.)Tj
0 Tw 22.8901 -2.5 Td
[(ST)79.7 (AR,)-6649.2 (ARMADA,)]TJ
0 Tc 0.02499 Tw -0.1941 -1.25 Td
[(n = 636)-7244.8 (n = 271)]TJ
-0.00011 Tc -26.4568 -2.5 Td
(Sex, n \(%\))Tj
1.2611 -1.25 Td
(Male)Tj
25.03267 0 Td
(130 \(21\))Tj
10.60854 0 Td
(63 \(23\))Tj
-35.64121 -1.25 Td
(Female)Tj
25.03276 0 Td
(501 \(79\))Tj
10.35854 0 Td
(208 \(77\))Tj
-36.6524 -1.25 Td
[(Race/ethnicity)64.8 (, n \(%\))]TJ
1.2611 -1.25 Td
(White, non-Hispanic)Tj
25.03216 0 Td
(553 \(88\))Tj
10.35853 0 Td
(220 \(81\))Tj
-35.3907 -1.25 Td
(Black, non-Hispanic)Tj
25.53196 0 Td
(31 \(5\))Tj
10.35876 0 Td
(23 \(9\))Tj
-35.89072 -1.25 Td
(Other)Tj
25.53267 0 Td
(47 \(7\))Tj
10.10875 0 Td
(28 \(10\))Tj
-36.90251 -1.25 Td
(Age, median \(range\), yrs)Tj
25.79322 0 Td
(56 \(21\32086\))Tj
10.35832 0 Td
(56 \(28\32084\))Tj
-36.15155 -1.25 Td
(C-reactive protein, median \(range\), mg/l)Tj
26.0436 0 Td
(9 \(4\320197\))Tj
9.73344 0 Td
(22 \(0.5\320226\))Tj
-35.77704 -1.25 Td
[(T)69.9 (ender joint count \(of 68 joints\), median \(range\), n)]TJ
26.0424 0 Td
(25 \(7\32068\))Tj
10.35844 0 Td
(26 \(9\32068\))Tj
-36.40083 -1.25 Td
[(Swollen joint count \(of 66 joints\), median \(range\), n)-4961 (19 \(6\32066\))]TJ
36.40072 0 Td
(15 \(2\32043\))Tj
0.03011 Tw -36.40072 -2.5 Td
[(ST)79.7 (AR: Safety )17.7 (T)35 (rial of )54.8 (Adalimumab in Rheumatoid )54.8 (Arthritis; )54.8 (ARMADA: )54.8 (Anti-TNF Research Study Program of)]TJ
0.02499 Tw 0 -1.25 TD
[(the Monoclonal )54.8 (Antibody )54.8 (Adalimumab \(D2E7\) in Rheumatoid )54.8 (Arthritis.)]TJ
ET
125.532 266.676 m
486.5 266.676 l
125.532 240.676 m
485.532 240.676 l
125.532 119.676 m
486.5 119.676 l
S
Q
Q
q
0 0 612 792 re
W n
BT
0 g
/GS2 gs
/T1_4 8 Tf
108.828 74 Td
(Personal non-commercial use only.  The Journal of Rheumatology Copyright\ \251 2005.  All rights reserved.)Tj
ET
Q
BT
0 g
/GS2 gs
/T1_5 1 Tf
10 0 0 10 540 17 Tm
( )Tj
0 0.48627 0.77255 rg
/GS2 gs
-7.22298 0 Td
(www.jrheum.org)Tj
0 g
/GS2 gs
-18.00796 0 Td
(Downloaded on December 3, 2023 from )Tj
ET

endstream
endobj
48 0 obj
<</BitsPerComponent 8/ColorSpace 66 0 R/Filter[/ASCII85Decode/FlateDecode]/Height 99/Length 887/Width 76>>stream
8;Z\6$#Thg%.sQaaEOXrRDU"IBP8kq6#+kd=F4XBfTbr0s(Fi-`BR!XG'n3Xf0=g&
nAR6N/6TMm5@TrEG7>V\<o>Zn'c*GB)o1`uB,k-uV\WcrTN$(Lo*-fMEgd>A+"iaF
0^<R`i+Iu4"$f][,5l"Ra!9<q`hG-1=%#!PjO8d"HRV2LC9)3OA:;c_%$TT7'aEd:
'(j:+1N23g;5Pq8VF94u==\TI%pMa?c@WdYE@br19?-WU9uh6KZqrC68Bl@NUjWGP
4(s@9C)IhY`;dld?h,ZV?R6U;9cIo*-Nmoq*9a4Zd:'VgA!aHI^ZA!k/>GA`9NF,A
_CH224La%"%hEfg;('$<8>T<Seod&4SfECJAaP,Hp(p3HYNWs(f.Tk/D3?J'PPk6(
*/*<fogl+M:Y(rJ8qJSuDIQQ37lQ+\4W7q/mCLtJ4GiJG3nkgehik;)J\bo3X53^]
ckk3ni-q=#g>crof>p=&3rid*3^<h<lUZ'iNC(iHAFqR6TMU8C.[_/Af*CQ+O@[qB
b=62R116XP:uL#)<NW6X5e!;-Ot<&uC,$^5%+YXj.&N/-qBaVBb\"Er'CS6^.)$3Q
)_oChiBeZZK"pAm<jiPV7qElPit%(k2e$XbeZ77Eba4&R*FQlP)cV'#JKYW#H-jF6
j5T5QD*:c'H5OoEgIAMLr7+?%*%7V!%6pG7H:rr-OSqQ.rMpZ;l]j;mn9*+V?dFqN
KB)rG%/OG;=X56"RVmEur33BD@[CCnr5LTWGl&I^@]aEqY)[35[@ttDhsC.HQNg:[
7Y\<o\2CuEdEQf=C_V'Wn_(,glejhX^[f[c]Z6cQS*B[PGSfCEM"+R0I8?r4A8>Ao
e,L2d9j(=/])&`sCV7@c!,@SdaT~>
endstream
endobj
148 0 obj
<</BG2/Default/OP true/OPM 1/SA false/SM 0.0200043/TR2/Default/Type/ExtGState/UCR2/Default/op true>>
endobj
149 0 obj
<</BG2/Default/OP false/OPM 0/SA false/SM 1.0/TR2/Default/UCR2/Default/op false>>
endobj
192 0 obj
<</A 193 0 R/Border[0 0 0]/Rect[466.77 15.0 541.0 27.0]/Subtype/Link/Type/Annot>>
endobj
193 0 obj
<</S/URI/URI(http://www.jrheum.org/)>>
endobj
141 0 obj
[194 0 R]
endobj
142 0 obj
<</Length 11059>>stream
1 g
/GS0 gs
0 792 m
0 792 l
f
q
13.5 787.5 585 -783 re
W n
q
0 792.03 612 -792 re
W n
0 0 0 1 K
/GS1 gs
53.468 76.5 m
558.468 76.5 l
S
0 0 0 0 k
494.29 69.365 64.178 -15.665 re
f*
BT
0 0 0 1 k
/T1_0 1 Tf
8 0 0 8 545.468 56.4344 Tm
(811)Tj
ET
0 0 0 0 k
53.532 70.501 203 -16.591 re
f*
BT
0 0 0 1 k
/T1_0 1 Tf
-0.00011 Tc 0.02499 Tw 8 0 0 8 54.532 56.6447 Tm
[(Cella, et al: F)128.8 (ACIT)-257.3 (scale in RA)]TJ
ET
0 0 0 0 k
/GS0 gs
103.631 82.583 407.5 -10.833 re
f*
0.5 w 
/GS1 gs
103.631 82.583 407.5 -10.833 re
S
BT
0 0 0 1 k
/T1_1 1 Tf
0 Tw 20.37 0 0 21 53.532 727.1089 Tm
[(\002)91.9 (\003\004\005\006\003\007\005\b\t\001)-25 (\b\n\001)-25 (\007\013\f\001)-25 (\r\016\t\017\007\005\b\t\003\004\001)11.8 (\020\021\021\f\021\021\022\f\t\007\001)-25 (\b\n\001)-25 (\023\013\024)17.7 (\b\t\005\017)]TJ
0 -1.1429 TD
[(\025\004\004\t\f\021\021\001)-25 (\026\013\f\024\003\027\030\001)-25 (\r\003\007\005\031\016\f\001)-25 (\032\017\003\004\f\001)-25 (\033\f\004\003\007\005\034\f\001)-25 (\007\b\001)-25 (\035\007\013\f\024)]TJ
T*
[(\025\t\021\007\024)7.7 (\016\022\f\t\007\003\007\005\b\t\001)-25 (\005\t\001)-25 (\036\003\007\005\f\t\007\021\001)-25 (\037\005\007\013\001)-25 (\033\013\f\016\022\003\007\b\005\006\001)11.8 (\020\024\007\013\024\005\007\005\021)]TJ
/T1_2 1 Tf
0.02499 Tw 10 0 0 10 53.532 656.0618 Tm
[(DA)128.8 (VID CELLA, SUSAN )36.8 (YOUNT)73.8 (, MARK SORENSEN, ELLIOT)-257.3 (CHAR)59.7 (T)79.9 (ASH, NISHAN SENGUPT)79.7 (A, )]TJ
0 -1.2 TD
(and JAMES GROBER)Tj
/T1_3 1 Tf
0 Tw 9 0 0 9 71.532 623.4618 Tm
[(ABSTRACT)91.7 (.)-729.3 (Objective.)]TJ
/T1_2 1 Tf
0.2953 Tw 10.6083 0 Td
(This study validated a brief measure of fatigue in rheumatoid arthritis \\(RA\), the)Tj
0.02499 Tw -4.6083 -1.2222 Td
[(Functional )54.8 (Assessment of Chronic Illness )17.7 (Therapy \(F)73.9 (ACIT\) Fatigue Scale.)]TJ
/T1_3 1 Tf
0 Tw 0 -1.2222 TD
(Methods.)Tj
/T1_2 1 Tf
0.18871 Tw 4.2263 0 Td
[(The F)73.9 (ACIT)-421 (Fatigue was tested along with measures previously validated in RA: the)]TJ
0.0235 Tw -4.2263 -1.2222 Td
[(Multidimensional )54.9 (Assessment of Fatigue \(MAF\) and Medical Outcomes Study Short-Form 36 \(\SF-)]TJ
0.10789 Tw T*
[(36\) )17.7 (V)59.8 (itality)64.9 (. )17.7 (The sample included 636 patients with RA)-303 (enrolled in a 24 week double blind, ran-)]TJ
0.02499 Tw T*
(domized clinical trial \(RCT\) of adalimumab versus placebo. )Tj
/T1_3 1 Tf
0 Tw T*
(Results.)Tj
/T1_2 1 Tf
0.04761 Tw 3.53 0 Td
[(The F)73.9 (ACIT)-279.9 (Fatigue showed good internal consistency \(alpha = 0.86 to 0.87\), stron\g asso-)]TJ
0.05479 Tw -3.53 -1.2222 Td
[(ciation with SF-36 )17.7 (V)59.8 (itality \(r = 0.73 to 0.84\) and MAF \(r = \3200.84 to \3200.88\), and t\he ability to dif-)]TJ
-0.0172 Tw T*
[(ferentiate patients according to clinical change using the )54.9 (American College of Rheumatology \(ACR\))]TJ
0.01601 Tw T*
[(response criteria \(ACR 20/50/70\). Psychometric performance of the F)73.9 (ACIT)-248.3 (Fatigue scale was com-)]TJ
0.0305 Tw T*
[(parable to that of the other 2 fatigue measures. )54.9 (A)-225.6 (minimally important dif)17.7 (ference in F)73.9 (ACIT)-262.7 (Fatigue)]TJ
0.0253 Tw T*
[(change score of 3\3204 points was confirmed in a separate sample of 271 \patients with RA)-220.5 (enrolled in)]TJ
0.02499 Tw T*
[(a second double blind RCT)-257.3 (of adalimumab versus placebo.)]TJ
/T1_3 1 Tf
0 Tw T*
(Conclusion.)Tj
/T1_2 1 Tf
-0.0352 Tw 5.1701 0 Td
[(The F)73.9 (ACIT)-197.1 (Fatigue is a brief, valid measure for monitoring this important symptom \and)]TJ
0.0249 Tw -5.1701 -1.2222 Td
[(its ef)17.7 (fects on patients with RA. \(J Rheumatol 2005;32:81)36.8 (1\3209\))]TJ
/T1_0 1 Tf
0 -2.4444 TD
[(Key Indexing T)91.7 (erms:)]TJ
/T1_2 1 Tf
0.0191 Tw 0 -1.2222 TD
[(RHEUMA)110.8 (T)17.9 (OID )54.9 (AR)59.7 (THRITIS                            F)73.9 (A)110.8 (TIGUE                             QUESTIONNAIRES)]TJ
/T1_0 1 Tf
0.02499 Tw 8 0 0 8 53.532 239.0331 Tm
[(Fr)36.8 (om the Center on Outcomes, Resear)36.8 (ch and Education, and Division of)]TJ
0 -1.125 TD
[(Rheumatology)54.8 (, Evanston Northwestern Healthcar)36.8 (e and Northwestern)]TJ
T*
[(University)54.8 (, Evanston, Illinois; University of North Car)36.8 (olina, Chapel Hill,)]TJ
T*
[(North Car)36.8 (olina; and )17.7 (Abbott Laboratories, Parsippany)54.8 (, New Jersey)54.8 (, USA.)]TJ
0 -1.425 TD
[(Supported by a grant fr)36.8 (om )17.7 (Abbott Laboratories.)]TJ
T*
[(D. Cella, PhD; S. Y)91.7 (ount, PhD, Center on Outcomes, Resear)36.8 (ch and)]TJ
0 -1.125 TD
[(Education, Evanston Northwestern Healthcar)36.8 (e and Northwestern)]TJ
T*
[(University; M. Sor)36.8 (ensen, PhD, University of North Car)36.8 (olina; E. Chartash,)]TJ
T*
[(MD, )17.7 (Abbott Laboratories; N. Sengupta, PhD, formerly of )17.7 (Abbott)]TJ
T*
[(Laboratories, )17.7 (Abbott Park, IL; J. Gr)36.8 (ober)110.7 (, MD, Division of Rheumatology)54.8 (,)]TJ
T*
[(Evanston Northwestern Healthcar)36.8 (e and Northwestern University)54.8 (.)]TJ
0 -1.425 TD
[(Addr)36.8 (ess r)36.8 (eprint r)36.8 (equests to D. Cella, The Center on Outcomes, Resear)36.8 (ch)]TJ
0 -1.125 TD
[(and Education \(CORE\), Evanston Northwestern Healthcar)36.8 (e, 1001)]TJ
T*
[(University Place, Suite 100, Evanston, IL)-257.3 (60201. )]TJ
T*
(E-mail: d-cella@northwestern.edu)Tj
0 -1.425 TD
(Accepted for publication December 17, 2004.)Tj
ET
0.75 w 
53.532 250.5 m
295.5 250.5 l
S
BT
/T1_2 1 Tf
0.02859 Tw 10 0 0 10 53.532 408.6616 Tm
[(Fatigue, a subjective sensation of weakness, lack of ener)17.7 (gy)64.8 (,)]TJ
0.0755 Tw 0 -1.2 TD
(or tiredness)Tj
0 Tc 0 Tw 7.5 0 0 7.5 100.6542 399.9616 Tm
(1)Tj
-0.00011 Tc 0.0755 Tw 10 0 0 10 104.4042 396.6616 Tm
(, is experienced by virtually everyone at some)Tj
-0.0273 Tw -5.0872 -1.2 Td
[(time. )54.8 (Acute fatigue is usually self-limiting, occurs in healthy)]TJ
0.0724 Tw T*
(individuals, frequently results from overexertion or lack of)Tj
0.04649 Tw T*
(sleep, and is typically relieved by rest)Tj
0 Tc 0 Tw 7.5 0 0 7.5 207.0963 363.9616 Tm
(2)Tj
-0.00011 Tc 0.04649 Tw 10 0 0 10 210.8463 360.6616 Tm
(. In the general pop-)Tj
0.1033 Tw -15.7314 -1.2 Td
(ulation, 20% of men and 30% of women complain of fre-)Tj
0.211 Tw T*
(quent tiredness)Tj
0 Tc 0 Tw 7.5 0 0 7.5 115.898 339.9616 Tm
(3)Tj
-0.00011 Tc 0.211 Tw 10 0 0 10 119.648 336.6616 Tm
(. On the other hand, chronic fatigue fre-)Tj
0.22279 Tw -6.6116 -1.2 Td
(quently accompanies medical illness, lasts longer than 6)Tj
0.0529 Tw T*
(months, is typically not related to overexertion, and is usu-)Tj
-0.0368 Tw T*
(ally poorly relieved by rest)Tj
0 Tc 0 Tw 7.5 0 0 7.5 159.7955 303.9616 Tm
(2)Tj
-0.00011 Tc -0.0368 Tw 10 0 0 10 163.5455 300.6616 Tm
(. Indeed, fatigue is often rated by)Tj
0.02299 Tw -11.0013 -1.2 Td
(patients with chronic disease as one of the key factors lead-)Tj
0.03799 Tw T*
(ing to decreased quality of life \(QOL\))Tj
0 Tc 0 Tw 7.5 0 0 7.5 207.406 279.9616 Tm
(4)Tj
-0.00011 Tc 0.03799 Tw 10 0 0 10 211.156 276.6616 Tm
(. Fatigue is the most)Tj
0.1134 Tw -15.7624 -1.2 Td
(common symptom reported by people with cancer)Tj
0 Tc 0 Tw 7.5 0 0 7.5 261.3767 267.9616 Tm
(5)Tj
-0.00011 Tc 0.1134 Tw 10 0 0 10 268.7604 264.6616 Tm
(and is)Tj
0.0919 Tw 5.024 14.4002 Td
(nearly ubiquitous among patients with many other chronic)Tj
0 Tw T*
(diseases.)Tj
-0.0282 Tw 1.2 -1.2 Td
(Fatigue is multidimensional in expression, with influence)Tj
-0.02361 Tw -1.2 -1.2 Td
(on physical, emotional, cognitive, and even social aspects of)Tj
0.1629 Tw T*
[(life. )17.7 (This creates a challenge in its measurement. Fatigue)]TJ
0.0647 Tw T*
(frequently coexists and interacts with other factors, includ-)Tj
0.13741 Tw T*
[(ing mood disturbance, anemia, infection/fever)39.7 (, pain, sleep)]TJ
0.27879 Tw T*
(disturbance, and stress)Tj
0 Tw 7.5 0 0 7.5 414.8154 327.9638 Tm
(6-8)Tj
0.27879 Tw 10 0 0 10 424.8111 324.6637 Tm
(, making assessment of fatigue)Tj
0.29131 Tw -10.5811 -1.2 Td
[(even more complex. )17.7 (The importance of fatigue and its)]TJ
0.2094 Tw T*
[(impact on patients\325)-385.5 (QOL)-422.6 (has been researched and docu-)]TJ
-0.00771 Tw T*
(mented for a number of diseases including cancer)Tj
0 Tc 0 Tw 7.5 0 0 7.5 516.9732 291.9638 Tm
(9)Tj
-0.00011 Tc -0.0078 Tw 10 0 0 10 520.7232 288.6637 Tm
(, multiple)Tj
0 Tw -20.1723 -1.2 Td
(sclerosis)Tj
0 Tc 7.5 0 0 7.5 353.4287 279.9638 Tm
(10)Tj
-0.00011 Tc 0.2816 Tw 10 0 0 10 360.9287 276.6637 Tm
(, systemic lupus erythematosus)Tj
0 Tc 0 Tw 7.5 0 0 7.5 493.7893 279.9638 Tm
(7)Tj
-0.00011 Tc 0.28149 Tw 10 0 0 10 497.5393 276.6637 Tm
(, chronic viral)Tj
0.0354 Tw -17.8539 -1.2 Td
(and cholestatic liver disease)Tj
-0.0491 Tc 0 Tw 7.5 0 0 7.5 431.9506 267.9638 Tm
(11)Tj
-0.00011 Tc 0.0354 Tw 10 0 0 10 439.082 264.6636 Tm
(, acquired immune deficiency)Tj
0.0199 Tc 0 Tw -12.0082 -1.2 Td
(syndrome)Tj
7.5 0 0 7.5 360.0333 255.9638 Tm
(12)Tj
0.35831 Tw 10 0 0 10 367.8333 252.6637 Tm
(, renal disease)Tj
0 Tw 7.5 0 0 7.5 434.3537 255.9638 Tm
(13)Tj
0.35831 Tw 10 0 0 10 442.1537 252.6637 Tm
(, and rheumatoid arthritis)Tj
-0.0002 Tc 0 Tw -12.3154 -1.2 Td
(\(RA\))Tj
0 Tc 7.5 0 0 7.5 339.5444 243.9638 Tm
(8,14)Tj
10 0 0 10 352.6694 240.6637 Tm
(.)Tj
-0.00011 Tc 0.1904 Tw -2.1669 -1.2 Td
[(RA)-385.6 (is a chronic inflammatory joint disease associated)]TJ
-0.01489 Tw -1.2 -1.2 Td
(with deformities and joint destruction. Because the manifes-)Tj
T*
[(tations of RA)-180.4 (include fatigue, chronic pain, and marked lim-)]TJ
0.18291 Tw T*
(itations in physical functioning and work disabilities, the)Tj
0.0779 Tw T*
[(disease has a profound ef)17.7 (fect on patients\325)-254 (QOL)]TJ
0 Tc 0 Tw 7.5 0 0 7.5 512.0539 183.9638 Tm
(15)Tj
-0.00011 Tc 0.0602 Tw 10 0 0 10 519.5539 180.6637 Tm
[(. The )-17.7 (dis-)]TJ
0.2094 Tw -20.0554 -1.2 Td
[(ease af)17.7 (fects roughly 1% of the population in the United)]TJ
-0.0002 Tc 0 Tw T*
(States)Tj
0 Tc 7.5 0 0 7.5 342.8818 159.9638 Tm
(16)Tj
-0.00011 Tc 0.134 Tw 10 0 0 10 350.3818 156.6637 Tm
(, is 2 to 3 times more common in women than in)Tj
0.1423 Tw -3.1382 -1.2 Td
(men, and has onset typically between 25 and 50 years of)Tj
-0.0002 Tc 0 Tw T*
(age)Tj
0 Tc 7.5 0 0 7.5 332.8769 135.9638 Tm
(17)Tj
-0.00011 Tc 0.1638 Tw 10 0 0 10 340.3769 132.6637 Tm
[(. )54.8 (An estimated 80% to 93% of individuals with RA)]TJ
0.0912 Tw -2.1377 -1.2 Td
(experience fatigue)Tj
0 Tc 0 Tw 7.5 0 0 7.5 393.4718 123.9638 Tm
(18)Tj
-0.00011 Tc 0.0912 Tw 10 0 0 10 400.9718 120.6637 Tm
(, and 57% identify fatigue as the most)Tj
0.02859 Tw -8.1972 -1.2 Td
(problematic aspect of the disease)Tj
0 Tc 0 Tw 7.5 0 0 7.5 452.2985 111.9638 Tm
(19)Tj
-0.00011 Tc 0.02859 Tw 10 0 0 10 459.7985 108.6637 Tm
(. Fatigue is such an inte-)Tj
0.05389 Tw -14.0798 -1.2 Td
(gral feature of the disease that its absence is identified as a)Tj
ET
Q
Q
q
0 0 612 792 re
W n
BT
0 g
/GS2 gs
/T1_4 8 Tf
108.828 74 Td
(Personal non-commercial use only.  The Journal of Rheumatology Copyright\ \251 2005.  All rights reserved.)Tj
ET
Q
BT
0 g
/GS2 gs
/T1_5 1 Tf
10 0 0 10 540 17 Tm
( )Tj
0 0.48627 0.77255 rg
/GS2 gs
-7.22298 0 Td
(www.jrheum.org)Tj
0 g
/GS2 gs
-18.00796 0 Td
(Downloaded on December 3, 2023 from )Tj
ET

endstream
endobj
46 0 obj
<</BitsPerComponent 8/ColorSpace 66 0 R/Filter[/ASCII85Decode/FlateDecode]/Height 99/Length 589/Width 76>>stream
8;Z\7JTepR#iu#8OPe_q'L>/U@[8i$HgM_]O1PLW'_*+q$33bLa2.6'nNtH<+SV`R
d%`91a0ARG?unpm>T/:AGsEt_R=Il'a[amUl4k[o/?&mu2ZQJhq,,^@edc^E&=Zm`
8HHM5Vb:n=CS)2r)E"Pd'<KMW*soXW'DFVN-NGb+7k8E*G`Q*&dRK3N?5DIiIQ8gI
oP<-rNDNj>/r`ZkM%J82oD"b9'^3jq0eCkKrnpc\Y/dms(Rip/ogFf5NY.TJ/Q]6)
1bS94jRo9iZUXn='ck7Jr=V>NH5$9]j"RT\3\ZVr\T6]7)C*k(<gbqW;Bp?&`u53W
.t=iU7mZNd>(3TLV&OTlBr?pS(qIDO=NC2F<fp"<=,=H(?GT6@:&bN@^#DIY&P(!k
EU*n\Z%Z#JMTmuZ-T\dp$MhW[$"!I.\+^qS/ZB2HhUniN^K*1':7,79lNst]N]Irm
\^(8SbJXU+pa$\*k/X'GbObf+igsH+=BkqH*b(u?4V"a*7PTiK\f#=B<C72)om+LA
>ZT?YZg3n6;2I]!rGOi<o@b7/DD.b=eJ[@<?LiERcL)eSNr6mBIKfe;%CL$~>
endstream
endobj
93 0 obj
<</BaseFont/PMJHAP+Palatino-Roman/Encoding 91 0 R/FirstChar 1/FontDescriptor 90 0 R/LastChar 31/Subtype/Type1/ToUnicode 89 0 R/Type/Font/Widths[250 722 500 291 291 611 326 546 582 333 582 479 556 603 444 778 424 883 709 395 337 613 601 556 556 525 668 565 786 604 834]>>
endobj
100 0 obj
<</BaseFont/PMJNHC+Times-BoldItalic/Encoding/WinAnsiEncoding/FirstChar 32/FontDescriptor 101 0 R/LastChar 181/Subtype/Type1/Type/Font/Widths[250 389 555 500 500 833 778 278 333 333 500 570 250 333 250 278 500 500 500 500 500 500 500 500 500 500 333 333 570 570 570 500 832 667 667 667 722 667 667 722 778 389 500 667 611 889 722 722 611 722 667 556 611 722 667 889 667 611 611 333 278 333 570 500 333 500 500 444 500 444 333 500 556 278 278 500 278 778 556 500 500 500 389 389 278 556 444 667 500 444 389 348 220 348 570 250 250 250 250 250 250 250 250 250 250 250 250 250 250 250 250 250 250 250 250 250 250 250 250 250 250 250 250 250 250 250 250 250 250 250 500 500 250 250 250 250 250 747 250 250 250 250 250 250 250 570 250 250 250 576]>>
endobj
101 0 obj
<</Ascent 699/CapHeight 669/CharSet(/s/A/i/t/j/M/n/u/O/B/v/b/l/C/o/R/c/T/S/e/d/period/h)/Descent -205/Flags 262242/FontBBox[-200 -218 996 921]/FontFile3 115 0 R/FontName/PMJNHC+Times-BoldItalic/ItalicAngle -15/StemV 121/Type/FontDescriptor/XHeight 462>>
endobj
115 0 obj
<</Filter/FlateDecode/Length 2626/Subtype/Type1C>>stream
H‰lUyTSWIxIt ¶<ƒøâ¼Dk-TY<
u+n¸±(bqa—YBˆ!XÜEsa+"[)ƒ×A«È´é‹ÓêiÏ´ãé8ß‹7=393çÌüóıqïù¾ßvæÃÅ8N`|Ì¦ØkæoWæ)´!«ÕªÌºt•R>¹ÉH0f‡ù-—¡xÌtŸb_.#õ@{PşË}/Cpê,çVëëê+€+ÓàÑ›7fM½àáğd[×@xøÂĞğğÈ5ê#­ÌÊÖÉ‚äÁ²…‘‹LÖ¥¯jäd—Eeª3²£V§ÈÓÊ6æËÕtšN×)2Ce²(•J¶mr‚V¶M¡UĞzvõe™R+K—éèôLE^:+Sï•mQæ«uÆ…,*Z–Ÿ¦¦eJ¶O[˜¡Uf*Ói¥Bû¯ŞI¹²×z_-ü	›†as¸X(†…cØ".¶†‡mäb1ÇÁ¶ó°@ÖDÌ›‡™8$ÇÀår·rGx±¼¼_}6ûŒâ‹ğÏø³ù§ùO·ĞO˜$²yDÈS
Añî‚Dì‹¥±`îœŞö¶K=9íRÑ-«6_d¢œ óSã0YKÇæ3i¾Wè}¼w«±J}p&INÁ¾dkgC}ƒãˆôæsrù'eV«Ü¥¬N1S4\x×B‚ÀÜ…Ìøälºnº¡©vú3K!d¼Cä€Ğ(¾di­–“••yUû)¢‰¼‰ûcÔUÙU3	Wğ‚ú`!ù<¢9ée9÷Noø‘ Eëìñrò!‹	İ°eÔ‚8d*‚‘DSçª·¯­§@Â˜Å}Æî8A2t&5E _ó²jV³q€yÏ ÊNN„2a-<O¤'JœÇ/:PQZ¨MhY,AfôÒ"m„9+! ¾é—æ5áa«7k–KJP€¢aLc°xâ“˜wË•YÊ¥m•¸:­Î"½g®Ó?ÿåz¢Ë3Â<Ÿ¾s¾î¢CèDÙtÛ«Á-üDFƒ#Í°4ZT¤Ùj,Ï¢Ç;E¨²ê]e¬Ûr§`·#·n€l:ñ™½ú™ÁpŸ(¸çíÇ›ùŒ€ùƒÍ‚]hšwwQ¼Ú”`f[î:I6ıá²Áq¦î4%±Ã3­ƒã‚¹Œ/Ìå1±©ø—š·ôHâ¥Ğúø”ŸŸN0!°Eê]ä¿ûM‡e`c……°Íüq¥¢d¡^•›màz¦
æÏà[æ;q“ıpS»dĞ§‰ˆÒJÍ%Y»$ÄZâASı¡\²ô@š•b©&mÓ›Ò*Yª}NÁÚ},Õc–›©kˆ·ğÿÆqHqòwÛ¶Â»p(fœ½=şÉ"½ÖZã(ÔÂ%±¢Dfƒÿ…–Nğƒ7ÀøÚf»ùçØ9›od)°±1J½Ò+{²ùøy´æÇçÀ?¸	ÊeÆ‰¾‹Œçñ‰¯5ej«9o«{›‘kçÏ“¢Å`ÙHCélä“.;ïWRù6\Tgu2/:9Ì¸‹ç¡<ÅŞ+|Zå<ˆ?ïØóƒy;ö­Ï¨J±±âÆ‚m6MÍEò¤£Ù~šS;`3ÛQğL—ÉJÛ™©÷aƒËmğ‡ax“xö•'@ÜQÓbU*Pˆ·"Ÿ4\•?fƒX `Åèî+1[2åÉJÊbÃ	æ	|ÏV—ÄVDUÁŒ~/Ù„4¯*°¶ÖÜ‚~ùÄš´Ÿ¡¥¥ƒŒ¨SÓ!|yğf‹·Ê÷æ¦HòSO=¼{'êO˜K¥%ú"5©t]œ®Ë½Y½Ë…æ¢å(ñ¾I»÷¢xğ2Å2^7¿^‚®ƒ¿Ş z˜U0Clª’oÑKXêí'?…•G>’}Àc‚q¢'»"¹M? ,8+hj¬ÔÓ‹#¤'JŒi$d‡'¢°Ôsß|{e´¯Ej«Á	İAUµ±ˆŒ°º6Ñ}"zĞOµâ¡1(èªI®ÌFíä–«öÿh³³sÕSÁñ^:+1QbØSû¨Ñv¬®A
‰îÁ¿]#‡£²ÑRD 4ùŒ§ßì÷ı­Ôz¸.n±Ò¦
BĞŒléOõÃœ;Q’é¾BÏÃ¯³)e>D%ğˆÑÍ°0º"yÜ>IU™ã¨”0ùê»ÉG	¶Âñj4/˜²Ô¼`BqBó~qBÅÊƒÂA»ÍmÍ&ËÌEæ
…zqğã;ŸtÂÔ;Â›û]’4ÖWH‰nÍ"”µ‚ÌiRü§ËÃƒ=”È4?¹š€éÏF(!.ƒŠM0Ï Ü©•TšìGÚnCV7¼%%˜è¢“¼šEk©qÊÕ­@µ©¤öhÚ/.İí§ˆ@ÄeÊØ§_Ó˜şi·ÛıQ—ªU‘¢O×²>Ê[™±ƒ ­2§ğ¶2óÅWjO˜hrÿÁü*† _RXœœ%9PvØ.­?é8G^TÔ—ki}®úì®Çşò¬è¥ØìùÌ&œğ®+.² Q¹˜8lù¿Ğ¦!ftÒb{yü—²C%¶ãgNİp4I‰¿ÂÛÌœx°¼xgÅ²I3İ¶v«jšãİG–XwÜë}ğy/õ:3èÓƒ`x»ËÁ/|	š=¡¹ì—'×è²’rs}½” [& û.9òMû»ÄˆÙk¨jÛ-ˆÅ‰ãò S¡¤@àrY5tŠLB	R6)‚†gÿ,Óıãğ½¤˜—´u3ûoDJÁ‹›ÙºØÁ« ~¨ø5¨ˆ÷÷b÷÷¦øE¥¡}Y@Qûª+W‹½ŸË½÷¯÷ •¨û2ûû@û.+ÙVİ÷4÷÷@÷)÷ûŸeûn~©ø0¬ºê´ë÷áøanzˆ‡|j¡YJFg2N§b¿O«f£cqrxme‚C‹÷|puû:¦œŸ¢¤w·Ëá°ìòûãÊ‹¼ÀÆ FY“¦‰‚Ñ÷îµ€÷÷­øUC²÷%hG!?ld|h¾_û2[û*b„‹OÓÙ¼ÙÅ°u™v~dPrŠ}—­Á÷C¬÷ŞX‚ÏGÓ÷ì¦šw¬wš÷÷÷N–øk÷}‚eOs†œ«Ş÷¡ŸÑû
l t<^:Ns~N,c~–—±é÷È}Š!t2‡np­‰¡ŠqQ@ûJFt‹TØ×µÅõ×Šmi`S¿‹šßÃê­û7“vø8¦§wä÷İ÷	¸ø›ø+¯—‹T–›:Š%Š]‡û¥¸÷>÷2÷÷)ï¶h¤osŠmtj]·iou`#û‡÷N†ÏuÛøO|c†Tƒyù1›û€˜÷‘÷”üu}™øV•÷^™ûnŒøs“÷‹	 Cyÿ	÷Œ÷ªøó ('(â
endstream
endobj
91 0 obj
<</Differences[1/space/V/a/l/i/d/t/o/n/f/h/e/F/u/c/A/s/m/C/r/I/T/p/y/g/S/R/v/O/P/w]/Type/Encoding>>
endobj
90 0 obj
<</Ascent 733/CapHeight 692/CharSet(/s/i/A/t/n/u/O/v/m/l/C/P/w/o/c/R/T/y/p/e/S/d/F/f/I/a/r/space/V/h/g)/Descent -281/Flags 6/FontBBox[-166 -283 1021 927]/FontFile3 92 0 R/FontName/PMJHAP+Palatino-Roman/ItalicAngle 0/StemV 84/Type/FontDescriptor/XHeight 469>>
endobj
89 0 obj
<</Filter/FlateDecode/Length 418>>stream
H‰\“ËnÂ0E÷|…—­ª*È$”´‹¶ÚîM2A‘ˆ™°àïë;C‘Ú£›OlÉj³Şøv4É6ôÕGÓ´¾|î/¡bsàcëMMİVãíIjÕ¹Á$±y=Üm|Ó›år’ìâËó®æaëNnl}ÿ¼ë;çŸì£I>BÍ¡õGóğI_ßì/Ãpâıh¬)KSs3IVonxwÇ#ıû„¼§ÛúšÏƒ«88d³´Tš%5¥a_ÿ}7™Ym94ú¬kµØ©-#˜"K±Y0C–bsH‘S+€9S° È‘s)@,ÅæÈs]ñ
°@^(xpÈNœã€|P0¨+@,Å¦ÒÂÈ¬ÛÊŠ¹Ñ–Yd¡Êj.GâN}²*H}äk ¨ õ‘Ê
¨ õQL ‚ÔG
¤>2\Ÿ ‚n>` ‚ÔG!-PA7 TúÈd[¨ õ‘É¶PAê£Àõ	*H¯ŸB2fBK\?çãw0*˜ãûÄU—â0Ê°ËbâZÏ÷ÿÃĞ0ü&? õÑÓ
endstream
endobj
92 0 obj
<</Filter/FlateDecode/Length 6499/Subtype/Type1C>>stream
H‰œU	PTG~ 3Óˆjxo2ïAMĞ ¥ DäÁ‘;¨*
È8oœ73o†sQÀ€Ácƒ¢ˆx!$¬åmiŒSî¦ÑFwÇ¤ÊİÚÚJÕ¦ÿêª®êîÿøúûú·Âl¬1+++§ğĞ @ßp·ğ¤mI;D™YîYI™ïv<&['ôdrŒÜxœ4ÿ ¸_òÏŞ/l9/ ×®úPÇû¸iú»Köÿå³šæ‚ùb«±/±µX˜U„õ,	Kfo³ÉaíÁ¬,†ÍÂ°96Ã\1l±¶ÄóÂ0?ógc¡6Øzƒa.–T-§æcw­*­k§|nãÀšÂÇ™ËyZÿÔòAÜT‘íòiSíLö÷*>\9cêG3?êpúØéw:w Ÿ_'zxgà/<æd™o<„½6pŞîàÙÜu|ÉC«ŞFòl¾eÛ½ñ´›X{î((È"‡9¡‰j&—,PïcŠ€b”:#~Ğp¬¦ƒ­ ‘51Ê†ö¨ŸeÈÕîŞ‹KRŠâS”DV (Ç+}KÀ¼ed¸)§^Zœmiô…d¡no…¸~Ç‰øŸ¿„^“+_‹¹Al”&@üí¡H=9À]…¼¾rçîJ,Ø¾O²O"..’yQšRH¬á0£×Õ—‰	-ÏFêÕ“?±&i6ÔOüÄ²ƒu<Ö&ã¸!uÃöù Ûçsñb%"¯KŠö$r€öë LÀ!§êYó(¿yôÄ¥.Ëèoªª7ı@8ıYAú9”Ş£R¡¸—ØšİPi¯îëÒÖŠ¶|u|©ooMH™PtÂõš0Qb rAŸèäâ‹üÑVÜ«Ô§6€_Ğt2ìdXwäPìPìw›fƒìÏŠ^şj¨ºET5~×şÍnşA–İW0œÇòs¬¢LR½X/Ön¦C ½TåéO&s”È_é¾W
eéÒ¢b‰XšOí¡b>% ˜£…s µz”¸sG!»KrV¨bÕùÌFlš¤&y[É PÜ+yğ‡	º«“î$ ~O&=NÖÈLÅÌ~5¥MÑ¯Ö[ê,†JÜÍ
aKC‹c¨,JêLIÅ²İ
°ã¹!X«¢}I˜Ã¡!N©ªUMêcšV ¿qU3L\éWPfÒL’~-6&Bo`Î-}QÕ›Fo¦“U@•œ Š%â—*•È‘T 'Ï’hÂÿ3Z3æ|¯ìTTQÀnrß„xÄ1ÿ}òÊA ü5ù‰dKXÕSU9mÖ6ëË£IWÅT1êqrdÈir-°€Ö¢ïııÿ`Â‹zÖé§
œeAÒûW$İÄªçŸ96»u~q)ğbàXôc=zÿwæÃˆè
İHèŒÂ0¸¿&½\x‘_8÷mN‡èBBÀ,0ûğhMó+‘5lgîŞ²ˆ\¸eY”Ÿ¿ïj¡wº'H÷(t…»Wº·¸ñaÖ«%í†Ç;Á™ñ'õÿ n‹w’—v˜³ÚÓÚÓ¥IlL¬‹®å®3qä‡¬S>å§|î»B„Ş³]Ÿ SC0ÜÑ.ìvoNÏ;SĞ#E—©ÁA²j^´?âÛ‡1”të^ªëˆ¾G¨ŞCõ¿ŞMÅ®j8…¹Î¯½1l$®]çv‘]¹m[êãA}|™0+ŠÊ‰áçÄlİœrâÄÑ„()'ú²$g;ä§ˆ®ÆÔNöUõénïn?ÑÕØû*úúñËù}"3_dm«uë–™f”äÈCÆR†G>3iÂÿƒapüÑšİ ¦$¾¿¯ığ{B›çh`ı£Ê¨j¢©[AÍĞ•Ò«´ºÛMvÇZ»§¯àBe¡iÄí*ZDJ2.ù]ùâš§ó©¨®5½Ş?£y7\OGMo'İN?­”›-AE;U	IÑ”E·bcÒ¹ÕOŞå†'Ÿ+¨\3ÒØÛÖÛzºãh8z¾¢§¿Pp>İÌO7Ç·	ê@­`¡	Í òÃ”òÙ¤Â;¼$•@‘Ú(UŠ*[åüoˆ\&Vd:B?8ûìß 5	­ŸŸ‡ :ã=’Îİ'ùy's[22âjCÿhZeZVêUfÚRU½ùP^ØÕ$9İ‹?míëç÷÷ı‘¹‘—z•lÌ«ÛU•«‘¨×ÓsÁ0›¾¦îÖ´jZ™vãIAcHm`¨Õ¯'Ü—ä¥z“Ş)ë¢6€My¾>x”qcM<¿&îpjKVs¦9çÚ®sâK’‘ı#’³Ô!ù7Ò–½‡óòjrÊÒAYº.5EeGó³£“6­ß¶E„ñ±ºÊ2º2¥:³&£fOµÔb²^Ås°†­DsŠçH‚ğh›¹„İM8gÓèÈ0­z“†)ÕVÒ€éºª¹GÀlù°T"UF>9ÎQ ÿ’_ÙBYØB½gËŠßØôRİ@\xhQˆíï*ä6ÇB«ûºA>´c·üE©è#{å-J£R§Ô*4
\-£¥´TÆônÜA6ç1ĞZ+R±T¦*-Ÿ¥L ’¼Tj4D‹5ˆ­^­fBÕÈZ…–€‹ìÒ–ÆØõê¨ÄÑt¼´ÅxÄØXv¬²}FsáåW†SÏu3Fg}¹Ñ`Ô5G5æwÿ©|‘¿¥Õn\Ikæ[´ó°ØL•ËAeàbiæŞ8şV4eËÜTwTşf6½jÚÙs=ë¡³ä°¼JëhFËğµŒASF—ÑgT·ipC!§ÅÊ(Bàù/Ö«5¦­ó«[¿©Ò&Y‚s¢sÚüJ—U­’°(©r-,K!ˆ„ØØ1Ø`ŒÁÆ—ãcÙ>Ûs±¶Çb.6®iîIYš-MÚ¥ÙÒNÑ¶.ÒtBM¤$š–m•úgß÷÷Óû>zŞ÷ù÷µP‰·™ Ëø¨¾KïÀ;t”Ö®òsG¶Ğß<r%±s"ñf_ø6)9±…v¬õqzF([OÇ3Õ1¡¢ğüt+6†Õ«=eÀ#¶†Ò4iÊmÛê7Šuj¬	cNc•R”"]I1ô±/7ÆGø±+õ÷á±°Í@:ï/Óé)äõykŸ1âèû…™UV=™ÚFêí¸èİ„?ÑsŒ¢3YWÛæšÆùEÑ8w„¸™]{`n±N%@ó2J·ç&3&•™ê›¡‹*»Ïî‰¦>Û¾ŞÃáqù"cı<^+.u†d¨4Ô26Eí£=Äéëìö¸z'{/÷|ÒsÇóUHøÙÉ‰ÀÚ#ú]NAm‰R¢ZI^ÈòDòĞ¼ÿ¢äüVùà1tÇyÙ?‹øfÃ#ã~à?ïZ„§Æu*† Õ°²_Ñ¡e,^C*I™	–’Úo‘3dÀ ÎÙ/TöTº«ìÀu"ß–gækO¡5~]VYV™@Ša)ËXú7» Ä¦ñøb;²ıúÍúxqrÆĞ˜3ŞˆŞH©°’o­-o`¥slx»Áªö2÷(áa‹¼BĞBUŸä·5	QaS,S”)T+’
Yq}6¨ÏÖ>méş(’DÒÏç_-¢+·wáè´­sè?‹ûˆ]¦,¢V¬ƒğ™%#ş ggPJÅ\MïĞ;ƒÄ, fM+7¡µ$¦rÛ¬ô¯¬ôÖ¥Ô–"e¡ª@Z ÎjÛ§¹ìß›âF·ŸsÀø±¡Ñòš„r±L\)-S€F±°§íÜÊFÜ¬zB'C÷\7û—şÅ‘Éx„â³îxf¦µ1µºiq¼$ö0Å+^{Fïåd—Ö
[@‹P ÂÙ9îĞ1ôXˆ?)Y‘¬(gzè;I««j³LR3`	Xü½ĞÕué
"]>5‘ìİûà¬\5ÆE…J&”
¤Uµõ²ªÚSõY >Kóë=Ğ{½iÑıHtÿBŞªˆ?ı¼ñ<5ÙŞE£WØÍLë½ñÁğjŠ²›µ~amg>~)xşt©¦h(ôíŞØfjUB¸ô¨i+,:`&7¡\‹Ø¢`¦aĞÿ0>$¯éŠ5†¡§l<‘IlÖBD¹¡–™Éuz½–Ìµ£
ş¥‰•ËıÎCë0ù³§?dô´•Ê§(UKâíÌµ.`t	§éşDÇ¶,LXBpp’ –Ñ¾§Š…s¹Äqø]Z˜ôeû‚#„8‚İ^pû†ì#p°×ö¡}Zo‹·Éß‘‚Ó;Yv©¼]—Jt*Z¯–Èù%‡2O¯4H•µ¨Å†#iP6[XS\ÇÅ€€M#vfŞ^»ô‹S:xÚ'`BøöSpÆ¦òèò£üò|P–ß”} *îà÷ˆÑ@ecÓ—”…ÜÓh8ª·@J›Ò£D<Ê³M‹
±4G²S„U7ËÚd ­—UAÜ®‚áÈğ‰Ñµj ½z¯ùk˜şÑ_½Ñ?¢&n,ÆnƒØªÿöMhNWœC£ÕC§û@ßé\Ç^8Q‰³v'íUhÙÜ¡qïò@nk§İ…8»ƒ©³WˆYrÌ¾äš÷ÏEf#ç&3 0ãƒ"ÚÑæ(BI²»™‡Qmo
q`3‘ø¼^q’3~î‚÷|ùbMá:Uè;¸ÚeóJ‘R^"æ	şr´Ü'(b@1¥Ï@Ÿõ.GÇ‘gûÿ‰Ôz5Ok§Â‰91›ÄÂEÍEU…HÕ	Şéœj Ë9ÔœoŞ;0æŸ—­Ü†ÆlcîQÄîµ¹m”•y/z\nªÓ¬—Íƒé¤káA“´ßÆ‰=`Zæ-¦e2Ì¥fÜ¬f,Ï@êIœÙ7u]x¿)brßé}€ş	{Î±v#–nªËîòô{ıı¾~oÀ3èĞj^«dgÑ³2•«8Ë©c»¡„™ı¾asÛ{ˆõñ%ËY$Œw™\/ÿ¯\n&W8Lç‰‡ˆ‘FXt:û¡úZı‚M‰FòÁ`^N×¸¢ÜĞVÊuºVFmk«V+Ç˜^$¯kÓ:Æ¬+²¾´|KÒo#æ3,³İlk‡Ú	’°"V#nÁaƒÀµèQéÆÚÄ/à(ûAÜˆ;P›±ıÉ³~ÈÄ[–;ñchİıBwÆ—ºÃ_×šÑİû¯t—òÆÆ’iÑƒajY%Té”û0óÔax(èôùPŸÏ††ÕAÌ‡ø0¹³–ÈÕ†V®/q»Ô ª‘<º	J¤ÿ°Ğú•u¾tßˆÿıõ¢‘¯ˆ4RàEÕ"Ğ«ªíô!ögúŠŞˆ`­%‰7¤	*•ùcFƒMf/ÎÍÏ†Çß‹ €ö?b=óüÙİúCì¶ÿã¡õ:œ¼–D/Ø9Wï_¿„)f`¶¾óUŸ%NïG>a_µ.Úârû½AïH7èëˆÂñhkm=Së¯tA§Ğ–•íú7áÿƒá%áíôÏYgà&û_¾—¤©Ä4mºo¤Ñ”ì'í×œÄqÆ7 á©YÏ"<3ÑRóOÚ«5¸‰ëŒ¦lİ¦šd¢‰¼[vÓñ¤	-dZÜLÂ«¤ÀócŒÂØÔ6BÈoÙ²VO¯V+kµzZ’eY–…,Û²‘%[Æ±ÃË“@èê¦àBZÒ2”iiç:Yÿèš6Ì´Ó™d¦ÓÙß÷~÷ìw¾ïœ“À‘£ŞÃ ù°c-·yƒ7²O¸®^SùÙè ©Ù'ø*ÿÏò}‹Ÿ<ã‘ .2İ0ôaêñ£#ûÀ@ş–öµ¨ì˜É(Ãe†JƒJ¯'UDU÷ô+âòKGF
â §`W •É©F~ÜXcT)Zgh ¸—¸ïŠ­—™Q[8¬v;â ù~~ÕMEjğ­ò×*9¤íé!ÕŒ{(—‰mdl5S˜­Ö]{î;_Ç[;wl(¿sÎ9EW®/Ø‡¯o%|Vpİõ~°ötu¦# 28âCÏŸ&Êy‰Uœ(ñJë(»1áV	¤¦l·cïLÙ’èĞY3u…/ğ²MÍèØFWV£Ëä7‡€©‡üp±y–êÆŒcªtU_Uï/c’0Kö5ç¡ûóõÊ<œÛÆå0¿aÆ™HÖÿó¯°ğ…{¶ó¨0fB¥¨µğDQ_qoÑì,o[Ï~¨ùıó:†‡ÏŒ|pyä¾ÙñÙâR˜™s»›Ãeâ^F¹%œP²l)¾tÙNÈ-AV¶¬îyƒŠ¹[¢Éñ«İ3èÄ™Ù(>*Kåõ¬=k?ùÂ½X±,¶5³|ºmw[*ÏOO•ßŠYÍìŸ?qoü"&<s¾¸$òĞnÊI:H»Ñ¦ã¿wlÜ³€á„÷'@8ÈƒÜL/5,€¬n$(’i2šyŒ–¥1q`Ò:ÂÅğiËc~ÿœ)¶’ÿä·´/ì~`P‘8b	.¬™U æ”'5qŞ}ÇãTštx“x«½ÇªãTGº3OõDBwÀß
Æ‚±Öî–Ş–^ïIOxúíiäñ¡â¦¸$Û–É­ëC+Ğõ{õ%¸‚øÅnQ6ø» ĞÔÊ„0¯ÕÅ"®…¼÷UkIšjÄ«4%š„„8d8B²¸’Ö¢;ğ{æXÎÕŠL„õah¨³»«;Öîo-ıIW'ÊÇñ±òTQ,Äòü[ŞFÖª7ÏÅçK
ä@^°G½-xÚâï†ŠºJ`N,Î:E3y~æ8·¿
fƒ$ÒX:1~í	Ş–©ƒÕÎ´^u|âùŒô‹½Šr‡U”“ú
¼B_M(UZ}}MeYEYy©¼Üf.³ƒØ7dvó¿˜mû7fé×)n#F¥ªH5eä¹M‘”Ñ¬£Iú°e…?ÍŞœ±İA…ÜÕ»ğ%­ ¤ĞM$…˜¬f±T¬ñŒ¨ş4m˜@ás{¯ŞÀo\Mşö÷È°>UÇ”ñÊˆ, kÙ\æŞËÜU•·ŞK´èÛ€>hêˆ"#­ƒ‰“X_â½à$:x’ÔÇğ˜.¢AÂ«uiZÁªù&c%|c¦mÓö¥­ı{¼À»[Â£›	Å|»âP‰B
RÍş|¤ÄQæ“c¾cÁÊ°2¬ìR%‰ˆáq»nVyNÕFµm*-ğ×8«È–šıÒ¬Dº§~ZxÌjSâJFéPº”®zoC‹ªE4†a2lî T˜îI!Û3éŸYvÑå@8ß—Ñ-œÏÉÔX´z„Î£"6‰³ÌË{<]h%Útíü´Ç¨‹2o#ØGÔİíÆOhSâ
}©¢­ª±”£%l…SíV»´^ƒ_ï'[Í!ª­i’yè˜û±xê´5q2eI£íŸ7:3èú
º¥·”5‘¨NÖdİ‹»àºÎW…ÄRÅîÊU€•2¯pË‘"åŞêw*A¡À6ØÏô¡Â3_^¸(ú¯fcAšh^üàbA’¹ÎÂoaÌe[š	—ÕáXàØ“#fRo.É®ä²x–XÚ»šúÑAŠôàja'°„MÁH³Á*U!+;éæ­47Pz“^¯&ê”uµõêŠÚ…œt¼ìÉĞÅî¯}¡Ú¨®èzMø–Ï?åaÌEfĞö¿?…˜JK-­ÄèÚ¦šj¤À^è)Å<¥-ŠPMTŞS  ‘1EúXGsu5w¼¯Ûç;wnôÔ@œŞdŞNåvlÌ6†ºb¦î>ñ@X9÷¥^ô j&à÷[ûïÃBñ|1ñ±'à‹øZü.¿«ÓfÀE);—®F¹Œı5|»à=DŒÀe²uˆÖÓ:LWX»M¶j·X¾Ô¼Ê)ÅÚhõÙÍã‰9!¼Q~E3B¼Ï…yCö_ºd-½İ÷&cçæo #´‡n6{HŞ­oVúå°p¾B<ÃíöTF7e=ÊÎuÌ…u¢Ş{ö±èDÌ€ì}Xëæ5Ê=ŸñÇLwÂŸnMÃŒèGîğ0\$ş´%f;Ï;²<şæf>Œ8¢lÊ
&¦·réwÑâŒı‡øNÁuzÈä3ŸÑIÔ#Jc©Z‚)~z„{JÂ½°++OË¯?àpHÜ’ß’B!ØŸyì­£«ËVs¯r3âµÜúš©ºIõÙ¬×á¯3”WƒÄÍ¸NÌátÛ}¶ ;ÈL=®ºz%½]±Š±¯ç«™â&ŸÉG6ÜZ·&(‰­Œ­è|£sùçÜ”8Íá÷3…‡ÍOˆ¨`ÈF‡Ó¶$Åc±şÎd|*ù)l˜ëÿV_ƒ?JN'§cÃmş ¯ÓÙÇxşÇ 8ÿÇ†PP‰OOG>OÑ„³„•„•„‘ƒ‰‰‚lm:WûWûf2w]Vû
qÅkÖeéL÷0sÅsÑqİ¬†¡–œ“—’•²ĞÃ†B?‰=:99Sº…©„™ƒ™ƒ˜z—s©L±1»û	÷3ü©@¤H¡OoAkChCs\wjzwzxy}wƒww†ww{‚‚’€”•sXû.¡ƒ…øè ¬_(†
endstream
endobj
143 0 obj
<</BG2/Default/OP true/OPM 1/SA false/SM 0.0200043/TR2/Default/Type/ExtGState/UCR2/Default/op true>>
endobj
144 0 obj
<</BG2/Default/OP false/OPM 0/SA false/SM 1.0/TR2/Default/UCR2/Default/op false>>
endobj
194 0 obj
<</A 195 0 R/Border[0 0 0]/Rect[466.77 15.0 541.0 27.0]/Subtype/Link/Type/Annot>>
endobj
195 0 obj
<</S/URI/URI(http://www.jrheum.org/)>>
endobj
67 0 obj
<</S/D/St 811>>
endobj
78 0 obj
<</D[75 0 R]/MS 77 0 R/Type/JobTicketContents>>
endobj
77 0 obj
<</Me 76 0 R>>
endobj
76 0 obj
<</Dm[612 792 612 792]>>
endobj
75 0 obj
<</Fi[72 0 R]/P[74 0 R]>>
endobj
74 0 obj
<</JTF 0/MB[0 0 612 792]/R 73 0 R/W[0 8]>>
endobj
73 0 obj
<</R[1200 1200]>>
endobj
72 0 obj
<</CP(Distiller)/Fi 71 0 R>>
endobj
71 0 obj
/This
endobj
70 0 obj
<</Dt(D:20050407175603)/JTM(Distiller)>>
endobj
80 0 obj
<</Author(Heather)/CreationDate(D:20050407175603Z)/Creator(QuarkXPressª: AdobePS 8.8.0 \(301\))/ModDate(D:20231203122420-08'00')/Producer(Acrobat Distiller 4.05 for Macintosh)/SaveStreams<</Q 120 0 R/q 119 0 R>>/Title(2004-566.may)>>
endobj
120 0 obj
<</Length 3>>stream
 Q 
endstream
endobj
119 0 obj
<</Length 3>>stream
 q 
endstream
endobj
xref
0 196
0000000081 65535 f
0000002316 00000 n
0000000000 00000 f
0000000000 00000 f
0000002638 00000 n
0000000000 00000 f
0000000000 00000 f
0000002960 00000 n
0000000000 00000 f
0000000000 00000 f
0000003258 00000 n
0000000000 00000 f
0000000000 00000 f
0000003569 00000 n
0000000000 00000 f
0000000000 00000 f
0000003892 00000 n
0000000000 00000 f
0000000000 00000 f
0000057285 00000 n
0000057194 00000 n
0000069234 00000 n
0000057025 00000 n
0000056748 00000 n
0000056664 00000 n
0000056361 00000 n
0000056064 00000 n
0000004226 00000 n
0000000000 00000 f
0000000000 00000 f
0000004537 00000 n
0000000000 00000 f
0000000000 00000 f
0000047118 00000 n
0000085613 00000 n
0000069312 00000 n
0000047873 00000 n
0000048126 00000 n
0000085861 00000 n
0000086371 00000 n
0000069540 00000 n
0000070011 00000 n
0000085783 00000 n
0000086064 00000 n
0000069480 00000 n
0000069729 00000 n
0000153649 00000 n
0000000000 00000 f
0000141110 00000 n
0000000000 00000 f
0000127147 00000 n
0000000000 00000 f
0000111290 00000 n
0000000000 00000 f
0000099915 00000 n
0000000000 00000 f
0000084917 00000 n
0000000000 00000 f
0000055496 00000 n
0000000000 00000 f
0000046331 00000 n
0000000000 00000 f
0000015311 00000 n
0000000000 00000 f
0000000000 00000 f
0000016369 00000 n
0000016321 00000 n
0000166244 00000 n
0000001850 00000 n
0000001886 00000 n
0000166614 00000 n
0000166592 00000 n
0000166547 00000 n
0000166513 00000 n
0000166454 00000 n
0000166412 00000 n
0000166371 00000 n
0000166340 00000 n
0000166276 00000 n
0000000108 00000 n
0000166671 00000 n
0000000117 00000 f
0000000016 00000 n
0000001992 00000 n
0000000000 00000 f
0000017755 00000 n
0000018696 00000 n
0000000000 00000 f
0000000000 00000 f
0000158801 00000 n
0000158526 00000 n
0000158410 00000 n
0000159288 00000 n
0000154379 00000 n
0000000000 00000 f
0000000000 00000 f
0000025643 00000 n
0000016933 00000 n
0000000000 00000 f
0000000000 00000 f
0000154666 00000 n
0000155427 00000 n
0000000000 00000 f
0000000000 00000 f
0000000000 00000 f
0000000000 00000 f
0000000000 00000 f
0000000000 00000 f
0000000000 00000 f
0000000000 00000 f
0000000000 00000 f
0000000000 00000 f
0000019113 00000 n
0000026218 00000 n
0000000000 00000 f
0000155698 00000 n
0000033860 00000 n
0000000118 00000 f
0000000123 00000 f
0000166973 00000 n
0000166921 00000 n
0000018510 00000 n
0000000000 00000 f
0000000125 00000 f
0000000000 00000 f
0000000127 00000 f
0000000000 00000 f
0000000129 00000 f
0000000000 00000 f
0000000131 00000 f
0000000000 00000 f
0000000133 00000 f
0000000000 00000 f
0000000135 00000 f
0000000000 00000 f
0000000137 00000 f
0000000000 00000 f
0000000139 00000 f
0000000000 00000 f
0000000000 00000 f
0000000160 00000 n
0000142510 00000 n
0000142537 00000 n
0000165872 00000 n
0000165990 00000 n
0000018606 00000 n
0000128572 00000 n
0000128599 00000 n
0000142138 00000 n
0000142256 00000 n
0000112300 00000 n
0000112327 00000 n
0000128200 00000 n
0000128318 00000 n
0000100939 00000 n
0000100966 00000 n
0000111928 00000 n
0000112046 00000 n
0000087272 00000 n
0000087299 00000 n
0000100567 00000 n
0000100685 00000 n
0000070789 00000 n
0000070816 00000 n
0000086900 00000 n
0000087018 00000 n
0000050557 00000 n
0000050584 00000 n
0000070417 00000 n
0000070535 00000 n
0000034347 00000 n
0000034374 00000 n
0000050185 00000 n
0000050303 00000 n
0000004836 00000 n
0000004863 00000 n
0000033975 00000 n
0000034093 00000 n
0000034192 00000 n
0000034291 00000 n
0000050402 00000 n
0000050501 00000 n
0000070634 00000 n
0000070733 00000 n
0000087117 00000 n
0000087216 00000 n
0000100784 00000 n
0000100883 00000 n
0000112145 00000 n
0000112244 00000 n
0000128417 00000 n
0000128516 00000 n
0000142355 00000 n
0000142454 00000 n
0000166089 00000 n
0000166188 00000 n
trailer
<</Size 196/Root 82 0 R/Info 80 0 R/ID[<B1B9DA24BF07EB8731064B2557538A9E><A2DCD65AD21DB2110A00D10810000000>]>>
startxref
167025
%%EOF
